



# 2025 Annual Report



**[THIS PAGE INTENTIONALLY LEFT BLANK]**

# Avantor<sup>®</sup> 2025 performance snapshot


We serve customers in 180 countries across three end markets:



Biopharma &  
Healthcare



Education &  
Government



Advanced Technologies  
& Applied Materials

FULL YEAR

\$6.55B

Reported revenue

\$1.07B

Adjusted EBITDA<sup>1</sup>

\$496M

Free cash flow<sup>2</sup>

Laboratory Solutions

\$4,400M

Reported revenue

Bioscience Production

\$2,153M

Reported revenue

1. See "Reconciliations of non-GAAP measures" in our Annual Report on Form 10-K for a reconciliation of this non-GAAP measure.

2. See "Liquidity and capital resources-Historical cash flows" in our Annual Report on Form 10-K for a reconciliation of this non-GAAP measure.

# A message to our stockholders

## Emmanuel Ligner

President and Chief Executive Officer

### To our stockholders, customers and colleagues:

**With cutting-edge science and technology advancing at a historically rapid pace, Avantor's role in empowering the world's disruptors and innovators has never been more important. We are proud to stand as a partner to companies in the life sciences and advanced technologies industries, and a catalyst for innovation that contributes to a better, healthier world.**

### Capitalizing on Avantor's compelling opportunities

In the months since my appointment as Avantor's Chief Executive Officer in August of 2025, I have been energized and invigorated by the countless ways our company sets science in motion. We are stewards of many of the premier brands in scientific and laboratory production, and these brands will serve as the foundation of our program to accelerate value creation.

Our leadership team has listened carefully to our stakeholders, including stockholders, customers, suppliers, and employees. Two consistent themes have emerged across our conversations:

**Customers value the unique capabilities Avantor delivers to them.** They continue to place their trust in our ability to support their work with our leading brands. We serve 300,000 customer locations globally, and our brands are used every day — embedded in every stage of our customers' activities.

**We have a significant opportunity ahead of us.** This continues to be a compelling industry supported by strong secular tailwinds, and we have confidence in the long-term trajectory of our end markets.

In 2026, we are single-mindedly focused on strengthening our platform through our Revival program, which we launched last October, to drive better top- and bottom-line performance.

### Five pillars to drive meaningful performance improvement

Revival centers on five key pillars that will drive meaningful performance improvements across our business.

**Evolving our go-to-market strategy** to ensure that each business line, product and service reaches the right customers. We are embracing VWR, Avantor's leading distribution channel, and will continue to elevate our key product and channel brands going forward.

**Strategically investing** in our manufacturing and supply chain organization. We have launched a comprehensive manufacturing improvement program to remove costs, improve the throughput and quality of our facilities, and simplify our supply chain.

**Optimizing our portfolio** to focus our operating model around our core distribution and product businesses.



"We are single-mindedly focused on strengthening our platform through our Revival program, which we launched last October, to drive better top- and bottom-line performance."

**Simplifying processes** across the organization to drive net cost savings. We are also establishing new operating norms that will better align priorities across our organization.

**Strengthening our talent** at Avantor and improving accountability. For example, last quarter, we announced the appointment of Mary Blenn as COO and new roles leading our Digital and Quality / Regulatory efforts – leadership changes that we expect will strengthen execution across the business.

#### **Our focus for 2026**

We are acting with urgency to advance the Revival program and drive profitable top-line growth across the business.

We know that the market opportunity is there — we need

to deliver. We strive to exceed our customers' expectations. And we seek to be worthy of the trust our investors place in us. Our board, our management team and our organization are committed to the execution of this strategy, and we look forward to sharing our progress with you.

Thank you for your continued support of Avantor. Together, we are setting science in motion and driving innovation across the life sciences and advanced technology industries. Our role is to empower progress, which we do every day in hundreds of thousands of customer locations across the globe. We are privileged to partner with the innovators, pioneers and disruptors working tirelessly to create a better world.

### Forward-Looking Statements

See "Cautionary factors regarding forward-looking statements" and "Item 1A: Risk Factors" in the enclosed Annual Report on Form 10-K for a discussion of risks and uncertainties relating to the forward-looking statements contained herein. Such statements speak only as of the date of this Annual Report and, except to the extent required by applicable law, the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

### Non-GAAP Financial Measures

As appropriate, we supplement our results of operations determined in accordance with U.S. generally accepted accounting principles ("GAAP") with certain non-GAAP financial measurements that are used by management, and which we believe are useful to investors, as supplemental operational measurements to evaluate our financial performance.

These measurements should not be considered in isolation or as a substitute for reported GAAP results because they may include or exclude certain items as compared to similar GAAP-based measurements, and such measurements may not be comparable to similarly titled measurements reported by other companies. Rather, these measurements should be considered as an additional way of viewing aspects of our operations that provide a more complete understanding of our business. We strongly encourage investors to review our consolidated financial statements in their entirety and not rely solely on any one, single financial measurement.

**[THIS PAGE INTENTIONALLY LEFT BLANK]**

# Form 10-K



UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

**FORM 10-K**

- ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

**For the fiscal year ended December 31, 2025**

- TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission file number: **001-38912**



**Avantor, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction of  
incorporation or organization)

**82-2758923**

(I.R.S. employer identification no.)

**Radnor Corporate Center, Building One, Suite 200**

**100 Matsonford Road**

**Radnor, Pennsylvania 19087**

(Address of principal executive offices) (zip code)

**610 386-1700**

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol	Exchange on which registered
<b>Common stock, \$0.01 par value</b>	<b>AVTR</b>	<b>New York Stock Exchange</b>

Securities registered pursuant to Section 12(g) of the Act: **None**

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.  Yes  No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.  Yes  No

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes  No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.  Large Accelerated Filer  Accelerated Filer  Non-accelerated Filer  Smaller reporting company  Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to § 240.10D-1(b).

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes  No

The aggregate market value of common stock held by our non-affiliates as of the last business day of the registrant’s most recently completed second fiscal quarter was \$9,173,395,483.

On February 5, 2026, 682,055,932 shares of common stock, \$0.01 par value per share, were outstanding.

## DOCUMENTS INCORPORATED BY REFERENCE

Portions of our definitive proxy statement for our 2026 annual meeting of stockholders will be filed with the SEC on or before 120 days after our 2025 fiscal year-end and are incorporated by reference into Part III of this report.

**Avantor, Inc. and subsidiaries**  
**Form 10-K for the fiscal year ended December 31, 2025**  
**Table of contents**

	<u>Page</u>
<a href="#">Glossary</a> .....	<a href="#">ii</a>
<a href="#">Cautionary factors regarding forward-looking statements</a> .....	<a href="#">iv</a>
<u>PART I</u>	
<a href="#">Item 1. Business</a> .....	<a href="#">1</a>
<a href="#">Item 1A. Risk factors</a> .....	<a href="#">9</a>
<a href="#">Item 1B. Unresolved staff comments</a> .....	<a href="#">24</a>
<a href="#">Item 1C. Cybersecurity</a> .....	<a href="#">24</a>
<a href="#">Item 2. Properties</a> .....	<a href="#">25</a>
<a href="#">Item 3. Legal proceedings</a> .....	<a href="#">25</a>
<a href="#">Item 4. Mine safety disclosures</a> .....	<a href="#">25</a>
<a href="#">Information about our executive officers</a> .....	<a href="#">26</a>
<u>PART II</u>	
<a href="#">Item 5. Market for registrant’s common equity, related stockholder matters and issuer purchases of equity securities</a> .....	<a href="#">27</a>
<a href="#">Item 6. Reserved</a> .....	<a href="#">30</a>
<a href="#">Item 7. Management’s discussion and analysis of financial condition and results of operations</a> .....	<a href="#">30</a>
<a href="#">Item 7A. Quantitative and qualitative disclosures about market risk</a> .....	<a href="#">46</a>
<a href="#">Item 8. Financial statements and supplementary data</a> .....	<a href="#">47</a>
<a href="#">Item 9. Changes in and disagreements with accountants on accounting and financial disclosure</a> .....	<a href="#">47</a>
<a href="#">Item 9A. Controls and procedures</a> .....	<a href="#">47</a>
<a href="#">Item 9B. Other information</a> .....	<a href="#">49</a>
<a href="#">Item 9C. Disclosure regarding foreign jurisdictions that prevent inspections</a> .....	<a href="#">49</a>
<u>PART III</u>	
<a href="#">Item 10. Directors, executive officers and corporate governance</a> .....	<a href="#">49</a>
<a href="#">Item 11. Executive compensation</a> .....	<a href="#">49</a>
<a href="#">Item 12. Security ownership of certain beneficial owners and management and related stockholder matters</a> .....	<a href="#">49</a>
<a href="#">Item 13. Certain relationships and related transactions, and director independence</a> .....	<a href="#">50</a>
<a href="#">Item 14. Principal accountant fees and services</a> .....	<a href="#">50</a>
<u>PART IV</u>	
<a href="#">Item 15. Exhibits and financial statement schedules</a> .....	<a href="#">50</a>
<a href="#">Item 16. Form 10-K summary</a> .....	<a href="#">55</a>

## Glossary

	<b>Description</b>
the Company, we, us, our	Avantor, Inc. and its subsidiaries
2019 Plan	the Avantor, Inc. 2019 Equity Incentive Plan, a stock-based compensation plan
Adjusted EBITDA	our earnings or loss before interest, taxes, depreciation, amortization and certain other adjustments
Adjusted Operating Income	our earnings or loss before interest, taxes, amortization and certain other adjustments
Advanced Lab Services	Services and products designed to optimize and manage end-to-end laboratory operations for customers across industries such as biopharma, education, industrial, and technology sectors
AI	artificial intelligence
AMEA	Asia, Middle-East and Africa
AOCI	accumulated other comprehensive income or loss
Applied Solutions	Proprietary formulated solutions for semiconductor manufacturing, proprietary chemicals for healthcare, biopharma, and diagnostic applications as well as chemicals and PPE for industrial applications
ASC	Accounting Standards Codification
ASU	Accounting Standards Update
Bioprocessing	Process ingredients and excipients, single use systems and integrated solutions, and controlled environment consumables used to support the production of biologic drugs and therapies
BIS	the Bureau of Industry and Security
CERCLA	the Comprehensive Environmental Response Compensation and Liability Act
cGMP	Current Good Manufacturing Practice
CODM	chief operating decision maker
COVID-19	Coronavirus disease of 2019
DDTC	Directorate of Defense Trade Controls
DEA	Drug Enforcement Administration
DHHS	Department of Health and Human Services
EMA	European Medicines Agency
EPA	the U.S. Environmental Protection Agency
ERP	enterprise resource planning
EU	European Union
EURIBOR	the basic rate of interest used in lending between banks on the European Union interbank market
FASB	the Financial Accounting Standards Board of the United States

	<b>Description</b>
FCPA	the United States Foreign Corrupt Practices Act
FDA	United States Food and Drug Administration
FDII	Foreign-Derived Intangible Income
GAAP	United States generally accepted accounting principles
GDPR	the General Data Protection Regulation
GILTI	Global Intangible Low-Taxed Income
ICH Q7	the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients
IPO	initial public offering
ISO	International Organization for Standardization or international equivalents
ITAR	the International Traffic In Arms Regulations
Laboratory Specialty Products	Proprietary chemicals and products for multiple industries, including biopharma, healthcare, industrial, mining, and education, among others
Long-Term	period other than Short-Term
Masterflex	Masterflex LLC, a company we acquired in November 2021
NAV	Net Asset Value
NIH	National Institutes of Health
NuSil	NuSil Acquisition Corp, NuSil Investments LLC and subsidiaries, a business organization with which we merged in 2016
NYSE	the New York Stock Exchange
OCI	other comprehensive income or loss
OEM	original engineering manufacturers
OFAC	the U.S. Department of the Treasury's Office of Foreign Assets Control
OSHA	the U.S. Occupational Safety & Health Administration
Ritter	Ritter GmbH and affiliates, a company we acquired in June 2021
RSU	restricted stock units represent equity awards that may be subject to service, performance, or market conditions, or a combination of these criteria
SEC	the United States Securities and Exchange Commission
SG&A expenses	selling, general and administrative expenses
Short-Term	period less than a year from the reporting date
Silicones	Ultra-high purity medical and aerospace grade silicone formulations
SKU	stock keeping unit
SOFR	secured overnight financing rate
specialty procurement	product sales related to customer procurement services
Total Science Solutions	Mission-critical consumables, chemicals, and equipment and instrumentation used by scientists in their labs
VWR	VWR Corporation and its subsidiaries, a company we acquired in November 2017

## Cautionary factors regarding forward-looking statements

This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this report are forward-looking statements. Forward-looking statements discuss our current expectations and projections relating to our financial condition, results of operations, plans, including our cost transformation initiative, objectives, future performance and business. These statements may be preceded by, followed by or include the words “aim,” “anticipate,” “assumption,” “believe,” “continue,” “estimate,” “expect,” “forecast,” “goal,” “guidance,” “intend,” “likely,” “long-term,” “near-term,” “objective,” “opportunity,” “outlook,” “plan,” “potential,” “project,” “projection,” “prospects,” “seek,” “target,” “trend,” “can,” “could,” “may,” “should,” “would,” “will,” the negatives thereof and other words and terms of similar meaning.

Forward-looking statements are inherently subject to risks, uncertainties and assumptions; they are not guarantees of performance. You should not place undue reliance on these statements. We have based these forward-looking statements on our current expectations and projections about future events. Although we believe that our assumptions made in connection with the forward-looking statements are reasonable, we cannot assure you that the assumptions and expectations will prove to be correct.

You should understand that the following important factors, in addition to those discussed under Part I, Item 1A, “Risk factors” and Item 7, “Management’s discussion and analysis of financial condition and results of operations” could affect our future results and could cause those results or other outcomes to differ materially from those expressed or implied in our forward-looking statements:

- disruptions to our operations;
- competition from other industry providers;
- our ability to implement our strategies for improving growth and optimizing costs;
- our ability to anticipate and respond to changing industry trends;
- adverse trends in consumer, business, and government spending (including impacts resulting from a U.S government shutdown);
- our dependence on sole or limited sources for some essential materials and components;
- our ability to successfully value and integrate acquired businesses;
- our products’ satisfaction of applicable quality criteria, specifications and performance standards;
- our ability to maintain our relationships with key customers;
- our ability to maintain our relationships with suppliers;
- our ability to maintain our customer base and our expected volume of customer orders;
- our ability to maintain and develop relationships with drug manufacturers and contract manufacturing organizations;
- the impact of new laws, regulations, government policies or orders or other industry standards;

- changes in the interest rate environment that increase interest on our borrowings;
- adverse impacts from currency exchange rates or currency controls imposed by any government in major areas where we operate or otherwise or from potential changes in trade restrictions, tariffs and exchange controls;
- our ability to implement and improve processing systems and prevent a compromise of our information systems or personal data;
- our ability to protect our intellectual property and avoid third-party infringement claims;
- exposure to product liability and other claims in the ordinary course of business;
- our ability to develop new products responsive to the markets we serve;
- supply chain constraints and the availability of raw materials;
- our ability to source certain of our products from certain suppliers;
- our ability to contain costs in an inflationary environment;
- our ability to avoid negative outcomes related to the use of chemicals;
- our ability to maintain highly skilled employees;
- our ability to maintain a competitive workforce;
- adverse impact of impairment charges on our goodwill and other intangible assets;
- currency fluctuations and uncertainties related to doing business outside the United States;
- our ability to obtain and maintain required regulatory clearances or approvals, which may constrain the commercialization of submitted products;
- our ability to comply with environmental, health and safety laws and regulations, or the impact of any liability or obligation imposed under such laws or regulations;
- our indebtedness, which could adversely affect our financial condition or prevent us from fulfilling our debt or contractual obligations;
- our ability to generate sufficient cash flows or access sufficient additional capital to meet our debt obligations or to fund our other liquidity needs; and
- our ability to maintain an effective system of internal control over financial reporting.

All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the foregoing cautionary statements. In addition, all forward-looking statements speak only as of the date of this report. We undertake no obligations to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise other than as required under the federal securities laws.

## PART I

### Item 1. Business

At Avantor, everything we do is tied to our unique mission of setting science in motion to create a better world.

We are a leading global provider of mission-critical products and services to customers in the biopharma & healthcare, education & government, and advanced technologies & applied materials end markets. Our business model is grounded in supporting our customers from discovery to delivery and Avantor is embedded in virtually every stage of the most important research, scale-up and manufacturing activities in the industries we serve.

We work with customers across these sophisticated, science-driven industries that require innovation and adherence to the most demanding technical and regulatory requirements. Our customer-centric innovation model enables us to provide solutions for some of the most demanding applications, and we leverage our comprehensive offering and access to early-stage research to identify and develop content and solutions that ultimately become specified into our customers' approved production platforms.

We go to market in two primary ways. First, in our channel business, VWR, we distribute consumables and equipment to laboratories around the world. Second, we manufacture proprietary products used in life sciences and medical technology applications.

The VWR channel includes a private label offering that enables more than 5,000 suppliers to provide products using the VWR label; millions of SKUs from the most renowned life sciences suppliers in the world; and value-add services where approximately 2,000 of our associates work alongside our customers to ensure scientists can focus on what they do best.

Our specialty product manufacturing offering includes J.T. Baker high-purity chemicals; Masterflex, a fluid handling company; and NuSil, which produces high-purity silicone for human implants.

We have a number of distinctive capabilities that set us apart from other companies in our space. For example, our global footprint offers extraordinary customer access, enabling us to serve more than 300,000 customer locations in approximately 180 countries around the world.


### Corporate History

Our legacy began in 1904 with the founding of the J.T. Baker Chemical Company. In 2010, we were acquired by New Mountain Capital from Covidien plc. Since then, we have expanded through a series of large acquisitions which have extended our global reach. In 2016, we merged with NuSil, a leading supplier of high-purity silicone products for the medical device and aerospace industries that was founded in 1985. In 2017, we acquired VWR, a global manufacturer and distributor of laboratory and production products and services founded in 1852.


Avantor, Inc. was incorporated in Delaware in May 2017 in anticipation of the VWR acquisition. We completed our initial public offering through Avantor, Inc. and listed our shares on the New York Stock Exchange in May 2019.

## Business segments

We report financial results in two segments: Laboratory Solutions and Bioscience Production. The following chart presents the approximate mix of net sales for each of those segments during 2025:



Within our reportable segments, we sell materials & consumables, equipment & instrumentation and services & specialty procurement to customers in the biopharmaceutical, healthcare, education & government and advanced technologies & applied materials industries. The following charts present the approximate mix of net sales for each of these groups during 2025:



## Products and services

Our portfolio includes a comprehensive range of products and services that allows us to create customized and integrated solutions for our customers. These products and services enable our customers to achieve precise analytical results in their research, diagnostic, and quality assurance and quality control activities. We also provide mission-critical, high-purity materials and solutions to customers that support the development and production of their life-changing treatments. More than 85% of our net sales were from product and service offerings that we consider to be recurring in nature. Our products and services are as follows:

- *Materials & consumables* include ultra-high purity chemicals and reagents, lab products and supplies, highly specialized formulated silicone materials, customized excipients, customized

single-use assemblies, process chromatography resins and columns, analytical sample prep kits and education and microbiology and clinical trial kits, and fluid handling tips. Some of these are proprietary products that we make while others are produced by third parties;

- *Equipment & instrumentation* include filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, peristaltic pumps, biological safety cabinets and critical environment supplies; and
- *Services & specialty procurement* include onsite lab and production, equipment, procurement and sourcing and biopharmaceutical material scale-up and development services.

In aggregate, we provide millions of SKUs, including high value specialty products developed to exacting purity and performance specifications. Our proprietary brands have been specified and trusted for decades. For example:

- VWR is one of the leading distribution brands in the U.S. and Europe.
- Masterflex is recognized for high-quality tubing and pump systems used in research and industrial fluid transfer applications.
- J.T. Baker is a top provider of high-purity bioprocessing chemicals, trusted by life sciences and electronic materials customers globally, with manufacturing capabilities that support ultra-stringent purity requirements.
- NuSil is a prominent supplier of human implant, high-purity silicone. These high-purity, customized silicones have been trusted for more than 30 years by leading medical device manufacturers and aerospace companies.

All of our capabilities are underpinned by our Avantor Business System which drives execution and continuous improvement. We manufacture products that meet or exceed the demanding requirements of our customers across a number of highly regulated industries.

Our services organization of approximately 2,000 associates work side-by-side with our customers to support their workflows. Our traditional service offerings focus on the needs of laboratory scientists and include procurement, logistics, inventory and stock room management, chemical and equipment tracking and glassware autoclaving. In addition, we offer more complex and value-added scientific research support and production services such as DNA extraction, media preparation, bioreactor servicing and compound management, and cleanroom control, monitoring, maintenance and sanitization.

## **Customers**

We benefit from longstanding customer relationships, and approximately 45% of our 2025 net sales came from customers that have had relationships with us for 15 years or more. We also have a diverse customer base with no single end customer comprising more than 5% of net sales.

## **Suppliers**

We sell proprietary products we make and third-party products sourced from a wide variety of product suppliers located across the globe. Many of our supplier relationships are based on contracts that vary in geographic scope, duration, product and service type, and some include exclusivity provisions. Those

relationships may include distribution, sales and marketing support as well as servicing of instruments and equipment. Many of our supplier relationships have been in place for more than twenty years.

### **Sales channels**

We reach our customers throughout the Americas, Europe and AMEA via a well-trained global sales force, comprehensive websites and targeted catalogs. Our sales force is comprised of approximately 3,400 sales and sales support professionals, including over 170 sales specialists selected for their in-depth industry and product knowledge. Our sales professionals include native speakers for each of the countries in which we operate, allowing us to have high impact interactions with our customers across the globe.

Our e-commerce platform plays a vital role in how we conduct business with our customers. In 2025, approximately 80% of our transactions came from our digital channels. Our websites utilize search analytics and feature personalized search tools, customer specific web solutions and enhanced data that optimize our customers' online purchasing experience with rich content and AI-based recommendations and better integrate our customers' processes with our own. Our websites are designed to integrate acquisitions, drive geographical expansion and serve segmented market needs with ease. In addition, we have introduced digital services and solutions that streamline lab procurement and operations and have become embedded into many customers' laboratories, such as Avantor's Inventory Manager.

### **Infrastructure**

We have more than 200 facilities strategically located throughout the globe that include manufacturing, distribution, service and research & technology.

We operate over 40 global manufacturing facilities, including 6 facilities that are cGMP compliant and have been registered with the FDA or comparable foreign regulatory authorities. Our facilities are strategically located in North America, Europe and the AMEA region to facilitate supply chain efficiency and proximity to customers. Our manufacturing capabilities include: (i) an ability to quickly change specifications depending on customer needs; (ii) our flexible unit operations, which allow for production scalability, from laboratory pre-clinical development to large-volume commercialization; (iii) proprietary purification technologies designed to ensure lot-to-lot consistency through ultra-low impurity levels; (iv) rigorous analytical quality control testing; and (v) robust regulatory and quality control procedures. Our global network of distribution centers gives our customers security of supply and real-time flexibility. We also have 15 innovation centers that enable extensive collaboration and customization, critical elements for serving highly regulated, specification-driven applications.

### **Information technology**

We have a highly automated suite of ERP systems that promote standardization and provide business insight. Our global web infrastructure provides seamless integration with our customers and suppliers. These ERP platforms support rapid development and deployment of enhancements so that we may quickly adapt to meet the technology needs of our customers and seamlessly integrate new acquisitions. We have made significant investments to implement common ERP and online platforms that enhance the customer experience and employ network and data security architecture.

### **Competition**

We operate in a highly competitive environment with a diverse and fragmented base of competitors, many of whom focus on specific regions, customers, and/or segments. We focus on service and delivery,

breadth of product line, customization capabilities, price, customer support, online capabilities and the ability to meet the special and local needs of our customers.

Competition is driven not only by the product quality and purity across industries we serve, but also by the adaptability of the supplier as a developmental and commercial partner. We rely on our scale, expertise, deep customer access, depth of product and value-added service offerings, marketing strategies and sales force, acquisition strategy, financial profile and management team to deliver superior solutions to our customers and provide extensive market channel access to our suppliers.

## **Sustainability**

Our Science for Goodness sustainability platform enhances our approach for creating long-term stakeholder value by embedding sound environmental and corporate responsibility practices into our operations and business strategy. The platform also enables us to regularly measure and report progress on relevant sustainability metrics and goals.

Our approach to sustainability is reflected in our people, the products we create, the transformative services we provide, and the integrity with which we serve our stockholders, business partners, suppliers, customers, associates, and communities. Our strategy includes programs to monitor, measure, and reduce greenhouse gas emissions, efficiently manage resource use, and reduce end of life impact of products. We directly engage our supply chain on these efforts through Avantor's Responsible Supplier Program. The program enables collaboration with supplier partners to identify challenges and solutions focused on four priority topic areas: climate change, human rights, resource circularity, and natural resource conservation.

In 2025, Avantor received several important accolades for our efforts. For a third consecutive year, we received a Bronze Medal from EcoVadis, a leader in sustainability ratings, and were also recognized for the second time as a "Best Place to Work for Disability Inclusion" by Disability:IN.

## **Employees and human capital resources**

Our success depends on our ability to attract, retain and motivate highly qualified and diverse talent. As of December 31, 2025, we had approximately 13,500 employees located in over 30 different countries in a variety of roles. Approximately 4,800 of our associates were employed in the U.S. We believe that our relations with our employees are good. As of December 31, 2025, approximately 5% of our employees in North America were represented by unions, and a majority of our employees in Europe were represented by workers' councils or unions. We compete in the highly competitive life sciences industry. Attracting, developing and retaining talented people in technical, marketing, sales, research and other positions is crucial to executing our strategy and our ability to compete effectively. Our ability to recruit and retain such talent depends on a number of factors, including a positive and inclusive work environment and culture, compensation and benefits, talent development and career growth and opportunities, and protecting the health, safety and well-being of our associates. To that end, we invest in our associates in order to be an employer of choice. Our associates reflect the communities in which we live and work, the customers we serve, and possess a broad range of thought and experiences that have helped Avantor achieve our goal of setting science in motion to create a better world.

### *People & culture*

Enhancing our Associate Experience is a strategic priority for Avantor. Our values give our associates a foundation for how we want to work together. Innovation, Customer-centricity, Accountability, Respect, and Excellence are the building blocks of our inclusive company culture and send a strong message to our associates, customers, suppliers, stockholders and communities: ICARE. In addition, our executive

leaders serve as sponsors of our Associate-Centric Teams (ACTs) in support of our belonging and engagement initiatives. ACTs are employee resource groups that foster an inclusive work environment, build connections, create community, and promote career opportunities. Based on common interests, backgrounds or characteristics, ACTs are open to all associates. Additionally, Avantor's Talent Philosophy is a part of commitment to our associates and guides our managers in their role in supporting our people and our culture.

### *Compensation and benefits*

We are committed to rewarding, supporting and developing the associates who make it possible to deliver on our strategy. To that end, we offer a comprehensive total rewards program aimed at the varying health, home-life and financial needs of our diverse global associates. Our total rewards package includes market-competitive pay, broad-based stock grants and bonuses, healthcare benefits, retirement savings plans, an employee stock purchase plan, paid time off and family leave, flexible work schedules, access to wellness programs, free physicals and flu vaccinations, and an Employee Assistance Program and other mental health services.

### *Growth and development*

We invest significant resources to develop talent with the right capabilities to deliver the growth and innovation needed to support our strategy. We offer associates and their managers numerous tools to help in their personal and professional development, including our Avantor Career Hub which enables associates to highlight their skills, capture development plans, make connections and find new opportunities inside Avantor. We have a robust portfolio of learning solutions that can be accessed in multiple formats and available to our global associates across various professional, personal and leadership development areas. Each year, we host a Learning & Career week program which is available to associates at all levels globally, and includes a diverse slate of learning opportunities, live sessions and on-demand resources designed to support the personal and professional growth and success of associates. In addition, we provide programs on the Avantor Business System, which drives excellence in people, processes and problem solving. These consistent lean leadership practices empower associates to continuously improve and add value to our operations and customer solutions. We have aligned our performance management system through which 100% of our associates receive annual performance reviews, to support our culture of feedback to increase the focus on continuous learning and development.

### *Health, safety and well-being*

We are committed to protecting the health, safety and well-being of our associates. Our approach involves environment, health and safety professionals and process engineers who identify risks and implement behavioral solutions to prevent accidents before they occur. A robust auditing program is in place at every facility to ensure that we measure performance and drive continuous improvement. Our primary focus is to keep associates safe and free from injury. We do this through compliance with regulatory and international requirements, active monitoring of regulatory agencies for changing requirements, partnering with operational leaders to meet Environment, Health & Safety, Security & Sustainability (EHSSS) requirements, and promoting effective communication throughout the organization.

### **Intellectual property**

We rely on intellectual property rights, nondisclosure and other contractual provisions and technical measures to protect our offerings, services and intangible assets. Much of our intellectual property is know-how and asset configurations that we treat as trade secrets. These proprietary rights are important to our ongoing operations. In some instances, we may license our technology to third parties or may elect to license intellectual property from others. We have applied in the United States and certain foreign

countries for registration of a number of trademarks, service marks and patents, some of which have been registered and issued. We also hold common law rights in various trademarks and service marks. Other than our Avantor, VWR, J.T. Baker, NuSil and Masterflex trademarks, we do not consider any particular patent, trademark, license, franchise or concession to be material to our overall business.

### **Government contracts**

We conduct business with various government agencies and government contractors. As such, we are subject to certain laws and regulations applicable to companies doing business with the government, as well as with those concerning government contracts. Failure to address or comply with these laws and regulations could harm our business by leading to a renegotiation of profits or termination of the contract at the election of the government agency. For a discussion of risks related to government contracting requirements, refer to Part I, Item 1A, "Risk factors." No government contract is of such a magnitude as to have a material adverse effect on our financial results.

### **Government regulation**

Our facilities that engage in the manufacturing, packaging, distribution of material used in biopharmaceutical and biomaterials production, as well as many of our products themselves, are subject to extensive ongoing regulation by U.S. governmental authorities, the EMA and other global regulatory authorities. Certain of our subsidiaries are required to register with these agencies, or to apply for permits and/or licenses with, and must comply with the operating, cGMP, quality and security standards of applicable domestic and foreign regulators, including the FDA, the DEA, the Bureau of Alcohol, Tobacco, Firearms and Explosives, DHHS, the equivalent agencies of EU member states, and comparable foreign, state and local agencies, as well as various accrediting bodies, each depending upon the type of operation and the locations of storage or sale of the products manufactured or services provided by those subsidiaries in the event of noncompliance.

In order to maintain certain certifications of quality and safety standards for our manufacturing facilities and operations, we must comply with numerous regulatory systems, standards, guidance and other requirements, as appropriate, including, but not limited to, ICH Q7, the guidelines of the International Pharmaceutical Excipients Council, European in vitro diagnostic medical device directives, U.S. Pharmacopeia / National Formulary, as well as the European, British, Japanese, Indian and Chinese Pharmacopeia, the Food Chemicals Codex and controlled substances regulations.

In addition, our operations, and some of the products we offer, are subject to a number of complex and stringent laws and regulations governing the production, handling, transportation and distribution of chemicals, drugs and other similar products. We are subject to various federal, state, local, foreign and transnational laws, regulations and recommendations, both in the U.S. and abroad, relating to safe working conditions, good laboratory and distribution practices, and the safe and proper use, transportation and disposal of hazardous or potentially hazardous substances. In addition, U.S. and international import and export laws and regulations, including those enforced by the U.S. Departments of Commerce, State and Treasury, OFAC and BIS, require us to abide by certain standards relating to the cross-border transit of finished goods, raw materials and supplies and the handling of related information. Our logistics activities must comply with the rules and regulations of the U.S. Department of Transportation, Department of Homeland Security, Department of Commerce, Department of Defense, and the Federal Aviation Administration and similar foreign agencies. We are also subject to various other laws and regulations concerning the conduct of our foreign operations, including the FCPA and other anti-bribery laws as well as laws pertaining to the accuracy of our internal books and records.

The costs associated with complying with the various applicable federal, state, local, foreign and transnational regulations could be significant, and the failure to comply with such legal requirements could have an adverse effect on our reputation, results of operations and financial condition. See Part I, Item 1A, “Risk factors—Risks related to regulation.” We are subject to audits by the FDA and other similar foreign regulatory bodies. To date, we have had no instances of noncompliance that have had a material impact on our operations.

In addition to the regulations described above, as part of our aerospace and military offerings, we are registered with the DDTC as a manufacturer and exporter of goods controlled by ITAR, and we are subject to strict export control and prior approval requirements related to these goods. In connection with our NuSil brand products, we have one ITAR site registration and one ITAR product registration, and we maintain control systems which enable ITAR compliance. With respect to our electronic materials products, we adhere to applicable industry guidelines which set stringent quality criteria for our products, and we are subject to import and export regulations and other restrictions regarding the safe use of these products as well.

We are also subject to various federal, state and international laws and regulations related to privacy and data protection, including the EU’s GDPR as well as the California Consumer Privacy Act of 2018, which became effective on January 1, 2020 (as amended by the California Privacy Rights Act, which took effect on January 1, 2023, the “CPRA”). The interpretation and application of data privacy, cross-border data transfers and data protection laws and regulations are often uncertain and are evolving in the U.S. and internationally, such as in the EU, China and other jurisdictions. We monitor pending and proposed legislation and regulatory initiatives to ascertain their relevance to, and potential impact on, our business and develop strategies to address regulatory trends and developments, including any required changes to our privacy and data protection compliance programs and policies. Globally, we see a growing trend toward data protection laws and regulations increasing in complexity and number, and we anticipate that our obligations will expand commensurately.

### **Environmental matters**

We are subject to various laws and governmental regulations concerning environmental, safety and health matters, including employee safety and health, in the U.S. and other countries. U.S. federal environmental legislation that affects us includes the Toxic Substances Control Act, the Resource Conservation and Recovery Act, the Clean Air Act, the Clean Water Act, the Safe Drinking Water Act, and CERCLA. These laws and regulations govern, among other things, air emissions, wastewater discharges, the use, handling and disposal of hazardous substances and wastes, soil and groundwater contamination and the general health and safety of our associates and the communities in which we operate. We are also subject to regulation by OSHA concerning employee safety and health matters. The EPA, OSHA, and other federal and foreign or local agencies have the authority to promulgate regulations that may impact our operations.

Under CERCLA, and analogous statutes in local and foreign jurisdictions, current and former owners and operators of contaminated land are strictly liable for the investigation and remediation of the land and for natural resource damages that may result from releases of hazardous substances at or from the property. Liability under CERCLA and analogous laws is strict, unlimited, joint, several, retroactive, may be imposed regardless of fault and may relate to historical activities or contamination not caused by the current owner or operator. It is possible that facilities that we acquire or have acquired may expose us to environmental liabilities associated with historical site conditions that have not yet been discovered.

In addition to the federal environmental laws that govern our operations, various states have been delegated certain authority under the aforementioned federal statutes as well as having authority over these matters under state laws. Many state and local governments have adopted environmental and employee safety and health laws and regulations, some of which are similar to federal requirements.

A number of our operations involve, in varying degrees, the handling, manufacturing, use or sale of substances that are or could be classified as toxic or hazardous materials within the meaning of applicable laws. Consequently, some risk of environmental harm is inherent in our operations and products, as it is with other companies engaged in similar businesses. For additional information about environmental matters, see note 13 to our consolidated financial statements beginning on page F-1 of this report.

### **Available information**

We file or furnish annual, quarterly and current reports, proxy statements and other documents with or to the SEC. The public can obtain any documents that we file with or furnish to the SEC at [www.sec.gov](http://www.sec.gov).

You may also access our press releases, financial information and reports filed with or furnished to the SEC through our own website at [www.avantorsciences.com](http://www.avantorsciences.com). Copies of any documents on our website may be obtained free of charge, and reports filed with or furnished to the SEC will be available as soon as reasonably practicable after they are filed with or furnished to the SEC. The information found on our website is not part of this or any other report filed with or furnished to the SEC.

### **Item 1A. Risk factors**

#### **Risks related to our business and our industry**

#### ***Significant interruptions in our operations could harm our business, financial condition and results of operations.***

Any significant disruptions to the operations of our manufacturing or distribution centers or logistics providers for any reason, including labor relations issues, power interruptions, severe weather, destruction or damage or other circumstances beyond our control could have a significant impact on our operating results, including an increase to our operating expenses without coverage or compensation, or seriously harm our ability to fulfill our customers' orders or deliver products on a timely basis, or both. We must also maintain sufficient production capacity to meet anticipated customer demand, which carries fixed costs that we may not be able to offset if orders slow, which would adversely affect our operating margins. If we are unable to manufacture our products consistently, in sufficient quantities, and on a timely basis, our net sales, gross margins and our other operating results will be materially and adversely affected. In addition, we have experienced problems with, or delays in, our production, shipping and logistics capabilities that have resulted in delays in our ability to ship finished products, and there can be no assurance that we will not encounter such problems in the future. Significant delays in our manufacturing, shipping or logistics processes could damage our customer relationships, cause disruption to our customers and adversely affect our business, financial condition and operating results.

#### ***We have been impacted by supply chain constraints and inflationary pressures***

We have experienced challenges in sourcing certain products and raw materials as a result of global supply chain disruptions and have experienced inflationary pressures across all of our cost categories. While we have implemented pricing and productivity measures to combat these pressures, they may continue to adversely impact our results.

***We compete in highly competitive markets. Failure to compete successfully could adversely affect our business, financial condition and results of operations.***

We face competition across our products and the markets in which we operate, both domestically and internationally. Competition is driven by proprietary technologies and know-how, capabilities, consistency of operational performance, quality, supply chain control, price, value and speed. Our competitors range from regional companies, which may be able to more quickly respond to customers' needs because of geographic proximity, to large multinational companies, which may have greater financial, marketing, operational and research and development resources (R&D) than we do, allowing for a more rapid response with new, alternative or emerging technologies. Such actions may increase pricing pressure on us or cause us to lose existing market share. In addition, consolidation trends in the biopharma and healthcare industries have served to create fewer customer accounts and to concentrate purchasing decisions for some customers, resulting in increased pricing pressures. New competitors in low-cost manufacturing locations, particularly developing markets, may create increased pricing and competitive pressures and impede our goal to grow in those markets. Failure to anticipate and respond to competitors' actions may adversely affect our results of operations and financial condition.

***It may be difficult for us to implement our strategies for improving growth and optimizing costs.***

Effective January 1, 2024, we transitioned to a new operating model consisting of two complementary business segments, the Laboratory Solutions segment and the Bioscience Production segment. In conjunction with our new operating model, we launched a multi-year cost transformation initiative, with the objective to deliver approximately \$300 million in annual gross run-rate savings by the end of 2026. We have expanded this initiative and now expect to generate approximately \$400 million in run rate gross savings by the end of 2027. We have also committed to certain significant restructuring activities in connection with the initiative. The initiative and restructuring activities are subject to a variety of known and unknown risks and uncertainties, including the potential that we may not be able to successfully execute on the initiative or achieve the anticipated benefits and cost-saving opportunities, or that achieving such benefits and opportunities may take longer to realize than expected. If we are unable to achieve the expected benefits from the initiative and manage the effects of the restructuring activities, this could have an adverse effect on our business, results of operations and financial condition.

As we continue to refine our business model, we may also pursue divestitures in line with our new operating model. Our ability to manage our business and conduct our global operations while also pursuing our strategies for improving growth and optimizing costs requires considerable management attention and resources and is subject to the challenges of supporting a rapidly growing business in an environment with varying cultural, commercial, legal and regulatory frameworks. Our failure to implement these strategies in a cost-effective and timely manner could have an adverse effect on our business, results of operations and financial condition.

***Part of our growth strategy is to pursue strategic acquisitions, which will subject us to a variety of risks that could harm our business.***

As part of our business strategy, we may pursue and complete selective acquisition opportunities. There can be no assurances that we will be able to complete suitable acquisitions for a variety of reasons, including the identification of, and competition for, acquisition targets, the need for regulatory approvals, the inability of the parties to agree to the structure or purchase price of the transaction and the inability to finance the transaction on commercially acceptable terms. In addition, any completed acquisition will subject us to a variety of other risks, including: (i) potential adverse effects on our business relationships with existing or future suppliers and other business partners (in particular, to the extent we consummate acquisitions that vertically integrate portions of our business); (ii) the assumption of substantial actual or contingent liabilities, known or unknown, including environmental liabilities; (iii) failure to meet

expectations of future financial performance; (iv) delays or reductions in realizing expected synergies; (v) substantial unanticipated costs or other problems associated with acquired businesses or devoting time and capital to investigate a potential acquisition that is not completed; (vi) failure to achieve intended objectives for a transaction; (vii) failure to retain key personnel, customers and suppliers of the acquired business; and (viii) adverse impacts resulting from impairment charges on goodwill, other intangible assets and tangible assets. These factors related to our acquisition strategy, among others, could have an adverse effect on our business, financial condition and results of operations.

***The customers we serve have experienced, and will continue to experience, significant industry-related changes that could adversely affect our business.***

Many of the customers we serve have experienced, and are expected to continue to experience, significant industry-related changes, including reductions in governmental funding or payments for biopharmaceutical products, expirations of significant patents, adverse changes in legislation or regulations regarding the delivery or pricing of general healthcare services or mandated benefits, and increased requirements on quality. General industry changes include: (i) development of large and sophisticated group purchasing organizations and on-line auction sites that increase competition for, and reduce spending on, laboratory products; (ii) consolidation of biopharmaceutical companies resulting in a rationalization of research expenditures; (iii) increased regulatory scrutiny over drug production requiring safer raw materials; (iv) customers' purchasing the products that we supply directly from our suppliers; and (v) significant reductions in development and production activities.

Some of our customers have implemented, or may in the future implement, certain measures described above in an effort to control and reduce costs. The ability of our customers to develop new products to replace sales decreases attributable to expirations of significant patents, along with the impact of other past or potential future changes in the industries we serve, may result in our customers significantly reducing their purchases of products from us or the prices they are willing to pay for those products. While we believe we will be able to adapt our business to maintain existing customer relationships and develop new customer relationships, if we are unsuccessful or untimely in these efforts, our results of operations may suffer.

***Reductions in customers' research budgets or government funding may adversely affect our business.***

Many of our customers are universities, government research laboratories, private foundations and other institutions that are dependent on grants from government agencies, such as the NIH, for funding. R&D spending by our customers may fluctuate based on spending priorities and general economic conditions. The level of government funding for R&D is unpredictable. Reductions or delays in governmental spending could cause customers to delay or forego purchases of our products. If government funding necessary for the purchase of our products were to decrease, our business and results of operations could be adversely affected. Spending by some of these customers fluctuates based on budget allocations and the timely passage of the annual federal budget. An impasse in federal government budget decisions could lead to substantial delays or reductions in federal spending.

***Our offerings are highly complex, and, if our products do not satisfy applicable quality criteria, specifications and performance standards, we could experience lost sales, delayed or reduced market acceptance of our products, increased costs and damage to our reputation.***

The high-purity materials and customized solutions we offer are highly exacting and complex due to demanding customer specifications and stringent regulatory and industry requirements. Our operating results depend on our ability to execute and, when necessary, improve our global quality control systems, including our ability to effectively train and maintain our employees with respect to quality control. A

failure of our global quality control systems could result in problems with facility operations or preparation or provision of defective or non-compliant products. Nearly all of our products are subsequently incorporated into products sold to end users by our customers, and we have no control over the manufacture and production of such products. Our success depends on our customers' confidence that we can provide reliable, high-quality products. We believe that customers in our target markets are likely to be particularly sensitive to product defects and errors. Our reputation and the public image of our products and technologies may be impaired if our products fail to perform as expected or fail to meet applicable quality criteria, specifications or performance standards. If our products experience, or are perceived to experience, a material defect or error, this could result in loss or delay of net sales, damaged reputation, diversion of development resources, and increased insurance or warranty costs, any of which could harm our business.

***The loss of a significant number of customers or a significant reduction in customer orders could reduce our net sales and harm our operating results.***

Our operating results could be negatively affected by the loss of revenue from a significant number of our customers, including direct distributors and end users. Though we often include pricing and volume incentives in our contracts, our customers are generally not obligated to purchase any fixed quantities of products, and they may stop placing orders with us at any time. If we experience a significant reduction in customer orders, increased order deferrals, our sales could decline, and our operating results may not meet our expectations. In addition, if customers order our products, but fail to pay on time or at all, our liquidity and operating results could be adversely affected.

Our contracts generally do not contain minimum purchase requirements, and we sell primarily on a purchase order basis. Therefore, our sales are subject to changes in demand from our customers, and these changes have been material in the past. The level and timing of orders placed by our customers vary for a number of reasons, including individual customer strategies, the introduction of new technologies, the desire of our clients to reduce their exposure to any single supplier and general economic conditions. If we are unable to anticipate and respond to the demands of our customers, we may lose customers because we have an inadequate supply of raw materials with which to manufacture our products or insufficient capacity in our sites. Alternatively, we may have excess inventory or excess capacity. Either of these factors may have a material adverse effect on our business, financial position and operating results.

***We are subject to risks associated with doing business globally, which may harm our business.***

We have global operations and derive a substantial portion of our net sales from customers outside of the United States. Accordingly, our international operations or those of our international customers could be substantially affected by a number of risks arising from operating an international business, including: (i) limitations on repatriation of earnings; (ii) taxes on imports; (iii) the possibility that unfriendly nations or groups could boycott our products; (iv) general economic and political conditions in the markets where we operate, including changes in inflation and interest rates, instability in the global banking industry, rising energy prices, potential energy shortages and actual or anticipated military or political conflicts, such as the ongoing Ukraine/Russia or Israel/Hamas conflicts; (v) foreign currency exchange rate fluctuations; (vi) escalation of geopolitical tensions or potential changes in diplomatic and trade relationships, including potential changes to trade restrictions, tariffs and exchange controls and political and trade uncertainty in China along with potential retaliatory tariffs by other countries; (vii) a global health crisis; (viii) potential increased costs associated with overlapping tax structures; (ix) potential increased reliance on third parties within less developed markets; (x) more limited protection for intellectual property rights in some countries; (xi) difficulties and costs associated with staffing and managing foreign operations; (xii) difficulties in complying with a wide variety of foreign laws and regulations and unexpected changes thereto and costs associated with compliance; (xiii) expanded

enforcement of laws related to data protection and personal privacy; (xiv) the risk that certain governments may adopt regulations or take other actions that would have a direct adverse impact on our business and market opportunities, including nationalization of private enterprise; (xv) violations of anti-bribery and anti-corruption laws, such as the FCPA; (xvi) violations of economic sanctions laws, such as the regulations enforced by OFAC; (xvii) longer accounts receivable cycles in certain foreign countries, whether due to cultural differences, exchange rate fluctuation or other factors; (xviii) the credit risk of local customers and distributors; (xix) limitations on our ability to enforce legal rights and remedies with third parties or partners outside of the United States; (xx) import and export licensing requirements and other restrictions, such as those imposed by OFAC, BIS, DDTC and comparable regulatory agencies and policies of foreign governments; and (xxi) changes to our distribution networks.

***Changes in exchange rates can adversely affect our financial condition, results of operations and cash flows.***

A substantial amount of our revenues is derived from international operations, and we anticipate that a significant portion of our sales will continue to come from outside of the United States in the future. Our consolidated results of operations are comprised of many different functional currencies that translate into our U.S. dollar reporting currency. The movement of the U.S. dollar against those functional currencies, particularly the Euro, has caused significant variability in our results in the past and may continue to do so in the future. The revenues we report with respect to our operations outside of the United States have been in the past and may be adversely affected by fluctuations in foreign currency exchange rates.

Further, we have a substantial amount of Euro denominated indebtedness, as well as intercompany loans and short-term intercompany balances with the Euro as their functional currency. Fluctuations in the exchange rate between U.S. dollars and Euros may have a material adverse effect on our ability to repay such indebtedness. See Part I, Item 7A, “Quantitative and qualitative disclosures about market risk.”

***Our business depends on our ability to use and access information systems, and any failure to successfully maintain these systems or implement new systems to handle our changing needs could materially harm our operations.***

Our businesses rely on sophisticated information systems: (i) to obtain, rapidly process, analyze, and manage data to facilitate the purchase and distribution of thousands of inventory items from numerous distribution centers; (ii) to receive, process, and ship orders on a timely basis; (iii) to account for other product and service transactions with customers; (iv) to manage the accurate billing and collections for thousands of customers; and (v) to process payments to suppliers. We continue to make substantial investments in data centers and information systems. To the extent our information systems are not successfully implemented or fail, or there are data center interruptions or outages, our business and results of operations may be adversely affected. Our business and results of operations may also be adversely affected if a third-party service provider does not perform satisfactorily, or if the information systems are interrupted or damaged by unforeseen events, including due to the actions or inactions of third parties.

While we have implemented cybersecurity and data protection measures, our efforts to minimize the risks and impacts of cyberattacks and protect our information systems may be insufficient and we may experience significant breaches or other failures or disruptions that could compromise our systems and data and, ultimately, affect our business operations and our financial position or results of operations. New technology that could result in greater operational efficiency, such as the development and adoption of AI and machine learning technology, may further expose our systems and businesses to the risk of cyberattacks. Like other companies, the systems and networks we maintain and third party systems and networks we use have in the past been, and will likely in the future be, subject to or targets of

unauthorized or fraudulent access, including physical or electronic break-ins or unauthorized tampering, as well as attempted cyber and other security threats and other attacks such as “denial of service” attacks, phishing, untargeted but sophisticated and automated attacks, ransomware, and other disruptive software. We are also exposed to similar risks resulting from cyberattacks that are experienced by our third-party service providers. For example, we and many of the third-party service providers we rely on use generative AI, which increases the risk that our confidential or proprietary information or personal data could be inadvertently or maliciously exposed. Security breaches can also occur as a result of intentional or inadvertent actions by our employees, third-party service providers or their personnel or other parties.

A failure, interruption, or breach of our systems, or those of our third-party service providers, as a result of cyber-attacks or information security breaches, could disrupt our business, result in the disclosure or misuse of confidential or proprietary information or personal data, damage our reputation, cause loss of customers or revenue, increase our costs, result in litigation and/or regulatory action, and/or cause other losses, any of which may have a material adverse impact on our business operations and our financial position or results of operations. Although we believe that we have robust information security procedures, controls and other safeguards in place, as cyber threats continue to evolve, we will be required to expend additional resources to continue to enhance our information security measures and/or to investigate and remediate information security vulnerabilities.

***Our actual or perceived failure to adequately protect personal data could adversely affect our business.***

Given the nature of our business, we collect and store confidential information that customers provide in order to, among other things, purchase products and services and register on our website. We are required to comply with increasingly complex and changing data privacy regulations both in the United States and beyond that regulate the collection, use, sharing, and transfer of personal data. Many of these regulations also grant rights to individuals. Many foreign data privacy regulations (including GDPR in the EU) and certain state laws and regulations (including California’s CPRA) impose requirements beyond those enacted under federal law including, in some instances, private rights of action. We are also required to comply with expanding and increasingly complex privacy and data protection regulations in the United States and abroad with respect to reporting adverse events and additional requirements for avoiding or responding to an adverse event. We also have contractual obligations to our customers related to the protection of personal data and compliance with privacy laws.

While we have taken various measures and made significant efforts and investment and designed our policies, processes and systems to be robust, a failure, or perceived failure, by us to comply with any applicable regulatory requirements or orders, including but not limited to privacy, data protection, information security, or consumer protection-related privacy laws and regulations, in one or more jurisdictions within the United States, the EU or elsewhere, could result in proceedings or actions against us by governmental entities or individuals; subject us to significant fines, penalties, and/or judgments; require us to change our business practices; limit access to our products and services in certain countries, incur substantial costs (even if we ultimately prevail) or otherwise adversely affect our business.

***Our inability to protect our intellectual property could adversely affect our business. In addition, third parties may claim that we infringe their intellectual property, and we could suffer significant litigation or licensing expenses as a result.***

We rely on a variety of intellectual property rights, including patents, trademarks, copyrights and trade secrets, to protect our proprietary technology and products. We place considerable emphasis on obtaining patent or maintaining trade secret protection for significant new technologies, products and processes because of the length of time and expense associated with bringing new products and processes through development and to the market. We may need to spend significant resources monitoring and enforcing our

intellectual property rights and we may not be able to prove infringement by third parties. Our competitive position may be harmed if we cannot enforce our intellectual property rights. In some circumstances, we may choose to not pursue enforcement for business reasons. In addition, competitors might avoid infringement by designing around our intellectual property rights or by developing non-infringing competing technologies. Intellectual property rights and our ability to enforce them may be unavailable or limited in some countries, which could make it easier for competitors to capture market share and could result in lost revenues.

***Our trademarks are valuable assets and if we are unable to protect them from infringement, our business prospects may be harmed.***

Our brands, particularly our J.T. Baker, NuSil, VWR and Masterflex brands, are valuable assets. Therefore, we actively manage our trademark portfolio, including by maintaining registrations for long-standing trademarks and applying to obtain trademark registrations for new brands. We also police our trademark portfolio against infringement. Our efforts to protect and defend our trademarks may be unsuccessful against competitors or other third parties for a variety of reasons. To the extent that third parties or distributors sell products that are counterfeit versions of our branded products, our customers could inadvertently purchase products that are inferior. This could cause our customers to refrain from purchasing our brands in the future and in turn could impair our brand equity and adversely affect our sales.

***We are subject to product liability and other claims in the ordinary course of business.***

Our business involves risk of product liability, intellectual property claims and other claims in the ordinary course of business arising from the products that we source from various manufacturers or produce ourselves. Furthermore, there may be product liability risks that are unknown or which become known in the future. Substantial, complex or extended litigation on any claim could cause us to incur significant costs and distract our management. We maintain insurance policies and in some cases, our suppliers, customers and predecessors of acquired companies have indemnified us against certain claims. We cannot assure you that our insurance coverage or indemnification agreements will be available in all pending or any future cases brought against us. Accordingly, we could be subject to uninsured and unindemnified future liabilities requiring us to provide additional reserves to address such liabilities. An unfavorable result in a case for which adequate insurance or indemnification is not available could adversely affect our business, financial condition and results of operations.

***We must develop new products, adapt to rapid and significant technological change and respond to introductions of new products by competitors to remain competitive.***

We sell our products in industries that are characterized by significant technological changes, frequent new product and technology introductions and evolving industry standards. As a result, our customers' needs are rapidly evolving. If we do not appropriately innovate and invest in new technologies, our offerings may become less desirable in the markets we serve, and our customers could move to new technologies offered by our competitors or make products themselves. Without the timely introduction of new products, services and enhancements, our offerings will likely become less competitive over time, in which case, our competitive position, net sales and operating results could suffer. To the extent we fail to timely introduce new and innovative products or services, adequately predict our customers' needs or fail to obtain desired levels of market acceptance, our business may suffer.

Accordingly, we focus significant efforts and resources on the development and identification of new technologies, products and services that are attractive to, and gain acceptance, in the markets we serve and further broaden our offerings. We have been and expect to continue to utilize AI and machine learning in certain of our products and services. As with many technological innovations, there are significant risks and challenges involved in maintaining and deploying these technologies, including risks related to cybersecurity, privacy and data use practices as well as related to accuracy issues, and there can be no assurance that the use of such technologies will enhance our products or services or be beneficial to our business. Further, the regulatory landscape surrounding AI is evolving and may impose restrictions that limit the usability or effectiveness of AI in our products and services and expose us to an increased risk of regulatory enforcement and litigation.

***We depend upon the availability of raw materials.***

Our operations depend upon our ability to obtain high-quality raw materials meeting our specifications and other requirements at reasonable prices, including various active pharmaceutical ingredients, components, compounds, excipients and other raw materials, many of which are sole-sourced due to market or customer demands. Our ability to maintain an adequate supply of such materials could be impacted by the availability and price of those raw materials and maintaining relationships with key suppliers.

Moreover, we are dependent upon the ability of our suppliers to provide materials and components that meet our specifications, quality standards, other applicable criteria, and delivery schedules. Our suppliers' failure to provide expected raw materials or components that meet such criteria could adversely affect production schedules and contract profitability and negatively impact our results of operations.

***We depend upon maintaining our relationships with suppliers.***

We offer products from a wide range of suppliers. While there is generally more than one source of supply for most of the categories of third-party materials & consumables and equipment & instrumentation that we sell, we currently do not manufacture the majority of our products and are dependent on these suppliers for access to those products. Our ability to sustain our gross margins has been, and will continue to be, dependent in part upon our ability to obtain favorable terms from our suppliers. These terms may change from time to time, and such changes could adversely affect our gross margins over time. In addition, our results of operations and cash flows could be adversely impacted by the acceleration of payment terms to our suppliers and/or the imposition of more restrictive credit terms and other contractual requirements.

***Our use of chemicals and chemical processes is subject to inherent risk.***

We use chemical ingredients in the manufacture of certain of our products. Due to the nature of the manufacturing process itself, there is a risk of incurring liability for damages caused by or during the storage or manufacture of both the chemical ingredients and the finished products. The processes used in certain of our facilities typically involve large volumes of solvents and chemicals, creating the potential for fires, spills and other safety or environmental impacts. If any of these risks materialize, it could result in significant remediation and other costs, potential adverse regulatory actions and liabilities, any of which could have an adverse effect on our business, results of operations and financial condition.

In addition, the manufacturing, use, storage, and distribution of chemicals are subject to threats including terrorism. We have several high-risk chemical facilities that contain materials that could be stolen and used to make weapons. We could also be subject to an attack on our high-risk facilities that could cause a

significant number of deaths and injuries. Such an occurrence could also harm the environment, our reputation and disrupt our operations.

***Climate change, and the legal or regulatory response thereto, may have a long-term impact on our business, financial condition and results of operations.***

We continue to focus on strategies and systems, such as reducing greenhouse gas emissions and packaging waste, to address climate change. However, we face climate and environmental risks and the occurrence of one or more unexpected events, including fires, tornadoes, tsunamis, hurricanes, earthquakes, drought, storms, sea level rise, floods, and other severe hazards or accidents in countries or regions in which we operate could adversely affect our operations and financial performance. The effects of climate change and legal or regulatory initiatives to address climate change could have a long-term adverse impact on our business, financial condition and results of operations. We also monitor rules and regulations related to sustainability and corporate responsibility disclosure obligations, which may expose us to increased costs associated with additional reporting obligations. In addition, we have established and publicly announced goals and commitments to reduce our carbon footprint, including targets to reduce greenhouse gas emissions (scope 1, scope 2 and scope 3). If we are unable to achieve, or improperly report on our progress toward, our carbon footprint reduction goals and commitments, this may result in litigation and/or regulatory action as well as negative publicity, which could lead to the loss of business, adverse reputational impacts, diluted market valuations and challenges in attracting and retaining customers and talented employees.

We also face increasing attention from investors, regulators, and other stakeholders, who may have conflicting views related to our positions, performance, and disclosures relating to sustainability and corporate responsibility-related matters, and the legal and regulatory landscape continues to evolve and may result in conflicting requirements and expectations. If we draw scrutiny for the positions we take or do not take on these matters (or for altering any such position) or receive unfavorable ratings from third-party organizations that provide information to investors on such matters, it could be used by investors, lenders, customers, employees and other stakeholders to inform their investment, financing, purchasing or employment decisions, which could have a negative impact on our business. Additionally, a failure to adequately meet regulatory expectations may result in non-compliance, the loss of business and reputational impacts, and we may become the target of litigation or investigations initiated by government authorities or private actors alleging that our activities related to these matters are anti-competitive, discriminatory or otherwise unlawful.

***We are highly dependent on our senior management and key employees.***

Our success depends on our ability to attract, motivate and retain highly qualified individuals. Competition for senior management and other key personnel in our industry is intense, and the pool of suitable candidates is limited. We have recently experienced changes in our senior management. The inability to identify, attract, retain and properly motivate members of our senior management team and other key employees, or to find suitable replacements for them could have a negative effect on our operating results. Additionally, changes in our organization as a result of senior management and board transitions, which we have recently experienced, may have a disruptive impact on our ability to implement our strategy and could negatively affect our business and financial condition.

***The indemnification provisions of acquisition agreements by which we have acquired companies may not fully protect us and as a result, we may face unexpected liabilities.***

Certain of the acquisition agreements by which we have acquired companies require the former owners to indemnify us against certain liabilities related to the operation of the company before we acquired it. In most of these agreements, however, the liability of the former owners is limited and certain former

owners may be unable to meet their indemnification responsibilities. We cannot assure you that these indemnification provisions will protect us fully or at all, and as a result, we may face unexpected liabilities that adversely affect our financial statements.

***We face risks related to health epidemics and pandemics.***

We face risks related to health epidemics and pandemics, including risks related to any responses thereto by the federal, state or foreign governments, as well as customers and suppliers. A pandemic has in the past and could in the future adversely affect our operations, supply chains and distribution network, and we could experience and expect prolonged unpredictable reductions in supply and demand for certain of our offerings similar to those experienced during the COVID-19 pandemic, as well as unpredictable increases in demand for certain of our offerings similar to those experienced during the COVID-19 pandemic. Further, it is possible that disruptions or delays in shipments of certain raw materials used in the products we manufacture and in the finished goods that we sell globally could be similar to those experienced during the COVID-19 pandemic. Any extended disruption in our ability to service our customers could have a negative effect on our operating results.

***Changes in tax law relating to multinational corporations could adversely affect our tax position.***

The U.S. Congress, foreign governments, and their agencies in non-U.S. jurisdictions where we and our affiliates do business, and the Organization for Economic Cooperation and Development (“OECD”), continue to focus on issues related to the taxation of multinational corporations. As part of this focus, the OECD has introduced a framework to implement a 15% global minimum corporate tax rate. Certain countries in which we operate have adopted legislation and other countries are in the process of introducing legislation to implement the minimum tax directive. While we do not currently expect the minimum tax directive to have a material impact on our effective tax rate, our analysis is ongoing as the OECD continues to release additional guidance. There can be no assurance that these changes, and any further contemplated changes when finalized and adopted by countries, will not have an adverse impact on our provision for income taxes. Additionally, on July 4, 2025, the One Big Beautiful Bill Act (“OBBBA”) was enacted, introducing broad changes to the U.S. tax code, including modifications to corporate and international tax provisions. As a result of OBBBA, our current cash tax obligations were reduced by approximately \$43.0 million due to changes to several provisions, including the reinstatement of immediate expensing for domestic R&D expenditures, the extension of 100% bonus depreciation for qualified properties and the relaxation of limitations on the deductibility of business interest expense. The impact on income tax expense resulting from OBBBA was immaterial.

Due to the potential for changes to tax laws and regulations or changes to the interpretation thereof, the ambiguity of tax laws and regulations, the subjectivity of factual interpretations, the complexity of our intercompany arrangements, uncertainties regarding the geographic mix of earnings in any particular period, and other factors, our estimates of effective tax rate and income tax assets and liabilities may be incorrect and our financial statements could be adversely affected. The impact of the factors referenced in the first sentence of this paragraph may be substantially different from period-to-period.

***Certain of our businesses rely on relationships with collaborative partners and other third parties for development, supply and marketing of certain products and potential products, and such collaborative partners or other third parties could fail to perform sufficiently.***

We believe that for certain of our businesses, success in penetrating target markets depends in part on their ability to develop and maintain collaborative relationships with other companies. Relying on collaborative relationships is risky because, among other things, our collaborative partners may (i) not devote sufficient resources to the success of our collaborations; (ii) fail to obtain regulatory approvals necessary to continue the collaborations in a timely manner; (iii) be acquired by other companies and

terminate our collaborative partnership or become insolvent; (iv) compete with us; (v) disagree with us on key details of the collaborative relationship; (vi) have insufficient capital resources; and (vii) decline to renew existing collaborations on acceptable terms. Because these and other factors may be beyond our control, the development or commercialization of our products involved in collaborative partnerships may be delayed or otherwise adversely affected. If we or any of our collaborative partners terminate a collaborative arrangement, we may be required to devote additional resources to product development and commercialization or we may need to cancel some development programs, which could adversely affect our business and financial statements.

### **Risks related to regulation**

***We are required to comply with a wide variety of laws and regulations, and are subject to regulation by various federal, state and foreign agencies, and our failure to comply with existing and future regulatory requirements could adversely affect our results of operations and financial condition.***

We compete in markets in which we and our customers are subject to federal, state, local, international and transnational laws and regulations, including the operating, quality and security standards of the FDA, various state health departments, the DHHS, similar bodies of the EU and its member states and other comparable agencies around the world, and, in the future, any changes to such laws and regulations could adversely affect us. We develop, configure and market our products to meet customer needs driven by those regulations. Among other rules affecting us, we are subject to laws and regulations concerning cGMP and product safety. Our subsidiaries may be required to register for permits and/or licenses with, and may be required to comply with, the laws and regulations of the FDA, the DHHS, the DEA, foreign agencies including the EMA, and other various state health departments and/or comparable state and foreign agencies as well as certain accrediting bodies depending upon the types of operations and locations of distribution and sale of the products manufactured or services provided by those subsidiaries. Any significant change in regulations could reduce demand for our products or increase our expenses. For example, many of our products are marketed to the biopharma industry for use in discovering, developing and manufacturing drugs, or are sold as raw materials or components to drug device manufacturers or for use in the manufacture of implantable devices. Changes in the domestic or foreign regulation of drug discovery, development or manufacturing processes or medical device manufacturing processes, or adverse findings concerning any health effects associated with these products, could have an adverse effect on the demand for these products and could also result in legal liability and claims.

We are also registered with the DDTC, as a manufacturer and exporter of goods controlled by ITAR, and we are subject to strict export control and prior approval requirements related to these goods. Our failure to comply with ITAR and other export control laws and regulations, as well as economic sanctions, could result in penalties, loss, or suspension of contracts or other consequences. Any of these could adversely affect our operations and financial condition. Failure by us or by our customers to meet one or more of these various regulatory obligations could have adverse consequences in the event of material non-compliance. Compliance with relevant sanctions and export control laws could restrict our access to, and increase the cost of obtaining, certain products and at times could interrupt our supply of imported inventory or our ability to service certain customers. Conversely, compliance with these regulatory obligations may require us to incur significant expenses.

In addition, certain of our facilities are certified to ISO, including ISO 13485, ISO 9001, AS9100, ISO 22000 and/or ISO 14001. These standards are voluntary quality management system standards, the maintenance of which indicates to customers certain quality and operational norms. Customers may rely on contractual assurances that we make with respect to ISO certificates to transact business. Failure to comply with these ISO standards can lead to observations of non-compliance or even suspension of ISO

or Aerospace Standard (AS) certifications or European Community (EC) Declarations of Conformity Certificates by the registrar. If we were to lose ISO or AS certifications or EC Declarations of Conformity, we could lose sales and customers to competitors or other suppliers. We are also subject to periodic inspections or audits by our customers. If these audits or inspections identify issues or the customer perceives there are issues, the customer may decide to cease purchasing products from us which could adversely affect our business.

***Our reputation, ability to do business and financial statements may be impaired by improper conduct by any of our employees, agents or business partners.***

We cannot provide assurance that our internal controls and compliance systems will always protect us from acts committed by employees, agents or business partners of ours (or of businesses we acquire or partner with) that would violate U.S. and/or non-U.S. laws, including the laws governing payments to government officials, bribery, fraud, kickbacks and false claims, pricing, sales and marketing practices, conflicts of interest, competition, export and import compliance, money laundering and data privacy. In particular, the FCPA, the U.K. Bribery Act and similar anti-bribery laws in other jurisdictions generally prohibit companies and their intermediaries from making improper payments for the purpose of obtaining or retaining business, and we operate in many parts of the world that have experienced corruption to some degree. Any such improper actions or allegations of such acts could damage our reputation and subject us to civil or criminal investigations in the United States and in other jurisdictions and related stockholder lawsuits, could lead to substantial civil and criminal, monetary and non-monetary penalties and could cause us to incur significant legal and investigatory fees. In addition, the government in relevant jurisdictions may seek to hold us liable as a successor for violations committed by companies in which we invest or that we acquire. We also rely on our suppliers to adhere to our supplier standards of conduct, and material violations of such standards could occur that could have a material effect on our business, reputation and financial statements.

***We are subject to laws and regulations governing government contracts, and failure to address these laws and regulations or comply with government contracts could harm our business by leading to a reduction in sales to these customers or penalties.***

We sell products to government entities and, as a result, we are subject to various statutes and regulations that apply to companies doing business with the government. The laws governing government contracts differ from the laws governing private contracts and government contracts may contain pricing terms and conditions that are not applicable to private contracts. We are also subject to investigation for compliance with the regulations governing government contracts. A failure to comply with these regulations could result in suspension of these contracts, criminal, civil and administrative penalties or debarment.

***We are subject to environmental, health and safety laws and regulations, and costs to comply with such laws and regulations, or any liability or obligation imposed under such laws or regulations, could negatively impact our business, financial condition and results of operations.***

We are subject to a broad range of foreign, federal, state and local environmental, health and safety laws and regulations, including those of the EPA, OSHA and equivalent local, state, and foreign regulatory agencies in each of the jurisdictions in which we operate, and we may be fined or penalized for non-compliance. In addition, contamination resulting from our current or past operations or from past uses of land that we own or operate may trigger investigation or remediation obligations, which may have an adverse effect on our business, financial condition and results of operations. We cannot be certain that identification of presently unidentified environmental, health and safety conditions, new regulations, more vigorous enforcement by regulatory authorities or other unanticipated events will not arise in the future

and give rise to additional environmental liabilities, business interruptions, compliance costs or penalties, which could have an adverse effect on our business, financial condition and results of operations.

We currently incur costs and may incur additional costs related to remediation of alleged environmental damage associated with past or current waste disposal practices or other hazardous materials handling at property that we currently own or operate, or formerly owned or operated, or facilities to which we arranged for the disposal of hazardous substances. Our liabilities arising from past or future releases of, or exposures to, hazardous substances may exceed our estimates or adversely affect our financial statements and reputation and we may be subject to additional claims for cleanup or other environmental claims in the future based on our past, present or future business activities, and we may not be able to recover any costs under any of our indemnifications that we have. For additional information regarding environmental matters, see note 13 to our consolidated financial statements beginning on page F-1 of this report.

***Changes in corporate governance and public disclosure requirements and expectations could impact compliance costs and the risks of noncompliance.***

We are subject to the rules and regulations promulgated by a number of governmental and self-regulatory organizations, including the SEC and NYSE, as well as evolving investor expectations around sustainability and corporate responsibility practices and disclosures. These rules and regulations continue to evolve in scope and complexity, and many new requirements have been created in response to laws and directives enacted by federal, state, local and foreign governments, making compliance more difficult and uncertain. The increasing complexity and costs to comply with such evolving expectations, rules and regulations, as well as any risk of noncompliance, could adversely affect our business.

***Changes to trade policy, including new or increased tariffs and changing import/export regulations, may adversely affect our business, financial condition and results of operations.***

Changes in U.S. or international laws and policies governing foreign trade could materially and adversely affect our business. The U.S. has instituted certain changes, and has proposed additional changes, in trade policies that include the negotiation or termination of trade agreements, the imposition of higher tariffs on imports into the U.S., and other government regulations affecting trade between the U.S. and other countries where we conduct our business. The new tariffs and other changes in U.S. trade policy have triggered retaliatory actions by affected countries, and foreign governments have instituted or are considering imposing trade sanctions on U.S. goods.

The imposition of tariffs and other trade restrictions, as well as the escalation of trade disputes and any downturns in the global economy resulting therefrom, could materially and adversely affect our business, financial condition and results of operations. The extent and duration of the tariffs and other trade restrictions and the resulting impact on general economic conditions and on our business are uncertain and depend on various factors, such as negotiations between the U.S. and affected countries, the responses of other countries or regions, exemptions or exclusions that may be granted, availability and cost of alternative sources of supply, and demand for our products in affected markets. Further, actions we take to adapt to new tariffs or other trade restrictions may cause us to modify our operations, which could be time-consuming and expensive, impact pricing of our products, which could impact our sales and profitability, or cause us to forgo business opportunities.

**Risks related to our indebtedness**

***Our indebtedness could adversely affect our financial condition and prevent us from fulfilling our debt or contractual obligations.***

We now have and expect to continue to have a significant amount of debt. Our indebtedness could have important consequences to us including: (i) making it more difficult for us to satisfy our debt or

contractual obligations; (ii) exposing us to the risk of increased interest rates as certain of our borrowings, including borrowings under our senior secured credit facilities, are at variable rates of interest; (iii) restricting us from making strategic acquisitions or causing us to make non-strategic divestitures; (iv) requiring us to dedicate a substantial portion of our cash flow from operations to payments on our indebtedness, which would reduce the funds available for working capital, capital expenditures, investments, acquisitions and other general corporate purposes; (v) limiting our flexibility in planning for, or reacting to, changes in our business, future business opportunities and the industry in which we operate; (vi) placing us at a competitive disadvantage compared to any of our less leveraged competitors; (vii) increasing our vulnerability to a downturn in our business and both general and industry-specific adverse economic conditions; and (viii) limiting our ability to obtain additional financing.

Our credit facilities and indentures contain financial and other restrictive covenants that could limit our ability to engage in activities that may be in our long-term best interests. Our failure to comply with those covenants could result in an event of default which, if not cured or waived, could result in the acceleration of all of our debt, which could adversely affect our business, earnings and financial condition.

***Despite our current level of indebtedness, we and our subsidiaries may still be able to incur substantially more debt.***

We and our subsidiaries may be able to incur significant additional indebtedness in the future. Although our credit agreement and indentures contain restrictions on the incurrence of additional indebtedness, these restrictions are subject to a number of qualifications and exceptions, and the additional indebtedness incurred in compliance with these restrictions could be substantial. If new debt is added to our current debt levels, the related risks that we now face could intensify. Additionally, we may not be able to obtain additional financing or refinancing on terms acceptable to us, or at all, which could adversely impact our ability to service our outstanding indebtedness or to repay our outstanding indebtedness as it becomes due and could adversely affect our business, earnings and financial condition. Further indebtedness also may increase the risk of a future downgrade in our credit ratings, which could increase future debt costs, limit the future availability of debt financing and adversely affect our business.

#### **Risks related to ownership of our stock**

***Because we have no current plans to pay cash dividends on our common stock, you may not receive any return on investment unless you sell your common stock for a price greater than that which you paid for it.***

We have no current plans to pay cash dividends on our common stock. The declaration, amount and payment of any future dividends on our common stock will be at the sole discretion of our Board of Directors. Our Board of Directors may take into account general and economic conditions, our financial condition and results of operations, our available cash and current and anticipated cash needs, capital requirements, contractual, legal, tax and regulatory restrictions and implications on the payment of dividends by us to our stockholders or by our subsidiaries to us, including restrictions under our credit agreement and other indebtedness we may incur, and such other factors as our Board of Directors may deem relevant. As a result, you may not receive any return on an investment in our common stock unless you sell our common stock for a price greater than your purchase price.

***If we fail to maintain an effective system of internal controls, we may not be able to accurately report our financial results.***

Effective internal controls are necessary for us to provide reliable and accurate financial statements and to effectively prevent fraud. We devote significant resources and time to comply with the internal control

over financial reporting requirements of the Sarbanes Oxley Act of 2002 and continue to enhance our controls. However, we cannot be certain that we will be able to prevent future significant deficiencies or material weaknesses. Inadequate internal controls could cause investors to lose confidence in our reported financial information, which could have a negative effect on investor confidence in our financial statements, the trading price of our stock and our access to capital.

***Our amended and restated certificate of incorporation provides, subject to limited exceptions, that state and federal courts (as appropriate) located within the State of Delaware will be the sole and exclusive forum for certain stockholder litigation matters, which could limit our stockholders' ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or stockholders.***

Our amended and restated certificate of incorporation provides that unless we consent to the selection of an alternative forum, the state or federal courts (as appropriate) located within the State of Delaware shall, to the fullest extent permitted by law, be the sole and exclusive forum for any (i) derivative action or proceeding brought on behalf of our company, (ii) action asserting a claim of breach of a fiduciary duty owed by any director, officer, or other employee or stockholder of our company to us or our stockholders, creditors or other constituents, (iii) action against us or any of our directors or officers involving a claim or defense arising pursuant to any provision of the Delaware General Corporation Law or our amended and restated certificate of incorporation or our amended and restated bylaws, (iv) action against us or any director or officer of the Company involving a claim or defense implicating the internal affairs doctrine, or (v) action against us or any of our directors or officers involving a claim or defense arising pursuant to the Exchange Act or the Securities Act. It is possible that these exclusive forum provisions may be challenged in court and may be deemed unenforceable in whole or in part. Our exclusive forum provision shall not relieve the company of its duties to comply with the federal securities laws and the rules and regulations thereunder, and our stockholders will not be deemed to have waived our compliance with these laws, rules and regulations.

Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and consented to the forum provisions in our amended and restated certificate of incorporation. This choice of forum provision may limit a stockholder's ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, other employees or stockholders which may discourage lawsuits with respect to such claims. Alternatively, if a court were to find the choice of forum provision contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, operating results and financial condition.

***Our business could be impacted as a result of actions by activist shareholders or others.***

We have in the past and may in the future be the focus of shareholder activism, which has become increasingly prevalent. Shareholder activism, particularly with respect to matters that our Board, in exercising its fiduciary duties, disagrees with, or has determined not to pursue, may adversely affect our business because responding to activist shareholders can be costly and time-consuming, disruptive to operations and divert the attention of our Board and management. Our ability to execute our strategic plan could also be impaired as a result. Responding to an activist campaign could cause us to incur substantial fees and expenses and could also lead to litigation, which could be a further distraction to our Board and management and require us to incur significant additional costs.

Perceived uncertainties as to our future direction, strategy or leadership created as a consequence of activist shareholders may result in the loss of potential business opportunities, harm our ability to attract new or retain existing investors, lenders, customers, directors, employees, or other partners, and negatively affect or create volatility in our stock price.

**Item 1B. Unresolved staff comments**

None.

**Item 1C. Cybersecurity**

**Risk Management and Strategy**

We rely on sophisticated information systems to obtain, rapidly process, analyze, and manage data in order to effectively operate our business. We are committed to protecting our business information, intellectual property, customer, supplier and employee data and information systems from cybersecurity risks and maintain an active cybersecurity risk management and strategy program, which is integrated in our enterprise risk management program.

We maintain enterprise-wide information security policies, standards, and procedures that govern acceptable use of systems and data, risk assessment and management, identity and access management, data security, security operations, incident response, and threat and vulnerability management. We perform formal risk assessments annually, aligned with the National Institute of Standards and Technology (NIST) Special Publication 800-171 and the NIST Cybersecurity Framework, to help ensure the confidentiality, integrity, and availability of our information systems and data. In August 2025, Avantor achieved ISO/IEC 27001 certification, reflecting the maturity of our Information Security Management System (ISMS) and providing independent validation of our security governance, risk management, and control environment. This certification complements our alignment with NIST-based frameworks and supports our continued focus on risk-informed control implementation, continuous improvement, and operational resilience. Our team of information security professionals monitors systems for cybersecurity threats, intrusions, and vulnerabilities; responds to incidents; develops and implements mitigation strategies; and facilitates cybersecurity training across the organization. We also engage consultants and other third-party advisors to conduct independent assessments of our cybersecurity readiness and control effectiveness. In collaboration with external cybersecurity firms, we seek to gain insights into emerging threats and vulnerabilities, industry trends, and leading practices to inform our cybersecurity response, risk remediation and resilience capabilities, including by working with an external retained incident response team, receiving third-party threat intelligence, participating in incident tabletops, and performing assessments and controls testing on our enterprise environment.

Our program includes procedures to oversee and identify cybersecurity risks and threats of our third-party service providers, which include third-party evaluations performed by our team of information security professionals, review of independent assessment documentation, and continuous monitoring of third-party independent posture scoring. We also include security and data protection provisions in our contractual arrangements with third-party service providers where applicable. Additionally, we have purchased a cybersecurity risk insurance policy that would reduce the costs associated with a covered cybersecurity incident if it occurred.

Although no cybersecurity incident during the year ended December 31, 2025 resulted in an interruption of our operations, known losses of critical data, or otherwise had a material impact on Avantor's strategy, financial condition or results of operations, the scope and impact of any future incident cannot be predicted. See "Item 1A. Risk Factors" for more information on how material cybersecurity attacks may impact our business.

## **Governance**

Management plays a critical role in assessing and managing material risks from cybersecurity threats. Our Vice President of Information Security & Risk Management and Chief Information Security Officer (CISO), in coordination with our Chief Information Officer, leads a team of information security professionals and manages our cybersecurity risk management program and activities. This involves monitoring our information systems for cybersecurity threats, reviewing cybersecurity incidents, analyzing emerging threats, and the development and implementation of risk mitigation strategies. Our CISO has over 25 years of experience working in the information technology and services industry and is a subject matter expert in a variety of areas including information security, and IT risk.

Our CISO reports to our executive leadership team composed of our Chief Executive Officer, Chief Financial Officer, and Chief Information Officer on cybersecurity matters, providing the leadership team with updates on enterprise risks, cybersecurity incidents, the status of ongoing initiatives, key metrics, and additional cybersecurity topics. Our information technology leaders also meet regularly to discuss the progress of ongoing program initiatives, cybersecurity priorities, identified risks and metrics. We have also developed a cross functional disclosure working group to assess elevated cybersecurity incidents and, as appropriate, report on such events to Avantor's standing Disclosure Committee to conclude on the materiality of the incident and any need for regulatory reporting.

The Board of Directors exercises direct oversight of strategic risks to the Company. The Board has delegated the responsibility for cybersecurity oversight to the Audit and Finance Committee. The Audit and Finance Committee's responsibilities include reviewing and discussing with management the strategies, process and controls pertaining to the management of Avantor's information technology operations, including cybersecurity risks and information security. The CISO and Chief Information Officer report to the Audit and Finance Committee annually and more frequently, as needed, on cybersecurity matters, including the cybersecurity threat landscape, key metrics demonstrating the overall management of our cybersecurity risk and risk management program, related key initiatives, enterprise program framework alignment, annual risk mitigation strategy, and review of cybersecurity incidents. Our Board is committed to maintaining a well-informed and cybersecurity-aware posture, regularly engaging through regular and requested updates on our strategy and evolving threat landscape.

### **Item 2. Properties**

As of December 31, 2025, the Company had facilities in over 30 countries, including approximately 200 significant administrative, sales, research and development, manufacturing and distribution facilities. Approximately 65 of these facilities are located in the United States across 20 states. Approximately 135 of these facilities are located outside the United States, primarily in Europe and to a lesser extent in AMEA. Refer to the Consolidated Financial Statements included in this Annual Report for additional information with respect to the Company's lease commitments.

### **Item 3. Legal proceedings**

For information regarding legal proceedings and matters, see note 13 to our consolidated financial statements beginning on page F-1 of this report, which information is incorporated into this item by reference.

### **Item 4. Mine safety disclosures**

Not applicable.

## Information about our Executive Officers

The following table sets forth certain information regarding our executive officers at February 5, 2026:

	Age	Position
Emmanuel Ligner	55	President and Chief Executive Officer
R. Brent Jones	56	Executive Vice President and Chief Financial Officer
Mary Blenn	53	Executive Vice President and Chief Operating Officer
Benoit Gourdier	55	Executive Vice President, Bioscience Production
Brittany Hankamer	45	Executive Vice President and Chief Human Resources Officer
Claudius O. Sokenu	58	Executive Vice President, Chief Legal and Compliance Officer and Corporate Secretary
Corey Walker	48	President, Laboratory Solutions

Unless indicated to the contrary, the business experience summaries provided below describe positions held by the named individuals during the last five years.

*Emmanuel Ligner* is our President and Chief Executive Officer, a position he has held since August 2025. Prior to joining the Company, Mr. Ligner served as Chief Executive Officer at Cerba HealthCare from March 2024 to March 2025. Prior to that, Mr. Ligner was President and Chief Executive Officer of Cytiva and a Group Executive of Danaher Corporation, a life sciences company, from April 2020 to March 2024. Before Cytiva, he held several leadership positions at GE in North America, Europe, the Middle East and Africa, culminating in his appointment to President and Chief Executive Officer of GE Life Sciences. Mr. Ligner began his career in Japan with Otsuka Pharmaceuticals before joining Abbott Japan.

*R. Brent Jones* is our Executive Vice President and Chief Financial Officer, a position he has held since August 2023. Prior to joining the Company, Mr. Jones served as Executive Vice President, Chief Financial Officer and Chief Operating Officer of LifeScan Global Corporation, a medical devices company, from March 2023 to July 2023 and as LifeScan's Chief Financial Officer from February 2020 to March 2023. Prior to that, Mr. Jones served as Chief Financial Officer of Klöckner Pentaplast Group, a plastics packaging manufacturer, from April 2016 to August 2018.

*Mary Blenn* is our Executive Vice President and Chief Operating Officer, a position she has held since November 2025. Prior to joining the Company, Ms. Blenn, age 53, provided consulting services to life sciences and medtech companies through her personal consulting firm Blenn Consulting from April 2024 to October 2025. Prior to that, Ms. Blenn served as Senior Vice President, Global Operations and Supply Chain of Cytiva, a life sciences company, from April 2020 to July 2023 and in several senior leadership roles at GE Healthcare from 1998 through 2020.

*Benoit Gourdier* is our Executive Vice President, Bioscience Production, a position he has held since January 2024. Prior to his current role, Mr. Gourdier served as Executive Vice President, Biopharma Production from October 2023 to December 2023. Prior to joining Avantor, Mr. Gourdier spent 23 years at Merck KGaA, a chemical company, where he served in a number of leadership positions including, most recently, as Senior Vice President and General Manager, BioReliance Contract Testing Services at Millipore Sigma from September 2017 to September 2023.

*Brittany Hankamer* is our Executive Vice President and Chief Human Resources Officer, a position she has held since August 2023. Prior to assuming her current position, Ms. Hankamer served as Avantor's Senior Vice President of Talent and People Operations from May 2021 to August 2023 and as Vice President, Human Resources from September 2019 to May 2021. Prior to joining Avantor, Ms. Hankamer

was Vice President of Human Resources at Conquest Completion Services, LLC from May 2018 to September 2019.

*Claudius Sokenu* is our Executive Vice President, Chief Legal and Compliance Officer and Corporate Secretary, a position he has held since July 2023. Prior to joining Avantor, Mr. Sokenu was General Counsel, Corporate Secretary and Chief Administrative Officer at Unisys, a technology company, from May 2022 to June 2023, Senior Vice President and Global Deputy General Counsel at Cognizant, an information technology services and consulting company, from March 2020 to April 2022 and Deputy General Counsel, Global Head of Litigation, Investigations and Ethics & Compliance from May 2017 to October 2018. Previously, he was a partner at Shearman & Sterling LLP and Arnold & Porter LLP.

*Corey Walker* is our President of Laboratory Solutions, a position he has held since April 2025. Prior to joining Avantor, Mr. Walker was President and CEO of ILC Dover, a life sciences company, from November 2021 to June 2024, and President, DCP Midstream, an energy company, from March 2020 to November 2021. From 2016 to 2020, Mr. Walker was an Executive Vice President at Avantor and led the Americas region as well as the global Biomaterials and Electronic Materials businesses.

## **PART II**

### **Item 5. Market for registrant’s common equity, related stockholder matters and issuer purchases of equity securities**

#### **Principal markets for common stock**

Our common stock is listed on the NYSE under the symbol “AVTR.”

#### **Holders of common stock**

On February 5, 2026, we had 7 holders of record of our common stock. This does not include holdings in street or nominee names.

#### **Dividends**


We currently do not expect to pay any dividends on our common stock. Our ability to pay dividends is limited by the terms of our indebtedness. Certain of the debt agreements entered into by our wholly-owned subsidiaries restrict their ability to pay dividends or make other distributions to Avantor, Inc., which in turn limits our ability to fund future dividends or make other distributions to our common stockholders.

Additional information regarding these restrictions is included in the Liquidity and Capital Resources section of Management’s Discussion and Analysis and in note 14 to our consolidated financial statements beginning on page F-1 of this report.

## Stock performance graph

The following performance graph compares the cumulative five-year return to shareholders on our common stock relative to the cumulative total returns of the S&P 500 Index and the S&P 500 Health Care Index for the five-year period ended December 31, 2025. The comparisons assume the investment of \$100 on December 31, 2020 in our common stock and in each index. The S&P 500 Index is a broad equity market index of companies having market capitalization similar to ours. The S&P 500 Health Care Index is an industry-specific equity market index that we believe closely aligns to us based on the following: (i) the index follows companies of a similar size to us in terms of net sales and market capitalization; (ii) the index includes health care distributors, the segment of the Global Industry Classification Standard that we believe most closely aligns to us; and (iii) the index includes companies in the biopharma and healthcare industries, two of our primary customer groups that together comprise over half of our net sales.

The information in this section is not “soliciting material,” is not deemed “filed” with the SEC and is not to be incorporated by reference in any of our filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this report, except to the extent that we specifically incorporate such information by reference. The stock performance shown below is not necessarily indicative of future performance.



## Securities authorized for issuance under equity compensation plans

The information required by this item is incorporated by reference to the applicable information in our 2025 Proxy Statement (defined below).

## Issuer purchases of equity securities

In October 2025, our Board of Directors authorized the repurchase of up to \$500.0 million of our common stock, exclusive of fees, commissions and related transaction expenses. Repurchases may be funded through our available cash, borrowings under existing credit facilities or other financing arrangements approved by the Board of Directors.

Management is authorized to repurchase our common stock on the open market or in privately negotiated transactions, through one or more Rule 10b5-1 trading plans, Rule 10b-18 repurchase programs, accelerated share repurchase programs, including any collateral arrangements, or a combination thereof. The timing, manner, price and amount of repurchases will be determined by management depending upon economic, market and other conditions. The repurchase program may be modified, suspended, or terminated at any time. Shares repurchased under the program are held as treasury stock.

The following table presents a summary of the share repurchase activity during the quarter ended December 31, 2025:

<b>Period</b>	<b>Total number of shares purchased</b>	<b>Average price paid per share<sup>1</sup></b>	<b>Total number of shares purchased as part of publicly announced plans or programs</b>	<b>Approximate dollar value of shares that may yet be purchased under the plans or programs (in millions)<sup>1</sup></b>
October .....	—	\$ —	—	\$ 500.0
November (3 to 19) ..	6,629,063	11.31	6,629,063	425.0
December .....	—	—	—	425.0
Total .....	<u>6,629,063</u>	<u>\$ 11.31</u>	<u>6,629,063</u>	<u>\$ 425.0</u>

1. Amounts exclude excise taxes and other transaction costs.

Refer to Note 15 to the Consolidated Financial Statements included in this Annual Report for additional discussion of our common stock repurchase program.

**Item 6. [Reserved]**

**Item 7. Management’s discussion and analysis of financial condition and results of operations**

*This discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results may differ materially from those contained in or implied by any forward-looking statements. See “Cautionary factors regarding forward-looking statements.”*

**Overview**

For the fiscal year ended December 31, 2025, we recorded net sales of \$6,552.2 million, net loss of \$530.2 million, Adjusted EBITDA of \$1,069.4 million and Adjusted Operating Income of \$957.8 million. Net sales declined 3.4% which included 2.8% organic net sales decrease compared to the same period in 2024. See “Reconciliations of non-GAAP measures” for reconciliations of net (loss) income to Adjusted EBITDA and Adjusted Operating Income, and net (loss) income margin to Adjusted EBITDA margin and Adjusted Operating Income margin. See “Results of operations” for a reconciliation and explanation of changes of net sales growth (decline) to organic net sales growth (decline).

**Segment change**

Effective January 1, 2024, we changed our operating model and reporting segment structure from three reportable segments to two reportable segments, Laboratory Solutions and Bioscience Production. This structure aligns with how our Chief Executive Officer, who is our CODM, measures segment operating performance and allocates resources across our operating segments. This reportable segment change has no impact on our consolidated operating results.

In connection with the operating model and reporting structure change, our CODM changed the measure used to evaluate segment profitability from Adjusted EBITDA to Adjusted Operating Income. All disclosures relating to segment profitability, including those for comparative periods, have been revised as a result of this change.

**Trends affecting our business and results of operations**

The following trends have affected our recent operating results, and they may also continue to affect our performance and financial condition in future periods.

***Our results are impacted by a divestiture to further refine our business model***

We completed the sale of our Clinical Services business, a component of the Company’s Laboratory Solutions reportable segment, on October 17, 2024. The Clinical Services business was not classified as a discontinued operation as it did not represent a strategic shift that will have a major effect on the Company’s operations and financial results.

***We have been impacted by inflationary pressures***

We have experienced inflationary pressures across all of our cost categories. While we have implemented pricing and productivity measures to combat these pressures, they may continue to adversely impact our results.

### ***We continue to invest in a differentiated innovation model***

We are engaging with our customers early in their product development cycles to advance their programs from research and discovery through development and commercialization. These projects include enhancing product purity and performance characteristics, improving product packaging and streamlining workflows. We are also developing new products in emerging areas of science such as cell and gene therapy.

### ***We continue to advance our cost transformation initiative to reduce our expenses***

We are advancing a global cost transformation initiative to further enhance productivity through increased organizational efficiency, footprint optimization, reduced cost-to-serve and procurement savings that are expected to generate approximately \$300 million in run rate gross cost savings by the end of 2026.

We have expanded this initiative and now expect to generate approximately \$400 million in run rate gross savings by the end of 2027.

### ***We refinanced our debt and increased our liquidity***

In the fourth quarter of 2025, we issued €400.0 million and €550.0 million of senior secured term loans, maturing in October 2030 and October 2032, respectively. These loans bear interest at EURIBOR plus 150 basis points and EURIBOR plus 250 basis points, respectively. The proceeds from these issuances, along with cash on hand, were used to repay our outstanding U.S. dollar term loans B-6, Euro term loans B-4, Euro term loans B-5, the remaining 2.625% secured notes, and the receivables facility.

In connection with the refinancing, we amended our revolving credit facility to obtain an additional \$425.0 million in available funding, increasing the total availability under the facility to \$1,400.0 million.

### ***Changes in foreign currency exchange rates are impacting our financial condition and results of operations***

Our consolidated results of operations are comprised of many different functional currencies that translate into our U.S. dollar reporting currency. The movement of the U.S. dollar against those functional currencies, particularly the Euro, has caused significant variability in our results and may continue to do so in the future. See Part I, Item 7A, “Quantitative and qualitative disclosures about market risk.”

### ***Our results may be impacted by changes in trade policy***

The imposition of tariffs and other trade restrictions by the U.S., as well as reciprocal trade restrictions imposed by other countries, could adversely affect global economies, financial markets and the overall environment in which we do business.

### ***Goodwill impairment related to our Distribution reporting unit***

In the third quarter of 2025, we recorded a goodwill impairment charge of \$785.0 million related to our Distribution reporting unit, formerly referred to as our Buy Sell reporting unit. This impairment was primarily driven by sustained decreases in our publicly quoted share price and market capitalization, as well as changes in operating results. While the impairment is a non-cash charge, it reflects underlying business conditions that may continue to affect our future results. We are actively implementing initiatives and evaluating strategic actions to mitigate these pressures.

## Key indicators of performance and financial condition

To evaluate our performance, we monitor a number of key indicators. As appropriate, we supplement our results of operations determined in accordance with GAAP with certain non-GAAP financial measurements that we believe are useful to investors, creditors and others in assessing our performance. These measures should not be considered in isolation or as a substitute for reported GAAP results because they may include or exclude certain items as compared to similar GAAP-based measures, and such measures may not be comparable to similarly titled measures reported by other companies. Rather, these measures should be considered as an additional way of viewing aspects of our operations that provide a more complete understanding of our business.

The key indicators that we monitor are as follows:

- ***Net sales, gross margin, operating income, operating income margin, net income or loss and net income or loss margin.*** These measures are discussed in the section entitled “Results of operations”;
- ***Organic net sales growth (decline)***, which is a non-GAAP measure discussed in the section entitled “Results of operations.” Organic net sales growth (decline) eliminates from our reported net sales change the impacts of revenues from acquisitions and divestitures that occurred in the last year (as applicable) and changes in foreign currency exchange rates. We believe that this measurement is useful to investors as a way to measure and evaluate our underlying commercial operating performance consistently across our segments and the periods presented. This measurement is used by our management for the same reason. Reconciliations to the change in reported net sales, the most directly comparable GAAP financial measure, are included in the section entitled “Results of operations”;
- ***Adjusted EBITDA and Adjusted EBITDA margin***, which are non-GAAP measures discussed in the section entitled “Results of operations.” Adjusted EBITDA is our net income or loss adjusted for the following items: (i) interest expense, (ii) income tax expense, (iii) amortization of acquired intangible assets, (iv) depreciation expense, (v) losses on extinguishment of debt, (vi) charges associated with the impairment of certain assets, (vii) gain on sale of business, and (viii) certain other adjustments. Adjusted EBITDA margin is Adjusted EBITDA divided by net sales as determined under GAAP. We believe that these measurements are useful to investors as ways to analyze the underlying trends in our business consistently across the periods presented. These measurements are used by our management for the same reason. A reconciliation of net income or loss and net income or loss margin, the most directly comparable GAAP financial measures, to Adjusted EBITDA and Adjusted EBITDA margin, respectively, are included in the section entitled “Reconciliations of non-GAAP measures”;
- ***Adjusted Operating Income and Adjusted Operating Income margin***, which are non-GAAP measures discussed in the section entitled “Results of operations.” Adjusted Operating Income is our net income or loss adjusted for the following items: (i) interest expense, (ii) income tax expense, (iii) amortization of acquired intangible assets, (iv) losses on extinguishment of debt, (v) charges associated with the impairment of certain assets, (vi) gain on sale of business, and (vii) certain other adjustments. This measurement is our segment reporting profitability measure under GAAP. Adjusted Operating Income margin is Adjusted Operating Income divided by net sales as determined under GAAP. We believe that these measurements are useful to investors as ways to analyze the underlying trends in our business consistently across the periods presented. These

measurements are used by our management for the same reason. A reconciliation of net income or loss and net income or loss margin, the most directly comparable GAAP financial measures, to Adjusted Operating Income and Adjusted Operating Income margin, respectively, are included in the section entitled “Reconciliations of non-GAAP measures”;

- **Cash flows from operating activities**, which we discuss in the section entitled “Liquidity and capital resources—Historical cash flows”;
- **Free cash flow**, which is a non-GAAP measure, is equal to our cash flows from operating activities, less capital expenditures, plus direct transaction costs and income taxes paid related to acquisitions and divestitures (as applicable) in the period. We believe that this measurement is useful to investors as it provides a view on the Company’s ability to generate cash for use in financing or investing activities. This measurement is used by management for the same reason. A reconciliation of cash flows from operating activities, the most directly comparable GAAP financial measure, to free cash flow, is included in the section entitled “Liquidity and capital resources—Historical cash flows.”

## Results of operations

We present results of operations in the same way that we manage our business, evaluate our performance and allocate our resources. We also provide discussion of net sales and Adjusted Operating Income by segment: Laboratory Solutions and Bioscience Production. Corporate costs are managed on a standalone basis, certain of which are allocated to our reportable segments.

### Years ended December 31, 2025 and 2024

#### Executive summary

<i>(dollars in millions)</i>	Year ended December 31,		Change
	2025	2024	
Net sales	\$ 6,552.2	\$ 6,783.6	\$ (231.4)
Gross margin	32.7 %	33.6 %	(90) bps
Operating (loss) income	\$ (246.2)	\$ 1,084.8	\$ (1,331.0)
Operating (loss) income margin	(3.8)%	16.0 %	(1,980) bps
Net (loss) income	\$ (530.2)	\$ 711.5	\$ (1,241.7)
Net (loss) income margin	(8.1)%	10.5 %	(1,860) bps
Adjusted EBITDA	\$ 1,069.4	\$ 1,198.8	\$ (129.4)
Adjusted EBITDA margin	16.3 %	17.7 %	(140) bps
Adjusted Operating Income	\$ 957.8	\$ 1,089.8	\$ (132.0)
Adjusted Operating Income margin	14.6 %	16.1 %	(150) bps

For the year ended December 31, 2025, net sales declined primarily due to the divestiture of our Clinical Services business within our Advanced Lab Services business and reduced customer demand in the Total Science Solutions business, both of which impacted the Laboratory Solutions segment. Gross margin and gross profit decreased, reflecting lower sales volume, inflationary pressures, the divestiture of our Clinical Services business and higher freight costs. Operating income declined largely due to a non-cash goodwill impairment charge recorded in the Distribution reporting unit in the current year and the absence of the

gain on sale of the Clinical Services business recognized in the prior year. The reduction in gross profit, partially offset by lower SG&A expenses, resulted in contraction of Adjusted EBITDA and Adjusted Operating Income margins.

*Net sales*

(in millions)

	Reconciliation of net sales growth (decline) to organic net sales growth (decline)					
	Year ended December 31,		Net sales growth (decline)	Foreign currency impact	Divestiture impact	Organic net sales growth (decline)
	2025	2024				
Laboratory Solutions	\$ 4,399.7	\$ 4,610.1	\$ (210.4)	\$ 86.0	\$ (147.9)	\$ (148.5)
Bioscience Production	2,152.5	2,173.5	(21.0)	18.7	—	(39.7)
Total	\$ 6,552.2	\$ 6,783.6	\$ (231.4)	\$ 104.7	\$ (147.9)	\$ (188.2)

Net sales decreased \$231.4 million or 3.4%, which included \$104.7 million or 1.6% of favorable foreign currency translation impact and \$147.9 million or 2.2% of impact related to our Clinical Services divestiture. Organic net sales decreased by \$188.2 million or 2.8% which is discussed below.

In the Laboratory Solutions segment, net sales decreased \$210.4 million or 4.6% which included \$86.0 million or 1.8% of favorable foreign currency translation impact and \$147.9 million or 3.2% of impact related to our Clinical Services divestiture. Organic net sales decreased by \$148.5 million or 3.2%. The sales decline was primarily driven by decreased demand for consumables and equipment and instrumentation from our Total Science Solutions business due to the uncertainty around funding and increased competitive intensity.

In the Bioscience Production segment, net sales decreased \$21.0 million or 1.0%, which included \$18.7 million or 0.8% of favorable foreign currency translation impact. Organic net sales decreased \$39.7 million or 1.8%. The sales decrease was primarily driven by lower demand for third party clean room consumables due to reduced usage and decreased volume in our proprietary clinical and industrial chemicals offerings. These decreases were partially offset by increased volume of our formulated offerings to customers in the semiconductor industry.

*Gross margin*

	Year ended December 31,		Change
	2025	2024	
Gross margin	32.7 %	33.6 %	(90) bps

Gross margin decreased 90 basis points primarily due to inflationary pressures, higher freight costs, unfavorable manufacturing variances, unfavorable product mix and the divestiture of our Clinical Services business, partially offset by lower inventory reserves.

*Operating (loss) income*

<i>(in millions)</i>	<b>Year ended December 31,</b>		<b>Change</b>
	<b>2025</b>	<b>2024</b>	
Gross profit	\$ 2,139.4	\$ 2,279.3	\$ (139.9)
Operating expenses (excluding impairment charges & gain on sale of business)	1,595.5	1,641.1	(45.6)
Impairment charges	785.0	—	785.0
Gain on sale of business	5.1	(446.6)	451.7
Operating (loss) income	<u>\$ (246.2)</u>	<u>\$ 1,084.8</u>	<u>\$ (1,331.0)</u>

Operating (loss) income decreased primarily due to a non-cash impairment charge recorded in our Distribution reporting unit, the absence of the gain on sale of our Clinical Services business recognized in the prior year, and lower gross profit, as previously discussed. These impacts were partially offset by a reduction in SG&A expenses. The decrease in SG&A expenses resulted from lower restructuring and severance charges, reduced annual incentive compensation expense, savings from our cost transformation initiative and the divestiture of our Clinical Services business, partially offset by inflationary pressures.

*Net (loss) income*

<i>(in millions)</i>	<b>Year ended December 31,</b>		<b>Change</b>
	<b>2025</b>	<b>2024</b>	
Operating (loss) income	\$ (246.2)	\$ 1,084.8	\$ (1,331.0)
Interest expense, net	(169.8)	(218.8)	49.0
Loss on extinguishment of debt	(4.6)	(10.9)	6.3
Other (expense) income, net	(20.7)	(1.2)	(19.5)
Income tax expense	(88.9)	(142.4)	53.5
Net (loss) income	<u>\$ (530.2)</u>	<u>\$ 711.5</u>	<u>\$ (1,241.7)</u>

Net (loss) income decreased primarily due to lower operating income, as previously discussed, and pension termination charges, partially offset by lower interest expense resulting from debt repayments made over the last twelve months and lower income tax expense driven by reduced income before income taxes.

*Adjusted EBITDA and Adjusted EBITDA margin*

For reconciliations of Adjusted EBITDA and Adjusted EBITDA margin to net (loss) income and net (loss) income margin, respectively, the most directly comparable measures under GAAP, see “Reconciliations of non-GAAP financial measures.”

<i>(dollars in millions)</i>	<b>Year ended December 31,</b>		<b>Change</b>
	<b>2025</b>	<b>2024</b>	
Adjusted EBITDA	\$ 1,069.4	\$ 1,198.8	\$ (129.4)
Adjusted EBITDA margin	16.3 %	17.7 %	(140) bps

Adjusted EBITDA decreased \$129.4 million or 10.8%, which included a favorable foreign currency translation impact of \$16.4 million or 1.3%. The remaining decline of \$145.8 million or 12.1% was primarily driven by the divestiture of our Clinical Services business and lower gross profit, as previously discussed, partially offset by savings from our cost transformation initiative and lower annual incentive compensation expense.

*Adjusted Operating Income and Adjusted Operating Income margin*

For reconciliations of Adjusted Operating Income and Adjusted Operating Income margin to net (loss) income and net (loss) income margin, respectively, the most directly comparable measures under GAAP, see “Reconciliations of non-GAAP financial measures.”

<i>(dollars in millions)</i>	<b>Year ended December 31,</b>		<b>Change</b>
	<b>2025</b>	<b>2024</b>	
<b>Adjusted Operating Income:</b>			
Laboratory Solutions	\$ 510.4	\$ 598.0	\$ (87.6)
Bioscience Production	517.8	558.2	(40.4)
Corporate	(70.4)	(66.4)	(4.0)
<b>Total</b>	<b>\$ 957.8</b>	<b>\$ 1,089.8</b>	<b>\$ (132.0)</b>
<b>Adjusted Operating Income margin</b>	<b>14.6 %</b>	<b>16.1 %</b>	<b>(150) bps</b>

Adjusted Operating Income decreased \$132.0 million or 12.1%, which included a favorable foreign currency translation impact of \$13.5 million or 1.2%. The remaining decline of \$145.5 million or 13.3% is discussed below.

In the Laboratory Solutions segment, Adjusted Operating Income declined \$87.6 million or 14.6%, or 16.2% when adjusted for favorable foreign currency translation impact. The decrease was primarily driven by the divestiture of our Clinical Services business, lower sales volume and inflationary pressures, partially offset by savings from our cost transformation initiative and lower annual incentive compensation expense.

In the Bioscience Production segment, Adjusted Operating Income declined \$40.4 million or 7.2% or 8.0% when adjusted for favorable foreign currency translation impact. The decrease was primarily driven by lower sales volume, unfavorable manufacturing variances and higher freight costs, partially offset by commercial excellence, savings from our cost transformation initiative and lower annual incentive compensation expense.

In Corporate, Adjusted Operating Income decreased \$4.0 million due to various immaterial factors.

***Year ended December 31, 2023***

A discussion and analysis covering the year ended December 31, 2023 is included in Item 7 of our 2024 10-K.

## Reconciliations of non-GAAP measures

The following table presents the reconciliation of net (loss) income and net (loss) income margin to Adjusted EBITDA and Adjusted EBITDA margin, respectively:

<i>(dollars in millions, % based on net sales)</i>	Year ended December 31,			
	2025		2024	
	\$	%	\$	%
Net (loss) income	\$ (530.2)	(8.1)%	\$ 711.5	10.5 %
Interest expense, net	169.8	2.5 %	218.8	3.2 %
Income tax expense	88.9	1.3 %	142.4	2.1 %
Depreciation and amortization	410.2	6.3 %	405.5	6.0 %
Loss on extinguishment of debt	4.6	0.1 %	10.9	0.2 %
Restructuring and severance charges <sup>1</sup>	29.8	0.5 %	82.8	1.2 %
Transformation expenses <sup>2</sup>	61.7	1.0 %	58.9	0.9 %
Reserve for certain legal matters, net <sup>3</sup>	7.3	0.1 %	9.2	0.2 %
Other <sup>4</sup>	20.9	0.3 %	(3.9)	(0.2)%
Impairment charges <sup>5</sup>	785.0	12.0 %	—	— %
Gain on sale of business <sup>6</sup>	5.1	0.1 %	(446.6)	(6.6)%
Pension termination charges <sup>7</sup>	16.3	0.2 %	9.3	0.2 %
Adjusted EBITDA	<u>\$ 1,069.4</u>	<u>16.3 %</u>	<u>\$ 1,198.8</u>	<u>17.7 %</u>

- Reflects the incremental expenses incurred in the period related to restructuring initiatives to increase profitability and productivity. Costs included in this caption are specific to employee severance, site-related exit costs, and contract termination costs. These expenses recognized in 2024 & 2025 represent costs incurred to achieve the Company's publicly-announced cost transformation initiative.
- Represents incremental expenses directly associated with the Company's publicly-announced cost transformation initiative, primarily related to the cost of external advisors.
- Represents charges and legal costs, net of recoveries, in connection with certain litigation and other contingencies that are unrelated to our core operations and not reflective of on-going business and operating results.
- Represents net foreign currency (gain) loss from financing activities, other stock-based compensation expense (benefit), \$6.7 million of severance and transition costs associated with the replacement of our Chief Executive Officer in 2025, and other costs.
- As described in notes 10 and 11 to our consolidated financial statements beginning on F-1 of this report.
- The amount reported in 2024 reflects the gain on the sale of our Clinical Services business. The amount reported in 2025 reflects post-closing purchase price adjustments related to that sale. The sale of the Clinical Services business is further described in note 4 to our consolidated financial statements beginning on page F-1 of this report.
- As described in note 17 to our consolidated financial statements beginning on F-1 of this report.

The following table presents the reconciliation of net (loss) income and net (loss) income margin to Adjusted Operating Income and Adjusted Operating Income margin, respectively:

<i>(dollars in millions, % based on net sales)</i>	<b>Year ended December 31,</b>			
	<b>2025</b>		<b>2024</b>	
	<b>\$</b>	<b>%</b>	<b>\$</b>	<b>%</b>
Net (loss) income	\$ (530.2)	(8.1)%	\$ 711.5	10.5 %
Interest expense, net	169.8	2.5 %	218.8	3.2 %
Income tax expense	88.9	1.3 %	142.4	2.1 %
Loss on extinguishment of debt	4.6	0.1 %	10.9	0.2 %
Other (expense) income, net	20.7	0.4 %	1.2	— %
Operating (loss) income	(246.2)	(3.8)%	1,084.8	16.0 %
Amortization	301.1	4.6 %	299.8	4.4 %
Restructuring and severance charges <sup>1</sup>	29.8	0.5 %	82.8	1.2 %
Transformation expenses <sup>2</sup>	61.7	1.0 %	58.9	0.9 %
Reserve for certain legal matters, net <sup>3</sup>	7.3	0.1 %	9.2	0.2 %
Other <sup>4</sup>	14.0	0.1 %	0.9	— %
Impairment charges <sup>5</sup>	785.0	12.0 %	—	— %
Gain on sale of business <sup>6</sup>	5.1	0.1 %	(446.6)	(6.6)%
Adjusted Operating Income	<u>\$ 957.8</u>	<u>14.6 %</u>	<u>\$ 1,089.8</u>	<u>16.1 %</u>

1. Reflects the incremental expenses incurred in the period related to restructuring initiatives to increase profitability and productivity. Costs included in this caption are specific to employee severance, site-related exit costs, and contract termination costs. These expenses recognized in 2024 & 2025 represent costs incurred to achieve the Company's publicly-announced cost transformation initiative.
2. Represents incremental expenses directly associated with the Company's publicly-announced cost transformation initiative, primarily related to the cost of external advisors.
3. Represents charges and legal costs, net of recoveries, in connection with certain litigation and other contingencies that are unrelated to our core operations and not reflective of on-going business and operating results.
4. Represents other stock-based compensation expense (benefit), \$6.7 million of severance and transition costs associated with the replacement of our Chief Executive Officer in 2025, and other costs.
5. As described in notes 10 and 11 to our consolidated financial statements beginning on F-1 of this report.
6. The amount reported in 2024 reflects the gain on the sale of our Clinical Services business. The amount reported in 2025 reflects post-closing purchase price adjustments related to that sale. The sale of the Clinical Services business is further described in note 4 to our consolidated financial statements beginning on page F-1 of this report.

### **Liquidity and capital resources**

We fund short-term cash requirements primarily from operating cash flows and credit facilities. The majority of our long-term financing is from indebtedness.

Our most significant contractual obligations are scheduled principal and interest payments for indebtedness. We also have obligations to make payments under operating leases, to purchase certain products and services and to fund defined benefit plan obligations, primarily outside of the United States.

In addition to contractual obligations, we use cash to fund capital expenditures and taxes. Changes in working capital may be a source or a use of cash depending on our operations during the period. We expect to fund our short-term and long-term capital needs with cash generated by operations and availability under our credit facilities. Although we believe that these sources will provide sufficient liquidity for us to meet our long-term capital needs, our ability to fund these needs will depend to a significant extent on our future financial performance, which will be subject in part to general economic, competitive, financial, regulatory and other factors that are beyond our control.

We believe that cash generated by operations, together with available liquidity under our credit facilities, will be adequate to meet our current and expected needs for cash prior to the maturity of our debt, although no assurance can be given in this regard.

In October 2025, our Board of Directors authorized the repurchase of up to \$500.0 million of our common stock. Repurchases may be funded through available cash, borrowings under existing credit facilities, or other financing arrangements. The program may be modified, suspended, or terminated at any time.

In November 2025, we repurchased \$75.0 million of our common stock. As of December 31, 2025, \$425.0 million remained available for repurchase under the program. Refer to Note 15 to the Consolidated Financial Statements included in this Annual Report for additional discussion of our common stock repurchase program.

### ***Liquidity***

The following table presents our primary sources of liquidity:

*(in millions)*

	<b>December 31, 2025</b>
Unused availability under our revolving credit facility:	
Capacity .....	\$ 1,400.0
Undrawn letters of credit outstanding .....	(19.5)
Unused availability .....	\$ 1,380.5
Cash and cash equivalents .....	365.4
Total liquidity .....	<u>\$ 1,745.9</u>

At December 31, 2025, \$243.1 million or 67% of our cash and cash equivalents was held by our non-U.S. subsidiaries and may be subject to certain taxes upon repatriation, primarily where foreign withholding taxes apply. We ordinarily generate significant cash flows in the U.S. and deploy U.S. cash flows promptly toward debt principal repayment. Our U.S. operations also benefit from substantial liquidity available under our credit facilities, which support our day-to-day operating cash needs.

## Historical cash flows

The following table presents a summary of cash provided by (used in) various activities:

<i>(in millions)</i>	Year ended December 31,		Change
	2025	2024	
<b>Operating activities:</b>			
Net (loss) income	\$ (530.2)	\$ 711.5	\$ (1,241.7)
Non-cash items <sup>1</sup>	1,354.2	81.9	1,272.3
Working capital changes <sup>2</sup>	(53.0)	89.9	(142.9)
All other	(147.2)	(42.5)	(104.7)
Total	<u>\$ 623.8</u>	<u>\$ 840.8</u>	<u>\$ (217.0)</u>
<b>Investing activities:</b>			
Capital expenditures	\$ (128.8)	\$ (148.8)	\$ 20.0
Cash proceeds from sale of disposal group, net	—	585.2	(585.2)
Other	(1.7)	2.5	(4.2)
Total	<u>\$ (130.5)</u>	<u>\$ 438.9</u>	<u>\$ (569.4)</u>
Financing activities	(409.4)	(1,281.2)	871.8

1. Consists of non-cash charges including depreciation and amortization, impairment charges, stock-based compensation expense, deferred income tax expense, non-cash restructuring charges, pension termination charges, gain on sale of business and others.
2. Includes changes to our accounts receivable, inventory, contract assets and accounts payable.

Cash flows from operating activities provided \$217.0 million less cash in 2025. The change was primarily due to higher net working capital requirements, increased customer rebate payments and higher incentive compensation payments made in 2025 related to fiscal year 2024.

Investing activities provided \$569.4 million less cash in 2025, primarily due to the absence of proceeds from the sale of our Clinical Services business, which were received in the prior year.

Financing activities provided \$871.8 million more cash in 2025, primarily due to lower net debt repayments during the year, partially offset by payments for the repurchase of common stock in 2025 and a decrease in proceeds from stock option exercises compared to the prior year.

## ***Free cash flow***

<i>(in millions)</i>	<b>Year ended December 31,</b>		<b>Change</b>
	<b>2025</b>	<b>2024</b>	
Net cash provided by operating activities	\$ 623.8	\$ 840.8	\$ (217.0)
Capital expenditures	(128.8)	(148.8)	20.0
Divestiture-related transaction expenses and taxes paid	1.4	76.3	(74.9)
Free cash flow	<u>\$ 496.4</u>	<u>\$ 768.3</u>	<u>\$ (271.9)</u>

Free cash flow was \$271.9 million lower in 2025 driven by changes in cash flows from operating activities noted above, partially offset by a decrease in capital expenditures.

A discussion and analysis of historical cash flows covering the year ended December 31, 2023 is included in Item 7 of the 2024 Form 10-K.

## ***Indebtedness***

A significant portion of our long-term financing is from indebtedness. The purpose of this section is to disclose how certain features of our indebtedness influence our liquidity and capital resources. Additional detail about the terms of our indebtedness may be found in note 14 to our consolidated financial statements beginning on page F-1 of this report.

*Our credit facilities provide us access to up to \$1,400.0 million of borrowing capacity.*

We have entered into a revolving credit facility that provide us access to cash to fund short-term business needs. See the section entitled “Liquidity” for additional information.

*Our indebtedness restricts us from paying dividends to common stockholders.*

Certain of the debt agreements entered into by our wholly-owned subsidiary, Avantor Funding, Inc., prevent it from paying dividends or making other payments to Avantor, Inc., subject to limited exceptions. At December 31, 2025 and 2024, substantially all of Avantor, Inc.’s net assets were subject to those restrictions.

*Our senior secured credit facilities require or may require us to make certain principal repayments prior to maturity*

We are required to make quarterly payments on our senior secured credit facilities, with the balance due on the maturity date. We have generated sufficient cash flows to make all required historical payments, and we expect that our cash flows will continue to be sufficient to make future payments.

To the extent our net leverage ratios, as defined in our credit agreement, reach certain levels, we are required to make additional prepayments if: (i) we generate excess cash flows, as defined in our credit agreement, at specified percentages that decline if certain net leverage ratios are achieved; or (ii) we receive cash proceeds from certain types of asset sales or debt issuances. We are required to make a prepayment of 50% of our excess cash flows if our first lien net leverage ratio, as defined in our credit agreement, exceeds 4.50:1.00, a prepayment of 25% of our excess cash flows if our first lien net leverage ratio is less than or equal to 4.50:1.00 but greater than 3.75:1.00, and no prepayment if our first lien net

leverage ratio is less than or equal to 3.75:1.00. As our first lien net leverage ratio was below 3.75:1.00 at December 31, 2025, no additional prepayments were required and no such prepayments have become due since the inception of the credit facilities.

*We are subject to certain financial covenants that, if not met, could put us in default of our debt agreements*

The revolving credit facility and our senior secured credit facilities contain certain customary covenants, including financial covenants. We may not have total borrowings and total interest expense in excess of a pro forma net leverage ratio and pro forma consolidated interest coverage ratio, as defined, respectively. At December 31, 2025, our net leverage and consolidated interest coverage ratio has been within the covenant requirement.

### **Contractual obligations**

The following table presents our contractual obligations at December 31, 2025:

<i>(in millions)</i>	<b>Payments due by period</b>		
	<b>Total</b>	<b>Short-Term</b>	<b>Long-Term</b>
<b>Debt:</b>			
Principal <sup>(1)(2)</sup> .....	\$ 3,967.9	\$ 30.8	\$ 3,937.1
Interest <sup>(1)</sup> .....	602.9	166.7	436.2
Operating leases .....	245.7	43.0	202.7
Purchase obligations <sup>(3)</sup> .....	223.4	113.0	110.4
<b>Other liabilities:</b>			
Underfunded defined benefit plans <sup>(4)</sup> .....	94.2	6.7	87.5
Other .....	4.7	1.2	3.5
<b>Total</b> .....	<b>\$ 5,138.8</b>	<b>\$ 361.4</b>	<b>\$ 4,777.4</b>

- (1) Includes finance lease liabilities. To calculate payments for principal and interest, we assumed that variable interest rates, foreign currency exchange rates and outstanding borrowings under credit facilities were unchanged from December 31, 2025 through maturity. For the variable interest rates and principal amounts used, see note 14 to our consolidated financial statements beginning on page F-1 of this report.
- (2) Our senior secured credit facilities would require us to accelerate our principal repayments should we generate excess cash flows, as defined, in future periods.
- (3) Purchase obligations for certain products and services are made in the normal course of business to meet operating needs.
- (4) Represents our obligation to fund defined benefit plans with obligations in excess of plan assets. The total obligation is equal to the aggregate excess of the discounted benefit obligation over the fair value of plan assets for all underfunded plans. The payments due in less than one year are estimated using actuarial methods. The payments due for all other years are estimated by distributing the remaining funding status to future periods in the same way as benefit payments are expected to be made by the plans following actuarial methods.

### **Critical accounting policies and estimates**

The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported throughout the financial statements. Those estimates and

assumptions are based on our best estimates and judgment. We evaluate our estimates and assumptions on an ongoing basis using historical experience and known facts and circumstances. We adjust our estimates and assumptions when we believe the facts and circumstances warrant an adjustment. As future events and their effects cannot be determined with precision, actual results could differ significantly from those estimates.

We consider the policies and estimates discussed below to be critical to an understanding of our financial statements because their application places the most significant demands on our judgment. Specific risks for these critical accounting policies are described in the following sections. For all of these policies, we caution that future events rarely develop exactly as forecasted, and such estimates naturally require adjustment.

Our discussion of critical accounting policies and estimates is intended to supplement, not duplicate, our summary of significant accounting policies so that readers will have greater insight into the uncertainties involved in these areas. For a summary of all of our significant accounting policies, see note 2 to our consolidated financial statements beginning on page F-1 of this report.

### ***Testing goodwill and other intangible assets for impairment***

We carry significant amounts of goodwill and other intangible assets on our consolidated balance sheet. At December 31, 2025, the combined carrying value of goodwill and other intangible assets, net of accumulated amortization and impairment charges, was \$8,180.7 million or 69% of our total assets.

#### *Required annual assessment*

On October 1 of each year, we perform annual impairment testing of our goodwill and indefinite-lived intangible assets, or more frequently if an event or change in circumstance occurs that would require reassessment of the recoverability of those assets. The impairment analysis for goodwill and indefinite-lived intangible assets consists of an optional qualitative test potentially followed by a quantitative analysis. These measurements rely upon significant judgment from management described as follows:

- The qualitative analysis for goodwill and indefinite-lived intangible assets requires us to identify potential factors that may result in an impairment and estimate whether they would warrant performance of a quantitative test;
- The quantitative impairment test requires us to estimate the fair value of our reporting units and indefinite-lived intangible assets. We estimate the fair value of each reporting unit using a weighted average of two valuation methods based on a discounted cash flows method and a guideline public company method. These valuation methods require management to make various assumptions, including, but not limited to, future profitability, cash flows, including revenues, gross margin, SG&A expenses, capital expenditures, and investments in debt free net working capital, current market assumptions for the discount rates, weighting of valuation methods and the selection of comparable publicly traded companies. Variations in any of these assumptions could result in materially different calculations of fair value.

Our estimates are based on historical trends, management's knowledge and experience and overall economic factors, including projections of future earnings potential. Developing future cash flows in applying the income approach requires us to evaluate our intermediate to longer-term strategies, including, but not limited to, estimates about net sales growth, operating margins, capital requirements, inflation and working capital management. The development of appropriate rates to discount the

estimated future cash flows requires the selection of risk premiums, which can materially impact the present value of future cash flows. Selection of an appropriate peer group under the market approach involves judgment, and an alternative selection of guideline companies could yield materially different market multiples. Weighing the different value indications involves judgment about their relative usefulness and comparability to the reporting unit.

As a result of sustained decreases in our publicly quoted share price and market capitalization as well as changes in the operating results of our Distribution reporting unit, we conducted an interim test of our goodwill as of September 30, 2025.

Based on the results of the impairment test, the carrying amount of our Distribution reporting unit exceeded its fair value, resulting in a non-deductible, non-cash goodwill impairment charge of \$785.0 million, which was recorded in the consolidated statement of operations for the three months ended September 30, 2025. We did not identify impairment of any other long-lived assets in this reporting unit. The remaining reporting units tested were not impaired, as their estimated fair values exceeded their respective carrying amounts as of the interim testing date.

Following the impairment charge, the carrying value of the Distribution reporting unit is equal to its estimated fair value. Recognition of additional impairment charges may be required in future periods if market conditions, projected results, or other valuation assumptions deteriorate further.

Since October 1, 2025 is our designated annual impairment testing date, management performed the required procedures to reassess impairment as of that date, including a review of key assumptions, market indicators, and other relevant factors. No conditions were identified that differed materially from those considered in the September 30, 2025 interim analysis. Accordingly, the conclusions reached in that interim test remained appropriate, and no additional impairment was recorded as of October 1, 2025.

#### ***Estimating valuation allowances on deferred tax assets***

We are required to estimate the degree to which tax assets and loss carryforwards will result in a future income tax benefit, based on our expectations of future profitability by tax jurisdiction. We provide a valuation allowance for deferred tax assets that we believe will more likely than not go unutilized. If it becomes more likely than not that a deferred tax asset will be realized, we reverse the related valuation allowance and recognize an income tax benefit for the amount of the reversal. At December 31, 2025, our valuation allowance on deferred tax assets was \$190.1 million, \$132.1 million of which relates to foreign net operating loss carry forwards that are not expected to be realized.

We must make assumptions and judgments to estimate the amount of valuation allowance to be recorded against our deferred tax assets, which take into account current tax laws and estimates of the amount of future taxable income, if any. Changes to any of the assumptions or judgments could cause our actual income tax obligations to differ from our estimates.

#### ***Accounting for uncertain tax positions***

In the ordinary course of business, there is inherent uncertainty in quantifying our income tax positions. We assess income tax positions for all years subject to examination based upon our evaluation of the facts, circumstances and information available at the reporting date. For those tax positions where it is more likely than not that a tax benefit will be sustained, we have recorded an amount having greater than 50% likelihood of being realized upon ultimate settlement with a taxing authority assumed to have full knowledge of all relevant information. For those income tax positions where it is not more likely than not

that a tax benefit will be sustained, no tax benefit has been recognized in the financial statements. Our reserve for uncertain tax positions was \$106.9 million at December 31, 2025, exclusive of penalties and interest. Where applicable, associated interest expense has also been recognized as a component of interest expense.

We operate in numerous countries under many legal forms and, as a result, we are subject to the jurisdiction of numerous domestic and non-U.S. tax authorities, as well as to tax agreements and treaties among these governments. Our tax positions may be scrutinized by local tax authorities upon examination. Determination of taxable income in any jurisdiction requires the interpretation of the related tax laws and regulations, including transfer pricing guidelines, and the use of estimates and assumptions regarding significant future events, such as the amount, timing and character of deductions and the sources and character of income and tax credits. Changes in tax laws, regulations, agreements and treaties, currency exchange restrictions or our level of operations or profitability in each taxing jurisdiction could have an impact upon the amount of current and deferred tax balances and hence our net income.

We file tax returns in each tax jurisdiction that requires us to do so. Should tax return positions not be sustained upon audit, we could be required to record an income tax provision. Should previously unrecognized tax benefits ultimately be sustained, we could be required to record an income tax benefit.

#### ***Calculating expense for long-term compensation arrangements***

Our employees receive various long-term compensation awards, including stock options, RSUs, performance stock units and cash-based awards. We calculate expense for some of those awards using fair value estimates based on unobservable inputs. Additionally, some of those awards contain performance or market conditions. We assess the probability of achieving those performance conditions, and in cases where partial or exceptional performance affects the size of the award, we also estimate the projected achievement level. We determine the fair value of awards with market conditions on their grant date using a Monte Carlo model, which incorporates the probability of achieving the market condition in the awards' fair value. We recognize the expense for such awards ratably over their vesting term.

Expense for stock options without performance or market conditions is determined on the grant date and recognized ratably over their vesting term. We estimate the grant date fair value of stock options using the Black-Scholes model. This model requires us to make various assumptions, with the most significant assumption currently being the volatility of our stock price. Through the year ended December 31, 2024, due to limited trading history, we estimated volatility using a peer group approach. Beginning in 2025, after sufficient trading history became available, we adopted a blended volatility methodology that combines Avantor's historical volatility with that of a peer group to provide a more stable and representative input. This approach is consistent with ASC 718 and SEC guidance for companies with evolving trading history. The fair value of our awards would have differed had we selected different peer companies or used a different technique to estimate volatility. Increasing our expected volatility assumption by 5 percentage points for all stock options at the date of grant would have increased our 2025 stock-based compensation expense by \$0.9 million.

#### ***Estimating the net realizable value of inventories***

We value our inventories at the lower of cost or net realizable value. We regularly review quantities of inventories on hand and compare these amounts to the expected use of each product or product line, which can require us to make significant judgments. If our judgments prove to be incorrect, we may be

required to record a charge to cost of sales to reduce the carrying amount of inventory on hand to net realizable value. As with any significant estimate, we cannot be certain of future events which may cause us to change our judgments.

## **Item 7A. Quantitative and qualitative disclosures about market risk**

### **Foreign currency exchange risk**

Although we report our results and financial condition in U.S. dollars, a significant portion of our operating and financing activities are denominated in foreign currencies, principally the Euro but also many others.

Certain of our U.S. subsidiaries carry Euro-denominated debt. This does not result in any material risks from an earnings perspective because the exposure from these instruments is substantially hedged by offsetting exposures from intercompany borrowing arrangements and from our derivative and hedging instruments. From a cash flow perspective, we have the risk of paying more or less cash for any optional or mandatory repayments of our Euro-denominated debt that may not be offset with equivalent cash repayments of our intercompany borrowings. For example, an optional debt repayment of €100 million on December 31, 2025 and December 31, 2024, with a 10% weakening of the U.S. dollar would have caused us to pay an additional \$11.7 million and \$10.3 million, respectively, to extinguish that debt.

Changes to foreign currency exchange rates could favorably or unfavorably affect the translation of our foreign operating results. For example, during times of a strengthening U.S. dollar, our reported international sales and earnings will be reduced because local currencies will translate into fewer U.S. dollars. For the year ended December 31, 2025, a 10% strengthening of the U.S. dollar compared to all other currencies would have decreased net income by \$0.5 million and decreased Adjusted Operating Income by \$26.2 million. For the year ended December 31, 2024, a 10% strengthening of the U.S. dollar compared to all other currencies would have decreased net income by \$16.2 million and decreased Adjusted Operating Income by \$30.6 million.

### **Interest rate risk**

We carry debt that exposes us to interest rate risk. A portion of our debt consists of variable-rate instruments. We have also issued fixed-rate secured and unsecured notes. None of our other financial instruments are subject to material interest rate risk.

At December 31, 2025, we had borrowings of \$1,114.4 million under our senior secured credit facilities. Borrowings under these facilities bear interest at variable rates based on prevailing EURIBOR and SOFR rates in the financial markets. Changes to those market rates affect both the amount of cash we pay for interest and our reported interest expense. At December 31, 2025, a 100 basis point increase to the applicable variable rates of interest would have increased the amount of interest by \$11.1 million per annum. At December 31, 2024, a 100 basis point increase to the applicable variable rates of interest would have increased the amount of interest by \$5.2 million per annum.

Our senior secured notes and senior unsecured notes bear interest at fixed rates, so their fair value will increase if interest rates fall and decrease if interest rates rise. At December 31, 2025, a 100 basis point decrease in the market rate of interest would have increased their aggregate fair value by \$75.9 million. At December 31, 2024, a 100 basis point decrease in the market rate of interest would have increased their aggregate fair value by \$99.9 million.

**Item 8. Financial statements and supplementary data**

The information required by this item is included at the end of this report beginning on page F-1.

**Item 9. Changes in and disagreements with accountants on accounting and financial disclosure**

None.

**Item 9A. Control and procedures****Management's evaluation of disclosure controls and procedures**

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) as of December 31, 2025. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of December 31, 2025, our disclosure controls and procedures were effective in providing reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized, reported, accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

**Changes in internal control over financial reporting**

There have been no changes to our internal control over financial reporting during the fiscal quarter ended December 31, 2025 that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

**Management's annual report on internal control over financial reporting**

Our management, including our Chief Executive Officer and Chief Financial Officer, is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. Our management conducted an assessment of the effectiveness of our internal control over financial reporting as of December 31, 2025 based on criteria established in *Internal Control - Integrated Framework (2013)* issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on this assessment, our management concluded that, as of December 31, 2025, our internal control over financial reporting was effective.

Deloitte & Touche LLP (PCAOB ID No. 34), an independent registered public accounting firm, which has audited and reported on the consolidated financial statements contained in this Form 10-K, has issued its report on the effectiveness of the Company's internal control over financial reporting which follows this report.

## **REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

To the shareholders and the Board of Directors of Avantor, Inc.

### **Opinion on Internal Control over Financial Reporting**

We have audited the internal control over financial reporting of Avantor, Inc. and subsidiaries (the "Company") as of December 31, 2025, based on criteria established in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2025, based on criteria established in Internal Control — Integrated Framework (2013) issued by COSO.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements as of and for the year ended December 31, 2025, of the Company and our report dated February 11, 2026, expressed an unqualified opinion on those financial statements.

### **Basis for Opinion**

The Company's management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management's Annual Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company's internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

### **Definition and Limitations of Internal Control over Financial Reporting**

A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk

that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ Deloitte & Touche LLP

Philadelphia, Pennsylvania

February 11, 2026

**Item 9B. Other information**

*Securities Trading Plans of Directors and Officers*

No directors or officers, as defined in Rule 16a-1(f) of the Securities Exchange Act of 1934, of the Company adopted or terminated (i) a Rule 10b5-1 trading arrangement, as defined in Item 408(a) under Regulation S-K of the Securities Act of 1933, or (ii) a non-Rule 10b5-1 trading arrangement, as defined in Item 408(c) under Regulation S-K of the Securities Act of 1933, during the three months ended December 31, 2025.

**Item 9C. Disclosure regarding foreign jurisdictions that prevent inspections.**

Not applicable.

**PART III**

See Part I, “Information about our executive officers” for information about our executive officers, which is incorporated by reference herein. The other information required by Part III is incorporated herein by reference to our definitive proxy statement for our 2026 annual meeting of stockholders.

**Item 10. Directors, executive officers and corporate governance**

See Part I, “Information about our executive officers” for information about our executive officers, which is incorporated by reference herein. The other information required by this Item is incorporated herein by reference to the applicable information in our definitive proxy statement for our 2026 annual meeting of stockholders which we intend to file with the SEC no later than 120 days after our 2025 fiscal year end (the “2026 Proxy Statement”).

**Item 11. Executive compensation**

The information required by this Item is incorporated by reference to the applicable information in our 2026 Proxy Statement.

**Item 12. Security ownership of certain beneficial owners and management and related stockholder matters**

The information required by this Item is incorporated by reference to the applicable information in our 2026 Proxy Statement.

### Item 13. Certain relationships and related transactions, and director independence

The information required by this Item is incorporated by reference to the applicable information in our 2026 Proxy Statement.

### Item 14. Principal accountant fees and services

The information required by this Item is incorporated by reference to the applicable information in our 2026 Proxy Statement.

## PART IV

### Item 15. Exhibits and financial statement schedules

The following documents are filed as part of this report.

1. Financial Statements and Schedules. See Index to Consolidated Financial Statements and Schedules on page F-1.
2. Exhibits:

Exhibit no.	Description	Location of exhibits		
		Form	Exhibit no.	Filing date
<a href="#">3.1</a>	<a href="#">Fourth Amended and Restated Certificate of Incorporation, effective May 9, 2024</a>	8-K	3.1	5/10/2024
<a href="#">3.2</a>	<a href="#">Fourth Amended and Restated Bylaws of Avantor, Inc.</a>	8-K	3.1	2/28/2024
<a href="#">4.1</a>	<a href="#">Description of capital stock</a>	10-K	4.1	2/7/2025
<a href="#">4.2</a>	<a href="#">Indenture, dated as of July 17, 2020, among Avantor Funding, Inc., the guarantors party thereto and The Bank of New York Mellon Trust Company, N.A., as Trustee.</a>	8-K	4.1	7/17/2020
<a href="#">4.3</a>	<a href="#">Indenture, dated as of November 6, 2020, among Avantor Funding, Inc., the guarantors party thereto and The Bank of New York Mellon Trust Company, N.A., as Trustee and Notes Collateral Agent.</a>	8-K	4.1	11/6/2020
<a href="#">4.4</a>	<a href="#">Indenture, dated as of October 26, 2021, among Avantor Funding, Inc., the guarantors party thereto and The Bank of New York Mellon Trust Company, N.A., as Trustee.</a>	8-K	4.1	10/26/2021
<a href="#">10.1</a>	<a href="#">Credit Agreement, dated as of November 21, 2017, by and among Vail Holdco Sub LLC, Avantor Funding, Inc. (f/k/a Avantor, Inc.), the guarantors party thereto, Goldman Sachs Bank USA and the other lenders, L/C issuers and parties thereto.</a>	S-1/A	10.1	4/10/2019

<b>Exhibit no.</b>	<b>Description</b>	<b>Location of exhibits</b>		
		<b>Form</b>	<b>Exhibit no.</b>	<b>Filing date</b>
<u>10.2</u>	<u>Amendment No. 1, dated as of November 27, 2018, to the Credit Agreement, dated as of November 21, 2017, among Vail Holdco Sub LLC, Avantor Funding, Inc., the guarantors party thereto, Goldman Sachs Bank USA, as administrative agent and collateral, Swing Line Lender and an L/C issuer, the lenders party thereto and Goldman Sachs Bank USA, as the Additional Euro Term Lender and the Additional Dollar Term Lender.</u>	S-1/A	10.2	4/10/2019
<u>10.3</u>	<u>Amendment No. 2, dated as of June 18, 2019, to the Credit Agreement, dated as of November 21, 2017, among Vail Holdco Sub LLC, Avantor Funding, Inc., each of the Guarantors, each of the lenders from time to time party thereto and Goldman Sachs Bank USA, as administrative agent and collateral, Swing Line Lender and an L/C Issuer, the lenders party thereto and Goldman Sachs Lending Partners LLC, as the Additional Initial B-2 Euro Term Lender and the Additional Initial B-2 Dollar Term Lender.</u>	8-K	10.1	6/18/2019
<u>10.4</u>	<u>Amendment No. 3, dated as of January 24, 2020, to the Credit Agreement, dated as of November 21, 2017, among Vail Holdco Sub LLC, Avantor Funding, Inc., each of the Guarantors, each of the lenders from time to time party thereto and Goldman Sachs Bank USA, as administrative agent and collateral agent, Swing Line Lender and an L/C Issuer, the lenders party thereto and Goldman Sachs Lending Partners LLC, as the Additional Initial B-3 Euro Term Lender and the Additional Initial B-3 Dollar Term Lender.</u>	8-K	10.1	1/27/2020
<u>10.5</u>	<u>Amendment No. 4, dated as of July 14, 2020, to the Credit Agreement, dated as of November 21, 2017, among Vail Holdco Sub LLC, Avantor Funding, Inc., each of the Guarantors, each of the lenders from time to time party thereto and Goldman Sachs Bank USA, as administrative agent and collateral agent, Swing Line Lender and an L/C Issuer.</u>	8-K	10.1	7/14/2020
<u>10.6</u>	<u>Amendment No. 5, dated as of November 6, 2020, to the Credit Agreement, dated as of November 21, 2017, among Vail Holdco Sub LLC, Avantor Funding, Inc., each of the Guarantors, each of the lenders from time to time party thereto and Goldman Sachs Bank USA, as administrative agent and collateral agent, the lenders party thereto and Goldman Sachs Lending Partners LLC, as Swing Line Lender, an L/C Issuer and the New Term Lender</u>	8-K	10.1	11/6/2020

<u>Exhibit no.</u>	<u>Description</u>	<u>Location of exhibits</u>		
		<u>Form</u>	<u>Exhibit no.</u>	<u>Filing date</u>
<u>10.7</u>	<u>Amendment No. 6, dated as of June 10, 2021, to the Credit Agreement, dated as of November 21, 2017, among Vail Holdco Sub LLC, Avantor Funding, Inc., each of the Guarantors, each of the lenders from time to time party thereto and Goldman Sachs Bank USA, as administrative agent and collateral agent, Goldman Sachs Lending Partners LLC, as Swing Line Lender and an L/C Issuer, the lenders party thereto and Citibank, N.A., as the New Term Lender</u>	8-K	10.1	6/14/2021
<u>10.8</u>	<u>Amendment No. 7, dated as of July 7, 2021, to the Credit Agreement, dated as of November 21, 2017, among Vail Holdco Sub LLC, Avantor Funding, Inc., each of the Guarantors, each of the lenders from time to time party thereto and Goldman Sachs Bank USA, as administrative agent and collateral agent, Goldman Sachs Lending Partners LLC, as Swing Line Lender and an L/C Issuer, the lenders party thereto and Bank of America, N.A., as the Additional Initial B-4 Dollar Term Lender and as the Additional Incremental B-5 Dollar Term Lender</u>	8-K	10.1	7/9/2021
<u>10.9</u>	<u>Amendment No. 8, dated as of November 1, 2021 to the Credit Agreement, dated as of November 21, 2017, among Vail Holdco Sub LLC, Avantor Funding, Inc., each of the Guarantors, each of the lenders from time to time party thereto and Goldman Sachs Bank USA, as administrative agent and collateral agent, and Goldman Sachs Bank USA, as the 2021 Incremental B-5 Dollar Term</u>	8-K	10.1	11/2/2021
<u>10.10</u>	<u>Amendment No. 9, dated as of April 7, 2022, to the Credit Agreement, dated as of November 21, 2017, between Avantor Funding, Inc., and Goldman Sachs Bank USA, as administrative agent and collateral agent for the lenders.</u>	10-Q	10.1	7/29/2022
<u>10.11</u>	<u>Amendment No. 10, dated as of March 17, 2023, to the Credit Agreement, dated as of November 21, 2017, among Avantor Funding, Inc., Goldman Sachs Bank USA, as administrative agent and collateral agent for the lenders and the Revolving Credit Lenders.</u>	10-Q	10.1	4/28/2023
<u>10.12</u>	<u>Amendment No. 11, dated as of June 29, 2023, to the Credit Agreement, dated as of November 21, 2017, among Vail Holdco Sub, LLC, Avantor Funding, Inc., each of the Guarantors, each of the lenders from time to time party thereto and Goldman Sachs Bank USA, as administrative agent and collateral agent, Swing Line Lender and an L/C Issuer</u>	8-K	10.1	7/5/2023

<b>Exhibit no.</b>	<b>Description</b>	<b>Location of exhibits</b>		
		<b>Form</b>	<b>Exhibit no.</b>	<b>Filing date</b>
<u>10.13</u>	<u>Amendment No. 12, dated as of April 2, 2024, to the Credit Agreement, dated as of November 21, 2017 among Vail Holdco Sub LLC, Avantor Funding, Inc., each of the guarantors, Goldman Sachs Bank USA, as administrative agent and collateral agent, the Swing Line Lender, a L/C issuer and Goldman Sachs Bank USA, as the Additional Incremental B-6 Dollar Term Lender (as defined in the Credit Agreement Amendment) and the other lenders party thereto.</u>	8-K	10.1	4/5/2024
<u>10.14</u>	<u>Amendment No. 13, dated as of July 31, 2025, to the Credit Agreement, dated as of November 21, 2017 among Vail Holdco Sub LLC, Avantor Funding, Inc., each of the guarantors, Goldman Sachs Bank USA, as administrative agent and collateral agent, the Swing Line Lender, a L/C issuer and the other lenders and L/C issuers party thereto.</u>	*		
<u>10.15</u>	<u>Amendment No. 14, dated as of October 9, 2025, to the Credit Agreement, dated as of November 21, 2017 among Vail Holdco Sub LLC, Avantor Funding, Inc., each of the guarantors, Goldman Sachs Bank USA, as administrative agent and collateral agent, the Swing Line Lender, a L/C issuer and the other lenders and L/C issuers party thereto.</u>	8-K	4.1	10/14/2025
<u>10.16</u>	<u>Security Agreement, dated as of November 21, 2017, among the grantors identified therein and Goldman Sachs Bank USA, as agent.</u>	S-1/A	10.3	4/10/2019
<u>10.17</u>	<u>First Lien Intercreditor Agreement, dated as of November 21, 2017, by and among Avantor Funding, Inc. (f/k/a Avantor, Inc.), Vail Holdco Sub LLC, the other grantors party thereto, Goldman Sachs Bank USA, as collateral agent for the credit agreement secured parties, the Bank of New York Mellon Trust Company, N.A., as collateral agent for the indenture secured parties and each additional agent party from time to time thereto.</u>	S-1/A	10.4	4/10/2019
<u>10.18</u> <sup>^</sup>	<u>Avantor Funding, Inc. (f/k/a Avantor, Inc.) Equity Incentive Plan (as amended through September 28, 2016).</u>	S-1/A	10.12	4/5/2019
<u>10.19</u> <sup>^</sup>	<u>Form of Nonqualified Stock Option Agreement under the Avantor Funding, Inc. Equity Incentive Plan.</u>	S-1/A	10.13	4/25/2019
<u>10.20</u> <sup>^</sup>	<u>Avantor, Inc. (f/k/a Vail Holdco Corp) Equity Incentive Plan.</u>	S-1/A	10.14	4/5/2019
<u>10.21</u> <sup>^</sup>	<u>Form of Nonqualified Stock Option Agreement under the Avantor, Inc. (f/k/a Vail Holdco Corp) Equity Incentive Plan.</u>	S-1/A	10.15	4/25/2019

Exhibit no.	Description	Location of exhibits		
		Form	Exhibit no.	Filing date
<a href="#"><u>10.22</u></a> <sup>^</sup>	<a href="#"><u>Avantor, Inc. 2019 Equity Incentive Plan</u></a>	8-K	10.2	5/21/2019
<a href="#"><u>10.23</u></a> <sup>^</sup>	<a href="#"><u>Form of Option Grant Notice under the Avantor, Inc. 2019 Equity Incentive Plan.</u></a>	*		
<a href="#"><u>10.24</u></a> <sup>^</sup>	<a href="#"><u>Form of Performance Stock Unit Grant Notice under the Avantor, Inc. 2019 Equity Incentive Plan (Employees)</u></a>	*		
<a href="#"><u>10.25</u></a> <sup>^</sup>	<a href="#"><u>Form of Restricted Stock Unit Grant Notice under the Avantor, Inc. 2019 Equity Incentive Plan (Employees).</u></a>	*		
<a href="#"><u>10.26</u></a> <sup>^</sup>	<a href="#"><u>Form of Restricted Stock Unit Grant Notice under the Avantor, Inc. 2019 Equity Incentive Plan (Non-Employee Directors).</u></a>	S-1/A	10.27	4/25/2019
<a href="#"><u>10.27</u></a> <sup>^</sup>	<a href="#"><u>Avantor, Inc. 2019 Employee Stock Purchase Plan</u></a>	8-K	10.3	5/21/2019
<a href="#"><u>10.28</u></a> <sup>^</sup>	<a href="#"><u>Amendment No. 1 to the Avantor, Inc. 2019 Employee Stock Purchase Plan</u></a>	S-8	4.4	11/14/2019
<a href="#"><u>10.29</u></a> <sup>^</sup>	<a href="#"><u>Amendment No.2 to the Avantor, Inc. 2019 Employee Stock Purchase Plan</u></a>	10-Q	10.1	10/28/2022
<a href="#"><u>10.30</u></a> <sup>^</sup>	<a href="#"><u>Amendment No.3 to the Avantor, Inc. 2019 Employee Stock Purchase Plan</u></a>	10-K	10.33	2/14/2024
<a href="#"><u>10.31</u></a> <sup>^</sup>	<a href="#"><u>Avantor, Inc. Executive Severance and Change in Control Plan</u></a>	10-Q	10.2	8/1/2025
<a href="#"><u>10.32</u></a> <sup>^</sup>	<a href="#"><u>Amended and Restated Employment Agreement, dated April 10, 2019, between Michael Stubblefield and Avantor, Inc. (f/k/a Vail Holdco Corp)</u></a>	S-1/A	10.16	4/25/2019
<a href="#"><u>10.33</u></a> <sup>^</sup>	<a href="#"><u>Transition Agreement, dated April 25, 2025 between Michael Stubblefield and Avantor, Inc.</u></a>	10-Q	10.1	8/1/2025
<a href="#"><u>10.34</u></a> <sup>^</sup>	<a href="#"><u>Contract of Employment, issued on July 11, 2025, between the Company and Emmanuel Ligner</u></a>	10-Q	10.1	10/29/2025
<a href="#"><u>10.35</u></a> <sup>^</sup>	<a href="#"><u>Offer Letter, dated July 12, 2023 between R. Brent Jones and VWR Management Services, LLC</u></a>	8-K	10.1	7/13/2023
<a href="#"><u>10.36</u></a> <sup>^</sup>	<a href="#"><u>Employment Letter Agreement, dated May 19, 2023 between Claudius Sokenu and VWR Management</u></a>	10-Q	10.1	4/25/2025
<a href="#"><u>10.37</u></a> <sup>^</sup>	<a href="#"><u>Employment Letter Agreement, dated July 19, 2023, between Benoit Gourdiere and VWR Management Services, LLC</u></a>	*		
<a href="#"><u>10.38</u></a> <sup>^</sup>	<a href="#"><u>Amended and Restated Employment Letter Agreement, dated April 2, 2019, between Jim Bramwell and VWR International, LLC</u></a>	10-Q	10.4	4/26/2024
<a href="#"><u>10.39</u></a> <sup>^</sup>	<a href="#"><u>Form of Indemnification Agreement (between Avantor, Inc. and its directors and officers)</u></a>	S-1/A	10.23	4/25/2019
<a href="#"><u>19</u></a>	<a href="#"><u>Insider Trading Policy</u></a>	10-K	19	2/7/2025
<a href="#"><u>21</u></a>	<a href="#"><u>List of subsidiaries of Avantor, Inc.</u></a>	*		
<a href="#"><u>23</u></a>	<a href="#"><u>Consent of Deloitte &amp; Touche LLP</u></a>	*		
<a href="#"><u>31.1</u></a>	<a href="#"><u>Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</u></a>	*		

Exhibit no.	Description	Location of exhibits		
		Form	Exhibit no.	Filing date
<a href="#">31.2</a>	<a href="#">Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a>	*		
<a href="#">32.1</a>	<a href="#">Certification of Principal Executive Officer pursuant to 18 U.S.C. 1350 (Section 906 of the Sarbanes-Oxley Act of 2002)</a>	**		
<a href="#">32.2</a>	<a href="#">Certification of Principal Financial Officer pursuant to 18 U.S.C. 1350 (Section 906 of the Sarbanes-Oxley Act of 2002)</a>	**		
<a href="#">97</a> <sup>^</sup>	<a href="#">Erroneously Awarded Compensation Recovery Policy</a>	10-K	97	2/14/2024
101	The following materials from this report, formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) the Consolidated Statements of Income, (ii) the Consolidated Statements of Comprehensive Income, (iii) the Consolidated Balance Sheets, (iv) the Consolidated Statements of Cash Flows, and (v) Notes to Consolidated Financial Statements.	*		
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)			

\* Filed herewith

\*\* Furnished herewith

<sup>^</sup> Indicates management contract or compensatory plan, contract or arrangement.

#### Item 16. Form 10-K summary

None.

## SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

### **Avantor, Inc.**

Date: February 11, 2026

By: /s/ Steven Eck

Name: Steven Eck

Title: Senior Vice President and Chief Accounting Officer  
(Principal Accounting Officer)

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities indicated, as of February 11, 2026.

/s/ Juan Andres

Director

Juan Andres

/s/ John Carethers

Director

John Carethers

/s/ Simon Dingemans

Director

Simon Dingemans

/s/ Steven Eck

Senior Vice President and Chief  
Accounting Officer  
(Principal Accounting Officer)

Steven Eck

/s/ R. Brent Jones

Executive Vice President and Chief  
Financial Officer  
(Principal Financial Officer)

R. Brent Jones

/s/ Lan Kang

Director

Lan Kang

/s/ Emmanuel Ligner

Director, President and Chief  
Executive Officer  
(Principal Executive Officer)

Emmanuel Ligner

/s/ Gregory T. Lucier

Director

Gregory T. Lucier

/s/ Dame Louise Makin

Director

Dame Louise Makin

/s/ Joseph Massaro Director  
Joseph Massaro

/s/ Sanjeev Mehra Director  
Sanjeev Mehra

/s/ Mala Murthy Director  
Mala Murthy

/s/ Michael Severino Director  
Michael Severino

/s/ Gregory L. Summe Chairman of the Board of Directors  
Greg Summe

**Avantor, Inc. and subsidiaries**  
**Index to consolidated financial statements**

	<u>Page</u>
<a href="#">Report of independent registered public accounting firm</a> .....	<a href="#">F-2</a>
<a href="#">Consolidated balance sheets</a> .....	<a href="#">F-4</a>
<a href="#">Consolidated statements of operations</a> .....	<a href="#">F-5</a>
<a href="#">Consolidated statements of comprehensive income or loss</a> .....	<a href="#">F-6</a>
<a href="#">Consolidated statements of stockholders' equity</a> .....	<a href="#">F-7</a>
<a href="#">Consolidated statements of cash flows</a> .....	<a href="#">F-9</a>
<a href="#">Notes to consolidated financial statements</a> .....	<a href="#">F-11</a>

## **REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

To the stockholders and the Board of Directors of Avantor, Inc.

### **Opinion on the Financial Statements**

We have audited the accompanying consolidated balance sheets of Avantor, Inc. and subsidiaries (the "Company") as of December 31, 2025 and 2024, the related consolidated statements of operations, comprehensive income or loss, stockholders' equity, and cash flows, for each of the three years in the period ended December 31, 2025, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2025, in conformity with accounting principles generally accepted in the United States of America.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2025, based on criteria established in *Internal Control — Integrated Framework (2013)* issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February 11, 2026, expressed an unqualified opinion on the Company's internal control over financial reporting.

### **Basis for Opinion**

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

### **Critical Audit Matter**

The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

**Goodwill Impairment - Distribution reporting unit - Refer to notes 2, 6, and 11 to the financial statements**

### *Critical Audit Matter Description*

Goodwill is tested for impairment at the reporting unit level on October 1 of each year or more frequently whenever an event or change in circumstance occurs that would require reassessment of the recoverability of the asset. The Company estimates the fair value of each reporting unit using a weighted average of two valuation methods based on a discounted cash flows method and a guideline public company method. These valuation methods require management to make various assumptions, which include, but are not limited to, future profitability, cash flows, discount rates, weighting of valuation methods, and the selection of comparable publicly traded companies (peer groups). If the Company determines the carrying value of a reporting unit exceeds its fair value, an impairment charge is recorded for the excess. As a result of sustained decreases in the Company's publicly quoted share price and market capitalization as well as changes in the operating results of the Distribution reporting unit, the Company conducted an interim impairment test as of September 30, 2025, which resulted in a non-cash goodwill impairment charge of \$785.0 million. No impairment charges were recorded to the other reporting units as their estimated fair values exceeded their respective carrying amounts.

The principal considerations for our determination that performing audit procedures relating to the Distribution reporting unit's goodwill impairment analysis is a critical audit matter are (i) the significant judgment by management when developing the fair value estimate of the reporting unit; (ii) a high degree of auditor judgment in evaluating the reasonableness of management's assumptions under the discounted cash flows method, in particular the estimates of net sales growth and the discount rate; and (iii) an increased extent of effort, including the need to involve our fair value specialists.

### *How the Critical Audit Matter Was Addressed in the Audit*

Our audit procedures over management's estimates of net sales growth and the discount rate for the Distribution reporting unit included the following, among others:

- We tested the effectiveness of controls over management's goodwill impairment testing, including those over management's assumptions of net sales growth and the discount rate under the discounted cash flows method.
- We evaluated management's ability to accurately forecast net sales growth by comparing actual results to management's historical forecasts.
- We evaluated the reasonableness of management's net sales growth by comparing the forecast to historical results and forecasted information included in available peer and industry data.
- With the assistance of our fair value specialists, we evaluated the reasonableness of the discount rate, by (1) testing the underlying information supporting this assumption; (2) testing the mathematical accuracy of the calculations; and (3) developing a range of independent estimates and comparing those to the discount rate selected by management.
- We evaluated the competency and objectivity of management's specialists who assisted with preparing the discounted future cash flows analysis.

/s/ Deloitte & Touche LLP

Philadelphia, Pennsylvania  
February 11, 2026

We have served as the Company's auditor since 2010.

**Avantor, Inc. and subsidiaries**  
**Consolidated balance sheets**

<i>(in millions)</i>	December 31,	
	2025	2024
<b>Assets</b>		
Current assets:		
Cash and cash equivalents . . . . .	\$ 365.4	\$ 261.9
Accounts receivable, net of allowances of \$29.6 and \$30.2 . . . . .	1,074.6	1,034.5
Inventory . . . . .	818.2	731.5
Other current assets . . . . .	193.0	118.7
Total current assets . . . . .	2,451.2	2,146.6
Property, plant and equipment, net (see note 10) . . . . .	766.8	708.1
Other intangible assets, net (see note 11) . . . . .	3,193.8	3,360.2
Goodwill, net (see note 11) . . . . .	4,986.9	5,539.2
Other assets . . . . .	396.0	360.4
Total assets . . . . .	\$ 11,794.7	\$ 12,114.5
<b>Liabilities and stockholders' equity</b>		
Current liabilities:		
Current portion of debt . . . . .	\$ 30.8	\$ 821.1
Accounts payable . . . . .	741.7	662.8
Employee-related liabilities . . . . .	162.7	168.2
Accrued interest . . . . .	47.3	48.6
Other current liabilities . . . . .	396.4	306.8
Total current liabilities . . . . .	1,378.9	2,007.5
Debt, net of current portion . . . . .	3,915.5	3,234.7
Deferred income tax liabilities . . . . .	557.1	557.3
Other liabilities . . . . .	378.2	358.3
Total liabilities . . . . .	6,229.7	6,157.8
Commitments and contingencies (see note 13)		
Stockholders' equity:		
Common stock including paid-in capital, 682.0 and 680.8 shares issued and outstanding . . . . .	3,984.8	3,937.7
Treasury stock at cost, 6.6 and 0.0 shares . . . . .	(75.7)	—
Accumulated earnings . . . . .	1,672.8	2,203.0
Accumulated other comprehensive loss . . . . .	(16.9)	(184.0)
Total stockholders' equity . . . . .	5,565.0	5,956.7
Total liabilities and stockholders' equity . . . . .	\$ 11,794.7	\$ 12,114.5

*The accompanying notes are an integral part of these consolidated financial statements*

**Avantor, Inc. and subsidiaries**  
**Consolidated statements of operations**

<i>(in millions, except per share data)</i>	<b>Year ended December 31,</b>		
	<b>2025</b>	<b>2024</b>	<b>2023</b>
Net sales	\$ 6,552.2	\$ 6,783.6	\$ 6,967.2
Cost of sales	4,412.8	4,504.3	4,603.4
Gross profit	2,139.4	2,279.3	2,363.8
Selling, general and administrative expenses	1,595.5	1,641.1	1,506.6
Impairment charges	785.0	—	160.8
Gain on sale of business	5.1	(446.6)	—
Operating (loss) income	(246.2)	1,084.8	696.4
Interest expense, net	(169.8)	(218.8)	(284.8)
Loss on extinguishment of debt	(4.6)	(10.9)	(6.9)
Other (expense) income, net	(20.7)	(1.2)	5.8
(Loss) income before income taxes	(441.3)	853.9	410.5
Income tax expense	(88.9)	(142.4)	(89.4)
Net (loss) income	<u>\$ (530.2)</u>	<u>\$ 711.5</u>	<u>\$ 321.1</u>
(Loss) earnings per share:			
Basic	\$ (0.78)	\$ 1.05	\$ 0.48
Diluted	\$ (0.78)	\$ 1.04	\$ 0.47
Weighted average shares outstanding:			
Basic	680.6	679.6	675.6
Diluted	680.6	681.9	678.4

*The accompanying notes are an integral part of these consolidated financial statements*

**Avantor, Inc. and subsidiaries**  
**Consolidated statements of comprehensive income or loss**

<i>(in millions)</i>	Year ended December 31,		
	2025	2024	2023
Net (loss) income .....	\$ (530.2)	\$ 711.5	\$ 321.1
Other comprehensive income (loss):			
Foreign currency translation:			
Unrealized gain (loss) .....	123.2	(83.3)	38.3
Reclassification of gain into earnings .....	—	(0.5)	—
Derivative instruments:			
Unrealized gain .....	9.3	18.2	21.3
Reclassification of gain into earnings .....	(9.5)	(34.5)	(31.0)
Activity related to defined benefit plans:			
Unrealized gain (loss) .....	11.0	(17.4)	(7.7)
Reclassification of loss (gain) into earnings .....	17.3	6.9	(5.9)
Other comprehensive income (loss) before income taxes .....	151.3	(110.6)	15.0
Income tax effect .....	15.8	(4.4)	16.3
Other comprehensive income (loss) .....	167.1	(115.0)	31.3
Comprehensive (loss) income .....	<u>\$ (363.1)</u>	<u>\$ 596.5</u>	<u>\$ 352.4</u>

*The accompanying notes are an integral part of these consolidated financial statements*

**Avantor, Inc. and subsidiaries**  
**Consolidated statements of stockholders' equity**

	Common stock including paid-in capital		Accumulated (deficit) earnings	AOCI	Total
	Shares	Amount			
Balance on December 31, 2022	674.3	\$ 3,785.3	\$ 1,170.4	\$ (100.3)	\$ 4,855.4
Comprehensive income	—	—	321.1	31.3	352.4
Stock-based compensation expense	—	40.2	—	—	40.2
Stock option exercises and other common stock transactions	2.3	4.6	—	—	4.6
Balance on December 31, 2023	676.6	\$ 3,830.1	\$ 1,491.5	\$ (69.0)	\$ 5,252.6
Comprehensive income (loss)	—	—	711.5	(115.0)	596.5
Stock-based compensation expense	—	47.0	—	—	47.0
Stock option exercises and other common stock transactions	4.2	60.6	—	—	60.6
Balance on December 31, 2024	680.8	\$ 3,937.7	\$ 2,203.0	\$ (184.0)	\$ 5,956.7

(in millions)

The accompanying notes are an integral part of these consolidated financial statements

**Avantor, Inc. and subsidiaries**  
**Consolidated statements of stockholders' equity (continued)**

<i>(in millions)</i>	Common stock including paid-in capital		Accumulated (deficit) earnings	Treasury Stock		AOCI	Total
	Shares	Amount		Shares	Amount		
Balance on December 31, 2024	680.8	\$ 3,937.7	\$ 2,203.0	—	\$ —	\$ (184.0)	\$ 5,956.7
Comprehensive (loss) income	—	—	(530.2)	—	—	167.1	(363.1)
Stock-based compensation expense	—	47.6	—	—	—	—	47.6
Stock option exercises and other common stock transactions	1.2	(0.5)	—	—	—	—	(0.5)
Purchases of company common stock	—	—	—	6.6	(75.7)	—	(75.7)
Balance on December 31, 2025	682.0	\$ 3,984.8	\$ 1,672.8	6.6	\$ (75.7)	\$ (16.9)	\$ 5,565.0

*The accompanying notes are an integral part of these consolidated financial statements*

**Avantor, Inc. and subsidiaries**  
**Consolidated statements of cash flows**

<i>(in millions)</i>	Year ended December 31,		
	2025	2024	2023
<b>Cash flows from operating activities:</b>			
Net (loss) income	\$ (530.2)	\$ 711.5	\$ 321.1
<b>Reconciling adjustments:</b>			
Depreciation and amortization	410.2	405.5	402.3
Impairment charges	785.0	—	160.8
Gain on sale of business	5.1	(446.6)	—
Stock-based compensation expense	46.4	46.8	40.5
Non-cash restructuring charges (see note 12)	3.2	16.9	—
Provision for accounts receivable and inventory	63.7	75.1	84.5
Deferred income tax expense (benefit)	7.7	(46.9)	(172.4)
Amortization of deferred financing costs	8.5	11.2	13.0
Loss on extinguishment of debt	4.6	10.9	6.9
Foreign currency remeasurement loss (gain)	1.7	(0.3)	(2.6)
Pension termination charges	18.1	9.3	—
<b>Changes in assets and liabilities:</b>			
Accounts receivable	13.6	45.9	77.0
Inventory	(109.4)	(18.5)	30.3
Accounts payable	42.4	59.6	(139.6)
Accrued interest	(1.3)	(1.6)	0.3
Other assets and liabilities	(144.2)	(37.7)	48.6
Other	(1.3)	(0.3)	(0.7)
Net cash provided by operating activities	<u>623.8</u>	<u>840.8</u>	<u>870.0</u>
<b>Cash flows from investing activities:</b>			
Capital expenditures	(128.8)	(148.8)	(146.4)
Proceeds from sale of disposal group, net of cash sold	—	585.2	—
Other	(1.7)	2.5	2.7
Net cash (used in) provided by investing activities	<u>\$ (130.5)</u>	<u>\$ 438.9</u>	<u>\$ (143.7)</u>

*The accompanying notes are an integral part of these consolidated financial statements*

**Avantor, Inc. and subsidiaries**  
**Consolidated statements of cash flows (continued)**

<i>(in millions)</i>	<b>Year ended December 31,</b>		
	<b>2025</b>	<b>2024</b>	<b>2023</b>
<b>Cash flows from financing activities:</b>			
Debt borrowings .....	\$ 1,107.6	\$ —	\$ —
Debt repayments .....	(1,426.3)	(1,341.8)	(846.0)
Payments of debt refinancing fees .....	(15.1)	—	(2.3)
Proceeds received from exercise of stock options .....	5.1	69.2	18.3
Shares repurchased to satisfy employee tax obligations for vested stock-based awards .....	(5.6)	(8.6)	(13.7)
Payments for repurchase of common stock .....	(75.1)	—	—
Net cash used in financing activities .....	(409.4)	(1,281.2)	(843.7)
Effect of currency rate changes on cash and cash equivalents ..	19.7	(21.5)	8.2
Net change in cash, cash equivalents and restricted cash .....	103.6	(23.0)	(109.2)
Cash, cash equivalents and restricted cash, beginning of year ..	264.7	287.7	396.9
Cash, cash equivalents and restricted cash, end of year .....	<u>\$ 368.3</u>	<u>\$ 264.7</u>	<u>\$ 287.7</u>

*The accompanying notes are an integral part of these consolidated financial statements*

**Avantor, Inc. and subsidiaries**  
**Notes to consolidated financial statements**

**1. Nature of operations and presentation of financial statements**

We are a global manufacturer and distributor that provides products and services to customers in the biopharmaceutical, healthcare, education & government and advanced technologies & applied materials industries.

***Basis of presentation***

The accompanying financial statements have been prepared in accordance with the rules and regulations of the SEC for annual reports and GAAP. The financial statements include the accounts of Avantor, Inc., its consolidated subsidiaries, and those business entities in which we maintain a controlling interest.

***Principles of consolidation***

All intercompany balances and transactions have been eliminated from the financial statements.

***Use of estimates***

The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported throughout the financial statements. Actual results could differ from those estimates.

**2. Summary of significant accounting policies**

***Earnings per share***

Basic earnings per share is computed by dividing net income available to common stockholders by the weighted average number of common shares outstanding during the reporting period.

Diluted earnings per share is computed based on the weighted average number of common shares outstanding increased by the number of additional shares that would have been outstanding had the potentially dilutive common shares been issued and reduced by the number of shares we could have repurchased with the proceeds from the issuance of the potentially dilutive shares. In the event that preferred shares are issued and outstanding, preferred dividends are added back to net income available to common stockholders, provided that inclusion of the preferred securities is not anti-dilutive.

***Segment reporting***

Effective January 1, 2024, we changed our operating model and reporting segment structure from three reportable segments to two reportable segments: Laboratory Solutions and Bioscience Production. This structure aligns with how our Chief Executive Officer, who is our CODM, measures segment operating performance and allocates resources across our operating segments.

None of our customers contributed more than 5% to our net sales, and we disclose net sales for the following product categories: proprietary and third-party.

We disclose geographic data for our largest country, the United States, as a percentage of consolidated net sales. No other countries were individually material. We disclose property and equipment by geographic

area because many of these assets cannot be readily moved and are illiquid, subjecting them to geographic risk. None of our other long-lived assets are subject to significant geopolitical risk. We do not manage total assets on a segment basis and as a result the Company does not report asset information by segment. Segment information about interest expense, income tax expense or benefit and other significant non-cash items other than depreciation and amortization, are not disclosed because they are not included in the segment profitability measurement nor are they otherwise provided to our CODM on a regular basis.

### ***Cash and cash equivalents***

Cash equivalents are comprised of highly-liquid investments with original maturities of three months or less. Bank overdrafts are classified as current liabilities, and changes to bank overdrafts are presented as a financing activity on our consolidated statements of cash flows.

### ***Accounts receivable and allowance for current expected credit losses***

Substantially all of our accounts receivable are trade accounts that are recorded at the invoiced amount and generally do not bear interest. Accounts receivable are presented net of an allowance for current expected credit losses. We consider many factors in estimating our allowance including the age of our receivables, historical collections experience, customer types, creditworthiness and economic trends. Account balances are written off against the allowance when we determine it is probable that the receivable will not be recovered.

### ***Inventory***

Inventory consists of merchandise inventory related to our distribution business and finished goods, raw materials and work in process related to our manufacturing business. Goods are removed from inventory as follows:

- Merchandise inventory purchased by certain U.S. subsidiaries using the last-in, first-out method.
- All other merchandise inventory using the first-in, first-out method.
- Manufactured inventories using an average cost method.

Inventory is valued at the lower of cost or net realizable value. Cost for manufactured goods is determined using standard costing methods to estimate raw materials, labor and overhead consumed. Variances from actual cost are recorded to inventory at period-end. Cost for other inventory is based on amounts invoiced by suppliers plus freight. If net realizable value is less than carrying value, we reduce the carrying amount to net realizable value and record a loss in cost of sales.

### ***Property, plant and equipment***

Property, plant and equipment are stated at cost. Depreciation is recognized using the straight-line method over estimated useful lives of ten to forty years for buildings and related improvements, three to ten years for machinery and equipment and three to fifteen years for capitalized software. Leasehold improvements are depreciated on a straight-line basis over the shorter of the estimated useful lives of the assets or the estimated remaining life of the lease. Depreciation is classified as cost of sales or SG&A expense based on the nature of the underlying asset.

Software development costs are capitalized as property, plant and equipment once the preliminary project stage is completed and management commits to funding the project if it is probable that the project will be completed for its intended use. Preliminary project planning and training costs related to software are expensed as incurred.

### ***Impairment of long-lived assets***

Long-lived assets include property, plant and equipment, finite-lived intangible assets and certain other assets. For impairment testing purposes, long-lived assets may be grouped with working capital and other types of assets or liabilities if they generate cash flows on a combined basis.

We evaluate long-lived assets or asset groups for impairment whenever events or changes in circumstances indicate a potential inability to recover their carrying amounts. Impairment is determined by comparing their carrying value to their estimated undiscounted future cash flows. If long-lived assets or asset groups are impaired, the loss is measured as the amount by which their carrying values exceed their fair value.

### ***Goodwill and other intangible assets***

Goodwill represents the excess of the price of an acquired business over the aggregate fair value of its identifiable net assets. Other intangible assets consist of both finite-lived and indefinite-lived intangible assets.

Goodwill and other indefinite-lived intangible assets are tested annually for impairment on October 1 of each year and whenever an impairment indicator arises. Goodwill impairment testing is performed at the reporting unit level.

As described above, we reorganized our segment reporting structure effective January 1, 2024. The segment reporting reorganization also resulted in a change to our reporting units for the purpose of goodwill impairment testing. As a result of the reorganization, our goodwill was reassigned to reporting units affected using a relative fair value approach similar to that used when a portion of a reporting unit is disposed of, to the new reporting units making up our Laboratory Solutions and Bioscience Production reporting segments.

Our finite-lived intangible assets are tested for impairment whenever an impairment indicator arises. Examples of impairment indicators include unexpected adverse business conditions, economic factors, unanticipated technological changes or competitive activities, loss of key personnel and acts or anticipated acts by governments and courts.

The impairment analysis for goodwill and indefinite-lived intangible assets consists of an optional qualitative assessment potentially followed by a quantitative analysis. If we determine that the carrying value of a reporting unit or an indefinite-lived intangible asset exceeds its fair value, an impairment charge is recorded for the excess.

Indefinite-lived intangible assets are not amortized. Annually, we evaluate whether these assets continue to have indefinite lives, considering whether they have any legal, regulatory, contractual, competitive or economic limitations and whether they are expected to contribute to the generation of cash flows indefinitely.

Finite-lived intangible assets are amortized over their estimated useful lives on a straight-line basis, with customer relationships amortized over lives of ten to twenty years, tradenames amortized over lives of ten to fifteen years and other finite-lived intangible assets amortized over lives of five to twenty years. Amortization is classified in SG&A expenses. We reevaluate the estimated useful lives of our finite-lived intangible assets annually.

### ***Restructuring and severance charges***

Restructuring plans are designed to improve gross margins and reduce operating costs over time. We typically incur up-front charges to implement these plans related to employee severance, facility closure and other actions:

- *Employee severance and related* — Employee severance programs can be voluntary or involuntary. Voluntary severances are recorded at their reasonably estimated amount when associates accept severance offers. Involuntary severances covered by plan or statute are recorded at estimated amounts when probable and reasonably estimable. Judgment is required to determine probability and whether the amount can be reasonably estimated. Involuntary severances requiring significant continuing service are measured at fair value as of the termination date and recognized on a straight-line basis over the service period.
- *Facility closure* — On the date we cease using a facility, facility leased assets are tested for impairment in the same way as other long-lived assets. The remaining lease expense is recognized between the period that we commit to cease use of a facility and the date we exit.
- *Other* — Other charges may be incurred to write down assets, divest businesses or for other reasons and are accounted for under applicable GAAP as described elsewhere in these policies.

Restructuring and severance charges are classified as SG&A expenses or cost of sales depending on the nature of the expense. Accrued restructuring and severance charges are classified as employee-related or current liabilities if we anticipate settlement within one year, otherwise they are included in other liabilities.

### ***Contingencies***

Our business exposes us to various contingencies including compliance with environmental laws and regulations, legal exposures related to the manufacture and sale of products and other matters. Loss contingencies are reflected in the financial statements based on our assessments of their expected outcome or resolution:

- They are recognized as liabilities on our balance sheet if the potential loss is probable and the amount can be reasonably estimated.
- They are disclosed if the potential loss is material and considered at least reasonably possible.

Significant judgment is required to determine probability and whether the amount can be reasonably estimated. Due to uncertainties related to these matters, accruals are based only on the information available at the time. As additional information becomes available, we reassess potential liabilities and may revise our previous estimates.

## ***Debt***

Borrowings under lines of credit are stated at their face amount. Borrowings under term debt and through the issuance of notes are stated at their face amounts net of unamortized deferred financing costs, including any original issue discounts or premiums.

The accounting for financing costs depends on whether debt is newly issued, extinguished or modified. That determination is made on an individual lender basis when the lenders are part of a syndication. When new debt is issued, financing costs and discounts are deferred and recognized as interest expense through maturity of the debt. When debt is extinguished, unamortized deferred financing costs and discounts are written off and presented as a loss on extinguishment of debt. When debt is modified, new financing costs and prior unamortized deferred financing costs may be either (i) immediately recognized as interest expense, other expense, or SG&A expense or (ii) deferred and recognized as interest expense through maturity of the modified debt, depending on the type of cost and whether the modification was substantial or insubstantial.

Borrowings and repayments under lines of credit are short-term in nature and presented on the statement of cash flows on a net basis.

## ***Equity***

Stockholders' equity or deficit comprises common stock and treasury stock. Our accounting policies for these instruments are as follows:

- Common stock is presented at par value plus additional paid-in amounts, net of issuance costs. Distributions are accounted for as reductions to common stock including paid-in capital and are classified as financing activities on the statement of cash flows.
- Upon issuance, paid-in capital is allocated among host stock instruments on a relative fair value basis.
- Treasury stock is accounted for under the cost method. When shares are repurchased, the cost of the shares, including any related transaction costs, is recorded as a reduction of stockholders' equity. Shares held in treasury are excluded from common shares outstanding and therefore reduce the weighted-average number of shares outstanding used in the calculation of both basic and diluted earnings per share. When treasury shares are reissued, the difference between the reissuance price and the recorded cost of those shares is recognized in additional paid-in capital.

Costs directly associated with new equity issuances are recorded as other current assets until the issuances are completed or abandoned. If the issuance is completed, the costs are reclassified to stockholders' equity and presented as a reduction of proceeds received. If the issuance is abandoned, the costs are reclassified to SG&A expenses. Costs associated with secondary equity offerings under a registration rights agreement are recorded as SG&A expenses.

Disclosures about certain classes of stock are provided in the footnotes and not stated separately on the balance sheet or statement of stockholders' equity when those presentations are not deemed to be material.

### ***Revenue recognition***

We recognize revenue by applying a five-step process: (i) identify the contract with a customer, (ii) identify the performance obligation in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations and (v) recognize revenue as the performance obligations are satisfied by transferring control of the performance obligation through delivery of a promised product or service to a customer.

Control of a performance obligation may transfer to the customer either at a point in time or over time depending on an evaluation of the specific facts and circumstances for each contract, including the terms and conditions of the contract as agreed with the customer, as well as the nature of the products or services to be provided. The substantial majority of our net sales are recognized at a point in time based upon the delivery of products to customers pursuant to purchase orders. We recognize service revenues and sales of certain of our custom-manufactured products over time as control passes to the customer concurrent with our performance. We are able to fulfill most purchase orders rapidly, and service and custom-manufacturing cycles are short. As a result, we do not record material contract assets or liabilities, nor do we have material unfulfilled performance obligations.

We have elected to use the practical expedient not to adjust the transaction price of a contract for the effects of a significant financing component if, at the inception of the contract, we expect that the period between when we transfer a promised good or service to a customer and when the customer pays for that good or service will be one year or less.

Some customer contracts include variable consideration, such as rebates and prebates, some of which depend upon our customers meeting specified performance criteria, such as a purchasing level over a period of time. We use judgment to estimate the value of these pricing arrangements at each reporting date and record contract assets or liabilities to the extent that estimated values are recognized at a different time than the revenue for the related products. When estimating variable consideration, we also apply judgment when considering the probability of whether a reversal of revenue could occur and only recognize revenue subject to this constraint.

The only significant costs we incur to obtain contracts are related to sales commissions. These commissions are primarily based on purchase order amounts, not recoverable and not applicable to periods greater than one year. We elected to apply the practical expedient to expense these costs as incurred as if the amortization period of the asset that would have otherwise been recognized is one year or less.

Performance obligations following the delivery of products, such as rights of return and warranties, are not material. No other types of revenue arrangements were material to our consolidated financial statements.

### ***Classification of expenses — cost of sales***

Cost of sales includes the cost of the product, depreciation of production assets, supplier rebates, shipping and receiving charges and inventory adjustments. For manufactured products, the cost of the product includes direct and indirect manufacturing costs, plant administrative expenses and the cost of raw materials consumed in the manufacturing process.

### ***Classification of expenses — selling, general and administrative***

Selling, general and administrative expenses include personnel and facility costs, amortization of intangible assets, depreciation of non-production assets, research and development costs, advertising expense, promotional charges and other charges related to our global operations. Research and development expenses were not material for the periods presented.

### ***Employee benefit plans***

Some of our employees participate in defined benefit plans that we sponsor. We present these plans as follows due to their differing geographies, characteristics and actuarial assumptions:

- *U.S. plans* — Our U.S. plans are closed to participants who joined the Company after 2018, and annual accruals of future pension benefits for participating employees are not material to our financial statements. One of our two U.S. plans was terminated during 2025, as discussed in note 17.
- *Non-U.S. plans* — We sponsor eight plans covering employees in various countries that we acquired from VWR in 2017. Most of these plans continue to accrue future pension benefits for participating employees.
- *Medical plan* — We provide a post-retirement medical plan for certain U.S. employees. The plan is closed to new employees, and annual accruals of future pension benefits for participating employees are not material to our financial statements.

We sponsor a number of other defined benefit plans in various countries that are not material individually or in the aggregate and therefore are not included in our disclosures. Defined contribution and other employee benefit plans are also not material.

The cost of our defined benefit plans is incurred systematically over expected employee service periods. We use actuarial methods and assumptions to determine expense each period and the value of projected benefit obligations. Actuarial changes in the projected value of defined benefit obligations are deferred to AOCI and recognized in earnings systematically over future periods. The portion of cost attributable to continuing employee service is included in SG&A expenses. The rest of the cost is included in other income or expense, net.

### ***Stock-based compensation expense***

Some of our management and directors are compensated with stock-based awards. Stock-based compensation expense is included in SG&A expenses on the statement of operations.

### ***Stock options and RSUs***

We measure the expense of stock options and RSUs based on their grant-date fair values. Awards that vest based on continued service are recognized as compensation expense on a straight-line basis over the requisite service period. For awards that are contingent upon the achievement of a performance condition, compensation expense is recognized over the performance period based on the probability of achievement. Awards with market conditions are measured at grant-date fair value using valuation techniques that incorporate the likelihood of achieving the market condition, and the resulting expense is recognized over the requisite service period regardless of whether the market condition is ultimately

satisfied. We recognize forfeitures of unvested awards as they occur by reversing any expense previously recorded in the period of forfeiture. Upon exercise or vesting of awards, we issue new shares of common stock.

The grant-date fair value of stock options is measured using the Black-Scholes pricing model, which incorporates assumptions based on the terms of each stock option agreement, the expected behavior of grant recipients, and our own and selected peer company data. Through the year ended December 31, 2024, due to limited trading history, we estimated volatility using a peer group methodology over a period equal to the expected life of the stock options. Beginning in 2025, after sufficient trading history became available, we adopted a blended volatility methodology that combines Avantor's historical volatility with that of a peer group to provide a more stable and representative input. The risk-free interest rate is based on U.S. Treasury observed market rates, continuously compounded over the expected life. The expected life of stock options is estimated as the midpoint between the weighted-average vesting period and the contractual term.

The grant-date fair value for RSUs in which the vesting condition is based only on continuing service is measured using the quoted closing price of our common stock on the grant date. The grant-date fair value of awards with performance conditions is also measured using the quoted closing price of our common stock on the grant date, adjusted for the probability of achieving the specified performance targets. For awards that contain market conditions, we determine the grant-date fair value using a Monte Carlo valuation model.

#### *Award modifications*

When stock-based compensation arrangements are modified, we treat the modification as an exchange of the original award for a new award and immediately recognize expense for the incremental value of the new award. The incremental value is measured as the excess of the fair value of new awards over the fair value of the original awards, each based on circumstances and assumptions as of the modification date. Fair value is measured using the same methods previously described. We have not had any such modifications for the periods presented in these financial statements.

#### *Income taxes*

Our worldwide income is subject to the income tax regulations of many governments. Income tax expense is calculated using an estimated global rate with recognition of deferred tax assets and liabilities for expected temporary differences between taxable and reported income. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income when those temporary differences are expected to reverse. We record a valuation allowance to reduce deferred tax assets to the amount that is more likely than not to be realized.

Income tax regulations change from time to time. The effect of a change in tax law on deferred tax assets and liabilities is recognized as a cumulative adjustment to income tax expense or benefit in the period of enactment. The effect of a change in tax law on the income tax expense or benefit itself is recognized prospectively for the applicable tax years.

Income tax regulations can be complex, requiring us to interpret tax law and take positions. Upon audit, tax authorities may challenge our positions. We regularly assess the outcome of potential examinations and only recognize positions that are more likely than not to be sustained. Recognized income tax positions are measured at the largest amount that is more likely than not of being realized. Changes in recognition or measurement are reflected in the period in which a change in judgment occurs, as a result

of information that arises or when a tax position is effectively settled. We recognize accrued interest and penalties related to unrecognized tax benefits as a component of interest expense in our consolidated financial statements.

### ***Fair value measurements***

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at a measurement date. We classify fair value measurements based on the lowest of the following levels that is significant to the measurement:

- *Level 1* — Quoted prices in active markets for identical assets or liabilities
- *Level 2* — Inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the asset or liability
- *Level 3* — Inputs that are unobservable for the asset or liability based on our evaluation of the assumptions market participants would use in pricing the asset or liability

We exercise considerable judgment when estimating fair value, particularly when evaluating what assumptions market participants would likely make. The use of different assumptions or estimation methodologies could have a material effect on the estimated fair values.

### ***Foreign currency translation***

Our operations span the globe, so we are impacted by changes in foreign currency exchange rates. We determine the functional currency of our subsidiaries based upon the primary currency used to generate and expend cash, which is usually the currency of the country in which the subsidiary is located. For subsidiaries with functional currencies other than the U.S. dollar, assets and liabilities are translated into U.S. dollars using period-end exchange rates, and revenues, expenses, income and losses of our subsidiaries are translated into U.S. dollars using monthly average exchange rates. The resulting foreign currency translation gains or losses are deferred as AOCI and reclassified to earnings only upon sale or liquidation of those businesses.

Gains and losses related to the remeasurement of debt and intercompany financing into functional currencies are reported in earnings as other income or expense, net. When foreign currency-denominated debt is designated as a hedge of our net investments in non-U.S. denominated subsidiaries, gains and losses are reported in AOCI as part of the cumulative translation adjustment. Gains and losses associated with the remeasurement of operating assets and liabilities into functional currencies are reported within the applicable component of operating income.

### ***Leases***

We primarily enter into real estate leases for manufacturing, warehousing and commercial office space to support our global operations. We also enter into vehicle and equipment leases to support those operations.

We determine if an arrangement is a lease at inception. Short-term leases, defined as having an initial term of twelve months or less, are expensed as incurred and not recorded on the balance sheet. We record the value of all other leased property and the related obligations as assets and liabilities on the balance sheet. Information about the amount and classification of lease assets and liabilities is included in note 23.

At inception, lease assets and liabilities are measured at the present value of future lease payments over the lease term. As most of our leases do not provide an implicit rate, we exercise judgment in selecting the incremental borrowing rate based on the information available at inception to determine the present value of future payments. Operating lease assets are further adjusted for lease incentives and initial direct costs.

Our lease terms may include options to extend or terminate the lease. We exercise judgment to calculate the term of those leases when extension or termination options are present and include such options in the calculation of the lease term when it is reasonably certain that we will exercise those options. Operating lease expense is recognized on a straight-line basis over the lease term, except for variable rent which is expensed as incurred. Short-term lease and variable rent expense was immaterial to the financial statements and has been included within operating lease expense. Finance lease expense includes depreciation, which is recognized on a straight-line basis over the expected life of the leased asset and interest expense.

Some of our lease agreements include both lease and non-lease components. We account for those components separately for real estate leases and as a combined single lease component for all other types of leases.

### ***Business combinations***

We account for business acquisitions under the accounting standards for business combinations. The results of each acquisition are included in our consolidated results as of the acquisition date and the purchase price of an acquisition is allocated to tangible and intangible assets and assumed liabilities based on their estimated fair values. Any excess of the fair value consideration transferred over the estimated fair values of the identifiable net assets acquired is recognized as goodwill.

Any purchase price that is considered contingent consideration is measured at its estimated fair value at the acquisition date. Contingent consideration is remeasured at the end of each reporting period, with changes in estimated fair value being recorded through SG&A expense within our statement of operations.

### ***Derivatives and hedging***

We use derivative instruments primarily to manage currency exchange and interest rate risks and recognize them as either assets or liabilities which are measured at fair value.

- *Cash flow hedges* — We use interest rate derivatives to add stability to interest expense and to manage our exposure to interest rate movements. For derivative instruments that are designated and qualify as a cash flow hedge, the gain or loss on the derivative is recorded in AOCI and reclassified into earnings in the same period(s) during which the hedged transaction affects earnings and is presented in the same income statement line item as the earnings effect of the hedged item.
- *Net Investment hedges* — We use foreign currency-denominated debt and cross-currency swaps to hedge our net investments in foreign operations against adverse movements in exchange rates. For derivatives designated as net investment hedges, the gain or loss on the derivative is reported in AOCI as part of the cumulative translation adjustment. Amounts are reclassified out of AOCI into earnings in the event the hedged net investment is either sold or substantially liquidated.

### **3. New accounting standards**

#### ***Income Taxes***

In December 2023, the FASB issued ASU 2023-09, *Improvements to Income Tax Disclosures*, which amends the existing income taxes guidance (ASC Topic 740) to require additional disclosures surrounding annual rate reconciliation, income taxes paid and other income tax related disclosures.

The amendments in this update are effective for annual periods beginning after December 15, 2024. Accordingly, we adopted this standard on a retrospective basis within our annual report for the year ended December 31, 2025. Adoption resulted in expanded disclosures within our income tax footnote, primarily related to the annual effective tax rate reconciliation and income taxes paid. Refer to note 20 for these disclosures.

#### ***Disaggregation of Income Statement Expenses (DISE)***

In November 2024, the FASB issued ASU 2024-03, *Disaggregation of Income Statement Expenses (DISE)*, requiring additional disclosure of the nature of expenses included in the income statement. The new standard requires disclosures about specific types of expenses included in the expense captions presented on the face of the income statement as well as disclosures about selling expenses.

The amendments in this update are effective for annual periods beginning after December 15, 2026 and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. We are currently evaluating the impact of our pending adoption of this standard on our financial statements.

#### ***Other***

There were no other new accounting standards that we expect to have a material impact on our financial position or results of operations upon adoption.

#### ***Adoption of rules to enhance and standardize climate-related disclosures for Investors***

In March 2024, the SEC adopted final rules to enhance and standardize climate-related disclosures in registration statements and annual reports. On April 4, 2024, the SEC voluntarily stayed the effectiveness of these rules pending judicial review, and on March 27, 2025, the SEC withdrew its defense of the rules in ongoing litigation. As a result, the rules remain subject to a stay and their future applicability is uncertain. We continue to monitor developments and will evaluate the impact of any final requirements on our disclosures and related processes.

### **4. Divestitures**

We completed the sale of our Clinical Services business, a component of the Company's Laboratory Solutions reportable segment, on October 17, 2024. In the fourth quarter of 2024, we received gross proceeds of approximately \$595.0 million. In connection with the sale, we recorded a gain of \$446.6 million in the consolidated statements of operations for the year ended December 31, 2024. During the year ended December 31, 2025, we recorded a \$(5.1) million post-closing purchase price adjustment to the originally recognized gain on sale in the consolidated statements of operations. The Clinical Services business was not classified as a discontinued operation because it did not represent a strategic shift that would have a major effect on our operations or financial results.

## 5. Earnings per share

The following table presents the reconciliation of basic and diluted (loss) earnings per share for the years ended December 31, 2025, 2024 and 2023:

(in millions, except per share data)	Year ended December 31, 2025			Year ended December 31, 2024			Year ended December 31, 2023		
	Loss (numerator)	Weighted average shares outstanding (denominator)	Loss per share	Earnings (numerator)	Weighted average shares outstanding (denominator)	Earnings per share	Earnings (numerator)	Weighted average shares outstanding (denominator)	Earnings per share
Basic	\$ (530.2)	680.6	\$ (0.78)	\$ 711.5	679.6	\$ 1.05	\$ 321.1	675.6	\$ 0.48
Dilutive effect of stock-based awards	—	—	—	—	2.3	—	—	2.8	—
Diluted	\$ (530.2)	680.6	\$ (0.78)	\$ 711.5	681.9	\$ 1.04	\$ 321.1	678.4	\$ 0.47

Certain stock options and RSUs are not included in the diluted earnings (loss) per share calculation when the effect would have been anti-dilutive. The number of anti-dilutive shares not included were 14.5 million, 5.9 million and 12.9 million for the year ended December 31, 2025, December 31, 2024 and December 31, 2023, respectively.

## 6. Risks and uncertainties

### *Remeasurement of foreign-denominated debt and intercompany borrowings*

Our operations span the globe. To fund those operations, we have entered into significant Euro-denominated indebtedness (see note 14), and we have also established intercompany borrowings among our subsidiaries that are denominated in various currencies. Changes in foreign currency exchange rates, particularly the Euro, have required us to record gains and losses, some of which have been significant, to remeasure the debt and the intercompany borrowings into functional currencies of the subsidiaries holding them.

Our intercompany capitalization structure and derivative and hedging instruments are intended to mitigate substantially all of our net Euro financing exposure in future periods. We expect to record gains and losses related to intercompany borrowings denominated in other currencies. Historically, the remeasurement of borrowings denominated in currencies other than the Euro has not been material.

### *Impairment testing*

On January 1, 2024, in connection with the Company's reporting segment structure change, we performed quantitative impairment testing of goodwill for each of our reporting units. We did not record any impairment charges as each reporting unit had a fair value that was in excess of its carrying value.

As a result of sustained decreases in our publicly quoted share price and market capitalization, as well as changes in the operating results of our Distribution reporting unit, formerly referred to as our Buy Sell Lab reporting unit, we conducted an interim goodwill impairment test as of September 30, 2025. Based on this test, the carrying amount of the Distribution reporting unit exceeded its fair value, resulting in a non-deductible, non-cash goodwill impairment charge of \$785.0 million, recorded in the consolidated

statements of operations for the three months ended September 30, 2025. Following the impairment, the carrying value of the Distribution reporting unit equals its estimated fair value.

Future goodwill impairment charges may be required if market conditions, projected operating results, or other key valuation assumptions deteriorate. Changes in forecasted results, discount rates, or other inputs used to estimate fair value could materially impact valuations and increase the risk of impairment in subsequent periods. We did not record any goodwill impairments during the years ended December 31, 2024 and December 31, 2023.

### ***Collective bargaining arrangements***

As of December 31, 2025, approximately 5% of our employees in North America were represented by unions, and a majority of our employees in Europe are represented by workers' councils or unions.

## **7. Segment financial information**

Effective January 1, 2024, we changed our operating model and reporting segment structure into two reportable business segments: Laboratory Solutions and Bioscience Production. Corporate costs are managed on a standalone basis, certain of which are allocated to our reportable segments.

In connection with this change, our CODM changed the measure used to evaluate segment profitability from Adjusted EBITDA to Adjusted Operating Income. The CODM uses this metric predominantly in the annual budget, forecasting and performance monitoring processes. All segment disclosures for 2023 reflect the changes to our reportable segments.

The following tables present information by reportable segment:

<i>(in millions)</i>	<b>Net sales</b> <b>Year ended December 31,</b>			<b>Adjusted Operating Income</b> <b>Year ended December 31,</b>		
	<b>2025</b>	<b>2024</b>	<b>2023</b>	<b>2025</b>	<b>2024</b>	<b>2023</b>
Laboratory Solutions . . . .	\$ 4,399.7	\$ 4,610.1	\$ 4,738.3	\$ 510.4	\$ 598.0	\$ 668.3
Bioscience Production . . . .	2,152.5	2,173.5	2,228.9	517.8	558.2	601.9
Corporate . . . . .	—	—	—	(70.4)	(66.4)	(58.4)
Total . . . . .	<u>\$ 6,552.2</u>	<u>\$ 6,783.6</u>	<u>\$ 6,967.2</u>	<u>\$ 957.8</u>	<u>\$ 1,089.8</u>	<u>\$ 1,211.8</u>

*(in millions)*

<b>Year ended December 31, 2025</b>	<b>Laboratory Solutions</b>	<b>Bioscience Production</b>	<b>Corporate</b>	<b>Total</b>
Net sales . . . . .	\$ 4,399.7	\$ 2,152.5	\$ —	\$ 6,552.2
Adjusted cost of sales <sup>1</sup> . . . . .	3,210.5	1,201.9	(0.2)	4,412.2
Adjusted operating expenses <sup>2</sup> . . . . .	678.8	432.8	70.6	1,182.2
Adjusted Operating Income . . . . .	<u>\$ 510.4</u>	<u>\$ 517.8</u>	<u>\$ (70.4)</u>	<u>\$ 957.8</u>

(in millions)

Year ended December 31, 2024	Laboratory Solutions	Bioscience Production	Corporate	Total
Net sales	\$ 4,610.1	\$ 2,173.5	\$ —	\$ 6,783.6
Adjusted cost of sales <sup>1</sup>	3,288.4	1,203.8	—	4,492.2
Adjusted operating expenses <sup>2</sup>	723.7	411.5	66.4	1,201.6
Adjusted Operating Income	<u>\$ 598.0</u>	<u>\$ 558.2</u>	<u>\$ (66.4)</u>	<u>\$ 1,089.8</u>

(in millions)

Year ended December 31, 2023	Laboratory Solutions	Bioscience Production	Corporate	Total
Net sales	\$ 4,738.3	\$ 2,228.9	\$ —	\$ 6,967.2
Adjusted cost of sales <sup>1</sup>	3,380.3	1,223.1	—	4,603.4
Adjusted operating expenses <sup>2</sup>	689.7	403.9	58.4	1,152.0
Adjusted Operating Income	<u>\$ 668.3</u>	<u>\$ 601.9</u>	<u>\$ (58.4)</u>	<u>\$ 1,211.8</u>

- Adjusted cost of sales excludes \$0.6 million and \$12.1 million of non-GAAP adjustments for the years ended December 31, 2025 and December 31, 2024, respectively, primarily related to restructuring and severance as described in more detail within the non-GAAP reconciliation presented below. There were no such non-GAAP adjustments to cost of sales for the year ended December 31, 2023.
- Adjusted operating expenses excludes \$1,203.4 million, \$(7.1) million and \$515.4 million of non-GAAP adjustments, for the years ended December 31, 2025, December 31, 2024 and December 31, 2023, respectively, primarily related to gain on sale of business, amortization, impairment charges, restructuring and severance charges and transformation expenses as described in more detail within the non-GAAP reconciliation presented below.

The following table presents depreciation and amortization by reportable segment:

(in millions)	Depreciation and amortization		
	Year ended December 31,		
	2025	2024	2023
Laboratory Solutions	\$ 205.8	\$ 212.8	\$ 215.0
Bioscience Production	204.4	192.7	187.3
Total	<u>\$ 410.2</u>	<u>\$ 405.5</u>	<u>\$ 402.3</u>

Information about our segments' assets and capital expenditures is not disclosed because this information is not provided to our CODM.

The amounts above exclude inter-segment activity because it is not material. All of the net sales presented for each segment are from external customers.

The following table presents the reconciliation of Adjusted Operating Income, our segment profitability measure, to (Loss) income before income taxes, the nearest measurement under GAAP:

<i>(in millions)</i>	<b>Year ended December 31,</b>		
	<b>2025</b>	<b>2024</b>	<b>2023</b>
Adjusted Operating Income	\$ 957.8	\$ 1,089.8	\$ 1,211.8
Amortization	(301.1)	(299.8)	(307.7)
Integration-related expenses <sup>1</sup>	—	—	(7.6)
Restructuring and severance charges <sup>2</sup>	(29.8)	(82.8)	(26.5)
Transformation expenses <sup>3</sup>	(61.7)	(58.9)	(5.4)
Reserve for certain legal matters, net <sup>4</sup>	(7.3)	(9.2)	(7.1)
Other <sup>5</sup>	(14.0)	(0.9)	(0.3)
Impairment charges <sup>6</sup>	(785.0)	—	(160.8)
Gain on sale of business <sup>7</sup>	(5.1)	446.6	—
Interest expense, net	(169.8)	(218.8)	(284.8)
Loss on extinguishment of debt	(4.6)	(10.9)	(6.9)
Other (expense) income, net	(20.7)	(1.2)	5.8
(Loss) income before income taxes	<u>\$ (441.3)</u>	<u>\$ 853.9</u>	<u>\$ 410.5</u>

1. Represents direct costs incurred with third parties and the accrual of a long-term retention incentive to integrate acquired companies. These expenses represent incremental costs and are unrelated to normal operations of our business. Integration expenses are incurred over a pre-defined integration period specific to each acquisition.
2. Reflects the incremental expenses incurred in the period related to restructuring initiatives to increase profitability and productivity. Costs included in this caption are specific to employee severance, site-related exit costs, and contract termination costs. These expenses recognized in 2024 & 2025 represent costs incurred to achieve the Company's publicly-announced cost transformation initiative.
3. Represents incremental expenses directly associated with the Company's publicly-announced cost transformation initiative, primarily related to the cost of external advisors.
4. Represents charges and legal costs, net of recoveries, in connection with certain litigation and other contingencies that are unrelated to our core operations and not reflective of on-going business and operating results.
5. Represents other stock-based compensation expense (benefit), \$6.7 million of severance and transition costs associated with the replacement of our Chief Executive Officer in 2025, and other costs.
6. As described in notes 10 and 11.
7. The amount reported in 2024 reflects the gain on the sale of our Clinical Services business. The amount reported in 2025 reflects post-closing purchase price adjustments related to that sale. The sale of the Clinical Services business is further described in note 4.

The following table presents net sales by product category:

<i>(in millions)</i>	<b>Year ended December 31,</b>		
	<b>2025</b>	<b>2024</b>	<b>2023</b>
Proprietary	\$ 3,448.9	\$ 3,615.1	\$ 3,720.2
Third-party	3,103.3	3,168.5	3,247.0
Total	<u>\$ 6,552.2</u>	<u>\$ 6,783.6</u>	<u>\$ 6,967.2</u>

The following table presents information by geographic area:

<i>(in millions)</i>	Net sales Year ended December 31,			Property, plant and equipment, net Year ended December 31,	
	2025	2024	2023	2025	2024
United States	\$ 3,279.7	\$ 3,549.6	\$ 3,705.2	\$ 470.4	\$ 445.8
All other countries	3,272.5	3,234.0	3,262.0	296.4	262.3
Total	<u>\$ 6,552.2</u>	<u>\$ 6,783.6</u>	<u>\$ 6,967.2</u>	<u>\$ 766.8</u>	<u>\$ 708.1</u>

## 8. Supplemental disclosures of cash flow information

The following tables present supplemental disclosures of cash balances:

<i>(in millions)</i>	December 31,	
	2025	2024
Cash and cash equivalents	\$ 365.4	\$ 261.9
Restricted cash classified as other assets	2.9	2.8
Total	<u>\$ 368.3</u>	<u>\$ 264.7</u>

<i>(in millions)</i>	Year ended December 31,		
	2025	2024	2023
Cash flows from operating activities:			
Cash paid for income taxes, net <sup>1</sup>			
Federal	\$ 56.4	\$ 159.1	\$ 110.6
State	22.8	34.2	27.8
Foreign	65.8	54.5	86.0
Total	145.0	247.8	224.4
Cash paid for interest, net, excluding financing leases	161.3	211.0	267.0
Cash paid for interest on finance leases	1.6	4.2	5.1
Cash paid under operating leases	43.2	44.0	43.8
Cash flows from financing activities:			
Cash paid under finance leases	6.3	5.7	5.1
Non-cash financing activities:			
Excise tax from stock repurchases	0.6	—	—

1. Income taxes paid (net of refunds) exceeded 5 percent of total income taxes paid (net of refunds) in the following jurisdictions: \$8.9 million in Luxembourg and \$7.7 million in Belgium for the year ended December 31, 2025 and \$24.9 million in Switzerland for the year ended December 31, 2023.

## 9. Inventory

The following table presents the components of inventory:

<i>(dollars in millions)</i>	December 31,	
	2025	2024
Merchandise inventory	\$ 499.4	\$ 416.0
Finished goods	102.3	101.2
Raw materials	151.8	149.3
Work in process	64.7	65.0
Total	<u>\$ 818.2</u>	<u>\$ 731.5</u>
Inventory under the LIFO method:		
Percentage of total inventory	22 %	22 %
Excess of current cost over carrying value	\$ 44.6	\$ 39.7

## 10. Property, plant and equipment

The following table presents the components of property, plant and equipment:

<i>(in millions)</i>	December 31,	
	2025	2024
Buildings and related improvements	\$ 458.7	\$ 414.3
Machinery, equipment and other	643.3	544.3
Software	268.3	238.9
Land	57.6	53.9
Assets not yet placed into service	83.6	86.2
Property, plant and equipment, gross	1,511.5	1,337.6
Accumulated depreciation and impairment charges	(744.7)	(629.5)
Property, plant and equipment, net	<u>\$ 766.8</u>	<u>\$ 708.1</u>

Depreciation expense was \$109.1 million in 2025, \$105.7 million in 2024 and \$94.6 million in 2023.

In the second quarter of 2023, persistently high customer inventory in the end markets served by Ritter and an overall slowdown in research activity caused Ritter's revenue to decline compared to prior expectations. Due to these circumstances, we performed an impairment test of the Ritter asset group, which resulted in a fair value that was lower than its carrying value. As a result, we recorded an impairment charge of \$54.4 million on Ritter's property, plant & equipment in the second quarter of 2023. This charge impacted our Laboratory Solutions reportable segment.

Our impairment test was performed as of June 30, 2023 and utilized our then latest estimates of Ritter's projected cash flows, including revenues, gross margin, SG&A expenses, capital expenditures to maintain the acquired assets, and investments in debt free net working capital, as well as current market assumptions for the discount rate.

## 11. Goodwill and other intangible assets

### *Goodwill*

As described in note 2, we reorganized our segment reporting structure effective January 1, 2024. The segment reporting reorganization also resulted in a change to our reporting units for the purpose of goodwill impairment testing. Our reporting units are Distribution (formerly referred to as Buy Sell Lab), Laboratory Specialty Products (formerly referred to as Proprietary Lab), Laboratory Services (formerly referred to as Services), Manufactured Products, Controlled Environment Consumables (formerly referred to as Buy Sell Production), and NuSil. As a result of the reorganization, our goodwill was reassigned to the new reporting units making up our Laboratory Solutions and Bioscience Production reporting segments.

We reassigned goodwill as of January 1, 2024 to align to our new segment structure by using a relative fair value approach as required under GAAP. We tested goodwill for impairment immediately before and after the reorganization of our reporting structure; no impairment was identified.

The following table presents goodwill by our reportable segments, on the effective date of the change:

	<b>Laboratory Solutions</b>	<b>Bioscience Production</b>	<b>Total</b>
Goodwill, gross	\$ 3,842.0	\$ 1,913.5	\$ 5,755.5
Accumulated impairment losses	(18.4)	(20.4)	(38.8)
Goodwill, net	<u>\$ 3,823.6</u>	<u>\$ 1,893.1</u>	<u>\$ 5,716.7</u>

As described in note 6, as a result of sustained decreases in our publicly quoted share price and market capitalization as well as changes in the operating results of our Distribution reporting unit, we conducted an interim test of our goodwill as of September 30, 2025.

We estimate the fair value of reporting units using a weighted average of two valuation methods based on a discounted cash flows method and a guideline public company method. These valuation methods require management to make various assumptions, including, but not limited to, future profitability, cash flows, including revenues, gross margin, SG&A expenses, capital expenditures, and investments in debt free net working capital, current market assumptions for the discount rates, weighting of valuation methods and the selection of comparable publicly traded companies. Variations in any of these assumptions could result in materially different calculations of fair value.

Based on the results of the impairment test, the carrying amount of our Distribution reporting unit exceeded its fair value, resulting in a non-deductible, non-cash goodwill impairment charge of \$785.0 million, which was recorded in the consolidated statement of operations. We did not identify impairment of any other long-lived assets in this reporting unit. The remaining reporting units tested were not impaired, as their estimated fair values exceeded their respective carrying amounts as of the interim testing date.

Following the impairment charge, the carrying value of the Distribution reporting unit is equal to its estimated fair value. Recognition of additional impairment charges may be required in future periods if market conditions, projected results, or other valuation assumptions deteriorate further.

Since October 1, 2025 is our designated annual impairment testing date, management performed the required procedures to reassess impairment as of that date, including a review of key assumptions, market

indicators, and other relevant factors. No conditions were identified that differed materially from those considered in the September 30, 2025 interim analysis. Accordingly, the conclusions reached in that interim test remained appropriate, and no additional impairment was recorded as of October 1, 2025.

The following tables present changes in goodwill by reportable segment:

<i>(in millions)</i>	<b>December 31, 2025</b>		
	<b>Laboratory Solutions</b>	<b>Bioscience Production</b>	<b>Total</b>
Beginning balance, net	\$ 3,651.2	\$ 1,888.0	\$ 5,539.2
Currency translation	223.1	9.6	232.7
Impairment loss	(785.0)	—	(785.0)
Ending balance, net	3,089.3	1,897.6	4,986.9
Accumulated impairment losses	803.4	20.4	823.8
Ending balance, gross	<u>\$ 3,892.7</u>	<u>\$ 1,918.0</u>	<u>\$ 5,810.7</u>

<i>(in millions)</i>	<b>December 31, 2024</b>		
	<b>Laboratory Solutions</b>	<b>Bioscience Production</b>	<b>Total</b>
Beginning balance, net	\$ 3,823.6	\$ 1,893.1	\$ 5,716.7
Currency translation	(113.4)	(5.1)	(118.5)
Divestitures	(59.0)	—	(59.0)
Ending balance, net	3,651.2	1,888.0	5,539.2
Accumulated impairment losses	18.4	20.4	38.8
Ending balance, gross	<u>\$ 3,669.6</u>	<u>\$ 1,908.4</u>	<u>\$ 5,578.0</u>

### ***Other intangible assets***

The following table presents the components of other intangible assets:

<i>(in millions)</i>	<b>December 31, 2025</b>			<b>December 31, 2024</b>		
	<b>Gross value</b>	<b>Accumulated amortization and impairment<sup>1</sup></b>	<b>Carrying value</b>	<b>Gross value</b>	<b>Accumulated amortization and impairment<sup>1</sup></b>	<b>Carrying value</b>
Customer relationships	\$4,915.0	\$ 2,172.7	\$ 2,742.3	\$4,697.5	\$ 1,840.4	\$ 2,857.1
Trade names	366.8	272.9	93.9	351.6	240.4	111.2
Other	641.6	376.3	265.3	626.8	327.2	299.6
Total finite-lived	<u>\$5,923.4</u>	<u>\$ 2,821.9</u>	3,101.5	<u>\$5,675.9</u>	<u>\$ 2,408.0</u>	3,267.9
Indefinite-lived			92.3			92.3
Total			<u>\$ 3,193.8</u>			<u>\$ 3,360.2</u>

1. As of December 31, 2025 and December 31, 2024, accumulated impairment losses on Customer relationships were \$65.9 million and on Other were \$40.5 million, totaling \$106.4 million.

Amortization expense was \$301.1 million in 2025, \$299.8 million in 2024 and \$307.7 million in 2023.

We recorded an impairment charge of \$106.4 million on Ritter’s finite-lived intangible assets in the second quarter of 2023 in connection with the impairment of Ritter’s property, plant & equipment, as previously discussed in note 10. This charge impacted our Laboratory Solutions reportable segment.

The following table presents estimated future amortization:

<i>(in millions)</i>	<b>December 31, 2025</b>
2026 .....	\$ 303.5
2027 .....	302.0
2028 .....	286.6
2029 .....	282.8
2030 .....	280.1
Thereafter .....	1,646.5
Total .....	<u>\$ 3,101.5</u>

## 12. Restructuring

The following table presents restructuring and severance expenses by plan:

<i>(in millions)</i>	<b>Year ended December 31,</b>		
	<b>2025</b>	<b>2024</b>	<b>2023</b>
2024 restructuring program .....	\$ (5.3)	\$ 82.8	\$ —
Other .....	35.1	—	26.5
Total .....	<u>\$ 29.8</u>	<u>\$ 82.8</u>	<u>\$ 26.5</u>

Restructuring and severance charges are classified as SG&A expenses or cost of sales depending on the nature of the expense.

### 2024 restructuring program

The 2024 restructuring program is a part of the Company’s multi-year cost transformation initiative designed to right-size the Company’s cost base and optimize its footprint and organizational structure with a focus on driving cost improvement and productivity. During 2025, we recognized a \$(5.3) million non-cash adjustment that reduced the previously recorded 2024 restructuring accrual, primarily reflecting updates to expected severance and other exit costs that were no longer required. No additional material charges were incurred in 2025, and we do not expect to incur additional material charges related to this program in future periods.

The following table presents information about expenses under the 2024 restructuring program for the periods covered under this report in which the plan was active:

<i>(in millions)</i>	<u>Year ended December 31,</u>		<u>As of year ended December 31, 2025</u>		
	<u>2025</u>	<u>2024</u>	<u>Charges incurred</u>	<u>Expected remaining charges</u>	<u>Total expected charges</u>
Employee severance and related	\$ (5.3)	\$ 64.3	\$ 59.0	\$ —	\$ 59.0
Facility closure	—	1.6	1.6	—	1.6
Other	—	16.9	16.9	—	16.9
Total	<u>\$ (5.3)</u>	<u>\$ 82.8</u>	<u>\$ 77.5</u>	<u>\$ —</u>	<u>\$ 77.5</u>
Laboratory Solutions	\$ (1.7)	\$ 41.3	\$ 39.6	\$ —	\$ 39.6
Bioscience Production	(3.6)	40.6	37.0	—	37.0
Corporate	—	0.9	0.9	—	0.9
Total	<u>\$ (5.3)</u>	<u>\$ 82.8</u>	<u>\$ 77.5</u>	<u>\$ —</u>	<u>\$ 77.5</u>

Other charges in the table above primarily relate to the write-downs of the carrying value of assets that we have disposed of under the program.

The following table presents changes to accrued employee severance and related expenses under the 2024 restructuring program, which are primarily classified as employee-related current liabilities:

<i>(in millions)</i>	<u>Year ended December 31,</u>	
	<u>2025</u>	
Beginning balance	\$	21.3
Non-cash adjustments		(5.3)
Cash payments		(12.5)
Currency translation		(0.6)
Ending balance	<u>\$</u>	<u>2.9</u>

### 13. Commitments and contingencies

Our business involves commitments and contingencies related to compliance with environmental laws and regulations, the manufacture and sale of products and litigation. The ultimate resolution of contingencies is subject to significant uncertainty, and it is reasonably possible that contingencies could be decided unfavorably against us.

#### *Environmental laws and regulations*

Our environmental liabilities are subject to changing governmental policy and regulations, discovery of unknown conditions, judicial proceedings, method and extent of remediation, existence of other potentially responsible parties and future changes in technology. We believe that known and unknown environmental matters, if not resolved favorably, could have a material effect on our financial position, liquidity and profitability. Matters to be disclosed are as follows:

### *Mallinckrodt indemnification*

In 2010, New Mountain Capital acquired us from Covidien plc in accordance with a stock purchase agreement dated May 25, 2010. At that time, we were organized as Mallinckrodt Baker, Inc. or MBI. Pursuant to the terms of that agreement, we are entitled to various levels of indemnification with respect to environmental liabilities involving the former MBI operations. In 2013, in connection with the Covidien plc divestiture of Mallinckrodt Group S.a.r.l and Mallinckrodt LLC, together “Mallinckrodt,” and by a second amendment to the stock purchase agreement dated June 6, 2013, but effective upon the consummation of the divestiture, Covidien plc assigned its obligations as described herein to Mallinckrodt, and Mallinckrodt assumed those obligations from Covidien plc subject to a continuing guarantee by Covidien International Finance, S.A (“CIFSA”). As a result of the stock purchase agreement and assignment, Mallinckrodt is contractually obligated to indemnify and defend us for all off-site environmental liabilities (for example, Superfund or CERCLA liabilities) arising from the pre-closing disposal of chemicals or wastes by former MBI operations.

In connection with environmental liabilities arising from pre-closing noncompliance with environmental laws, Mallinckrodt became contractually obligated to reimburse us for a percentage of the total liability, with such reimbursements made through disbursements from a \$30.0 million environmental escrow established at the time of the closing. Specifically, Mallinckrodt became responsible for reimbursement of 80% of the total costs up to \$40.0 million of such environmental liabilities. Mallinckrodt became responsible for reimbursement of 50% of the next \$40.0 million of such environmental liabilities. If such environmental liabilities exceed \$80.0 million in the aggregate, Mallinckrodt became responsible for reimbursement of 100% of such liabilities up to the next \$30.0 million in the aggregate. Currently, reimbursements are 80% of the amounts spent by us, with reimbursements and settlements to date exceeding \$12.0 million. In addition, in connection with operation and maintenance activities required pursuant to administrative consent orders and subsequently issued remedial action permits involving our Phillipsburg, New Jersey, facility, amounts in excess of a small annual threshold are also subject to reimbursement, currently at the 80% level.

In 2023, Mallinckrodt initiated bankruptcy proceedings under Chapter 11 of the Bankruptcy Code and notified us that it was seeking to reject the 2010 stock purchase agreement and its obligations thereunder. As noted above, Mallinckrodt’s obligations under the 2010 stock purchase agreement were guaranteed by CIFSA, who has agreed to honor its indemnity obligations going forward.

### *Other noteworthy matters*

The New Jersey Department of Environmental Protection has ordered us to remediate groundwater conditions near our plant in Phillipsburg, New Jersey. This matter is covered by the indemnification arrangement previously described. At December 31, 2025, our accrued obligation under this order is \$2.3 million, which is calculated based on expected cash payments discounted at rates ranging from 3.4% to 4.8% between 2026 and 2045. The undiscounted amount of that obligation is \$3.5 million.

In 2016, we assessed the environmental condition of our chemical manufacturing site in Gliwice, Poland. Our assessment revealed specific types of soil and groundwater contamination throughout the site. We are also monitoring the condition of a closed landfill on that site. These matters are not covered by our indemnification arrangement because they relate to an operation we subsequently acquired. At December 31, 2025, our balance sheet includes a liability of \$1.2 million for remediation and monitoring costs. That liability is estimated primarily on discounted expected remediation payments and is not materially different from its undiscounted amount.

### ***Manufacture and sale of products***

Our business involves risk of product liability, patent infringement and other claims in the ordinary course of business arising from the products that we produce ourselves or obtain from our suppliers, as well as from the services we provide. Our exposure to such claims may increase to the extent that we expand our manufacturing operations or service offerings.

We maintain insurance policies to protect us against these risks, including product liability insurance. In many cases the suppliers of products we distribute have indemnified us against such claims. Our insurance coverage or indemnification agreements with suppliers may not be adequate in all pending or any future cases brought against us. Furthermore, our ability to recover under any insurance or indemnification arrangements is subject to the financial viability of our insurers, our suppliers and our suppliers' insurers, as well as legal enforcement under the local laws governing the arrangements.

We have entered into indemnification agreements with customers of our self-manufactured products to protect them from liabilities and losses arising from our negligence, willful misconduct or sale of defective products. To date, we have not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions.

### ***Litigation***

The Company and certain current and former officers and directors have been named as defendants in two putative securities class action lawsuits filed in the United States District Court for the Eastern District of Pennsylvania on October 30, 2025, and November 25, 2025, respectively. The complaints allege violations of Sections 10(b) and 20(a) of the Securities Exchange Act and Rule 10b-5 related to alleged misleading or false statements concerning Avantor's competitive position and the purported effects of increased competition, as well as other aspects of the Company's business, operations, and management. The lawsuits seek unspecified damages, attorneys' fees, and other relief. The Company disputes the claims and intends to vigorously defend against them.

At this time, the outcome of this matter cannot be predicted, and management cannot reasonably estimate the possible loss or range of loss, if any.

Adverse developments in this litigation could result in significant costs or damages; however, based on the information currently available, management does not believe the resolution of this matter will have a material adverse effect on the Company's consolidated financial position, results of operations, or cash flows.

At December 31, 2025, there was no outstanding litigation that we believe would result in material losses if decided against us, and we do not believe that there are any unasserted matters that are reasonably possible to result in a material loss.

## 14. Debt

The following table presents information about our debt:

<i>(dollars in millions)</i>	December 31, 2025			December 31,
	Interest terms	Rate	Amount	2024
Receivables facility	SOFR <sup>1</sup> plus —%	— %	\$ —	\$ 125.0
Senior secured credit facilities:				
Euro term loans B-4	EURIBOR plus —%	— %	—	81.6
Euro term loans B-5	EURIBOR plus —%	— %	—	324.5
Euro term loans B-6	EURIBOR plus 2.50%	4.46 %	645.2	—
Euro term loans A-1	EURIBOR plus 1.50%	3.46 %	469.2	—
U.S. dollar term loans B-6	SOFR <sup>1</sup> plus —%	— %	—	86.6
2.625% secured notes	fixed rate	— %	—	672.6
3.875% unsecured notes	fixed rate	3.875 %	800.0	800.0
3.875% unsecured notes	fixed rate	3.875 %	469.2	413.9
4.625 % unsecured notes	fixed rate	4.625 %	1,550.0	1,550.0
Finance lease liabilities			26.9	15.0
Other			7.4	8.6
Total debt, gross			3,967.9	4,077.8
Less: unamortized deferred financing costs			(21.6)	(22.0)
Total debt			<u>\$ 3,946.3</u>	<u>\$ 4,055.8</u>
Classification on balance sheets:				
Current portion of debt			\$ 30.8	\$ 821.1
Debt, net of current portion			3,915.5	3,234.7

1. SOFR includes credit spread adjustment.

The following table presents mandatory future repayments of debt principal:

<i>(in millions)</i>	December 31, 2025
2026	\$ 30.8
2027	37.4
2028	2,056.1
2029	835.7
2030	391.0
Thereafter	616.9
Total debt, gross	<u>\$ 3,967.9</u>

Interest expense, net includes interest income of \$42.2 million, \$75.1 million and \$65.2 million for the year ended December 31, 2025, December 31, 2024 and December 31, 2023, respectively. The interest income for the year ended December 31, 2025, December 31, 2024 and December 31, 2023, primarily relates to income on our interest rate swaps and cross currency swaps discussed in note 21.

### ***Credit facilities***

The following table presents availability under our revolving credit facility:

<i>(in millions)</i>	<b>December 31, 2025</b>
Capacity .....	\$ 1,400.0
Undrawn letters of credit outstanding .....	(19.5)
Unused availability .....	<u>\$ 1,380.5</u>

In June 2023, we amended the revolving credit facility to increase its funding limit to \$975.0 million and extended the term to June 29, 2028. We capitalized \$2.3 million of fees in connection with this transaction.

In October 2025, we amended the revolving credit facility to increase its funding limit to \$1,400.0 million and extended the term to October 9, 2030. We capitalized \$3.8 million of fees in connection with this transaction. Refer to the “Senior secured credit facilities” section below for further discussion of this amendment.

### ***Receivables facility***

In October 2025, we terminated our receivables facility, which had a funding limit of \$400.0 million. The cost associated with terminating this arrangement was not material.

### ***Senior secured credit facilities***

On December 31, 2025, the senior secured credit facilities consisted of a \$1,400.0 million revolving credit facility that matures on October 9, 2030, a \$645.2 million term loan facility that matures on October 9, 2032 and a \$469.2 million term loan facility that matures on October 9, 2030. The revolving credit facility allows us to issue letters of credit and short-term notes. Borrowings under the facilities are guaranteed by substantially all of our domestic subsidiaries and secured by substantially all of their assets. The senior secured credit facilities bear interest at variable rates. The margin on the revolving credit facility decreases if certain net leverage ratios are achieved. Various other immaterial fees are payable under the facilities.

In October 2025, we completed a refinancing that included the issuance of €400.0 million and €550.0 million of senior secured term loans, maturing in October 2030 and October 2032, respectively. These loans bear interest at EURIBOR plus 150 basis points and EURIBOR plus 250 basis points, respectively. The proceeds from these issuances, along with cash on hand, were used to repay our outstanding U.S. dollar term loans B-6, Euro term loans B-4 and B-5, the remaining 2.625% secured notes, and the receivables facility. We capitalized \$8.0 million of fees and expensed \$4.4 million of fees in connection with this transaction.

In connection with the refinancing, we amended our revolving credit facility to obtain an additional \$425.0 million in available funding, increasing the total availability under the facility to \$1,400.0 million. The revolving credit facility will mature in October 2030.

Both the newly issued senior secured term loans and the amended revolving credit facility include covenants that we consider to be usual and customary. As part of the refinancing and the addition of the new €400.0 million term loan, (i) the leverage-based financial covenant in the credit facility agreement became a full-time financial maintenance covenant, whereas previously it had been a “springing covenant”, and (ii) a new consolidated interest coverage ratio financial maintenance covenant was added to the credit facilities agreement, in both cases on usual and customary terms for facility agreements governing these types of senior secured term loan and revolving credit facilities. As of December 31, 2025, our net leverage and consolidated interest coverage ratio were within the covenant requirements.

We are required to make additional prepayments if: (i) we generate excess cash flows, as defined, at specified percentages that decline if certain net leverage ratios are achieved; or (ii) we receive cash proceeds from certain types of asset sales or debt issuances. No additional required prepayments have become due since the inception of the credit facilities.

We may also prepay the term loans at our option. In 2025 and 2024, we made optional prepayments of \$449.4 million and \$526.4 million, respectively, of Euro term loans and \$80.8 million and \$690.0 million, respectively, of U.S. dollar term loans. In connection with the 2025 and 2024 prepayments, we recorded losses on extinguishment of debt of \$1.1 million and \$10.9 million, respectively, for the proportional write-off of related unamortized deferred financing costs.

## 15. Equity

The following table presents the equity capitalization of Avantor, Inc.:

<i>(shares in millions)</i>	<b>Par value per share</b>	<b>Shares authorized</b>
Undesignated preferred stock .....	\$ 0.01	75.0
Common stock .....	0.01	750.0

### ***Common stock***

Each share of common stock entitles the holder to one vote for applicable matters. Holders are entitled to receive dividends declared by the board of directors and a pro rata share of assets available for distribution after satisfaction of the rights of the preferred stockholders.

### ***Share purchase program***

In October 2025, our Board of Directors authorized the repurchase of up to \$500.0 million of our common stock, exclusive of fees, commissions and related transaction expenses. Repurchases may be funded through our available cash, borrowings under existing credit facilities or other financing arrangements approved by the Board of Directors.

Management is authorized to repurchase our common stock on the open market or in privately negotiated transactions, through one or more Rule 10b5-1 trading plans, Rule 10b-18 repurchase programs, accelerated share repurchase programs, including any collateral arrangements, or a combination thereof. The timing, manner, price and amount of repurchases will be determined by management depending upon economic, market and other conditions. The repurchase program may be modified, suspended, or terminated at any time. Shares repurchased under the program are held as treasury stock.

During the fourth quarter of 2025, we repurchased \$75.0 million of our common stock (6.6 million shares). As of December 31, 2025, \$425.0 million remained available for repurchase under the program.

## 16. Accumulated other comprehensive income (loss)

The following table presents changes in the components of AOCI:

<i>(in millions)</i>	<b>Foreign currency translation</b>	<b>Derivative instruments</b>	<b>Defined benefit plans</b>	<b>Total</b>
Balance on December 31, 2022	\$ (131.3)	\$ 19.9	\$ 11.1	\$ (100.3)
Unrealized gain (loss)	38.3	21.3	(7.7)	51.9
Reclassification of gain into earnings	—	(31.0)	(5.9)	(36.9)
Change due to income taxes	10.2	2.4	3.7	16.3
Balance on December 31, 2023	(82.8)	12.6	1.2	(69.0)
Unrealized (loss) gain	(83.3)	18.2	(17.4)	(82.5)
Reclassification of (gain) loss into earnings	(0.5)	(34.5)	6.9	(28.1)
Change due to income taxes	(10.8)	3.9	2.5	(4.4)
Balance on December 31, 2024	(177.4)	0.2	(6.8)	(184.0)
Unrealized gain	123.2	9.3	11.0	143.5
Reclassification of (gain) loss into earnings	—	(9.5)	17.3	7.8
Change due to income taxes	23.2	—	(7.4)	15.8
Balance on December 31, 2025	<u>\$ (31.0)</u>	<u>\$ —</u>	<u>\$ 14.1</u>	<u>\$ (16.9)</u>

The reclassifications effects shown above were immaterial to the financial statements and were made to either cost of sales, SG&A expense, other (expense) income, net or interest expense depending upon the nature of the underlying transaction. The income tax effects in 2025 and 2024 on foreign currency translation were due to our net investment hedge and cross-currency swap discussed in note 21.

## 17. Employee benefit plans

We sponsor many defined benefit plans across the globe. Those plans have resulted in significant obligations to pay benefits to current and former employees, many of which are at least partially funded with plan assets. Unless required otherwise, we typically seek to close the defined benefit plans to new participants. Defined benefit plans do not materially impact our earnings, and as a result, certain disclosures have been omitted.

We approved the termination of one of our two U.S. pension plans during 2024. The pension liability was partially settled in December 2024 due to lump sum distribution payments of \$54.2 million to plan participants. We recorded \$9.3 million of pension termination costs for the year ended December 31, 2024, which are included in other income or expenses as discussed in note 19.

The remaining pension liability was settled in 2025, primarily through the purchase of annuity contracts totaling \$97.7 million. As a result of the settlement, we recorded \$16.3 million of pension termination costs in 2025, which were primarily recognized in other income or expense.

The remaining pension surplus from the plan was used by the Company, as prescribed by applicable regulations, to fund a Qualified Replacement Plan, which will primarily fund future non-elective contributions to the Avantor U.S. 401(k) defined contribution plan.

The following table presents changes in benefit obligations and plan assets and the funded status of our plans:

<i>(in millions)</i>	U.S. pension plans Year ended December 31,		Non-U.S. pension plans Year ended December 31,		U.S. medical plan Year ended December 31,	
	2025	2024	2025	2024	2025	2024
<b>Benefit obligation:</b>						
Beginning balance	\$ 119.7	\$ 164.6	\$ 179.0	\$ 200.7	\$ 9.8	\$ 10.6
Service cost	0.8	1.9	3.4	3.2	0.1	0.1
Interest cost	0.9	8.1	6.8	6.8	0.6	0.5
Employee contributions	—	—	1.3	1.1	—	—
Actuarial (gain) loss	(2.2)	8.5	(11.4)	(7.9)	0.9	(1.0)
Benefits paid	(0.7)	(9.2)	(7.6)	(7.7)	(0.4)	(0.4)
Settlements and curtailments	(110.9)	(54.2)	(8.2)	(9.0)	—	—
Currency translation	—	—	20.1	(9.5)	—	—
Other	(0.1)	—	1.9	1.3	—	—
Ending balance	7.5	119.7	185.3	179.0	11.0	9.8
<b>Fair value of plan assets:</b>						
Beginning balance	153.7	214.7	109.0	124.8	—	—
Return (loss) on plan assets	0.6	1.7	5.5	(3.5)	—	—
Employer contributions	0.7	0.7	6.5	6.3	0.4	0.4
Employee contributions	—	—	1.3	1.1	—	—
Benefits paid	(0.7)	(9.2)	(7.6)	(7.7)	(0.4)	(0.4)
Settlements and curtailments	(110.9)	(54.2)	(7.4)	(9.0)	—	—
Currency translation	—	—	10.8	(4.4)	—	—
Other <sup>1</sup>	(43.4)	—	2.1	1.4	—	—
Ending balance	—	153.7	120.2	109.0	—	—
Funded status at end of year	<u>\$ (7.5)</u>	<u>\$ 34.0</u>	<u>\$ (65.1)</u>	<u>\$ (70.0)</u>	<u>\$ (11.0)</u>	<u>\$ (9.8)</u>

1. The amount reported for the year ended December 31, 2025, primarily reflects the transfer of the remaining pension surplus from the terminated U.S. Pension Plan to fund a Qualified Replacement Plan.

The following table presents other balance sheet information for defined benefit plans:

<i>(in millions)</i>	<b>U.S. pension plans December 31,</b>		<b>Non-U.S. pension plans December 31,</b>		<b>U.S. medical plan December 31,</b>	
	<b>2025</b>	<b>2024</b>	<b>2025</b>	<b>2024</b>	<b>2025</b>	<b>2024</b>
Accumulated benefit obligation	\$ 7.5	\$ 119.6	\$ 182.9	\$ 176.4	\$ 10.9	\$ 9.8
Amounts recorded in balance sheet:						
Other assets	\$ —	\$ 41.6	\$ 10.6	\$ 4.5	\$ —	\$ —
Other current liabilities	(0.7)	(0.7)	(3.2)	(2.8)	(0.9)	(0.7)
Other liabilities	(6.8)	(6.9)	(72.5)	(71.7)	(10.1)	(9.1)
Funded status	<u>\$ (7.5)</u>	<u>\$ 34.0</u>	<u>\$ (65.1)</u>	<u>\$ (70.0)</u>	<u>\$ (11.0)</u>	<u>\$ (9.8)</u>
Components of AOCI, excluding tax effects:						
Actuarial gain (loss)	\$ 0.4	\$ (19.1)	\$ 16.1	\$ 3.1	\$ 7.5	\$ 9.3
Prior service gain	—	—	0.6	1.0	—	—

The following table presents the assumptions used to determine the benefit obligation:

	<b>U.S. pension plans December 31,</b>		<b>Non-U.S. pension plans December 31,</b>		<b>U.S. medical plan December 31,</b>	
	<b>2025</b>	<b>2024</b>	<b>2025</b>	<b>2024</b>	<b>2025</b>	<b>2024</b>
Discount rate	5.2 %	5.5 %	4.1 %	3.7 %	5.3 %	5.2 %
Annual rate of salary increase	— %	3.5 %	2.1 %	2.2 %	—	—
Health care cost trends:						
Initial rate	n/a	n/a	n/a	n/a	7.5 %	6.9 %
Ultimate rate	n/a	n/a	n/a	n/a	4.0 %	4.0 %
Year ultimate rate is reached	n/a	n/a	n/a	n/a	2050	2048

Actuarial gains for the year ended December 31, 2025 were primarily attributable to higher discount rates (excluding the terminated U.S. plan) and increases in lump-sum conversion rates for the U.S. plans. Additional gains resulted from lower inflation assumptions. These favorable impacts were partially offset by experience losses in the non-U.S. plans during the year. For 2024, increases in discount rates in both the U.S. and U.K. generated most of the actuarial gains in the U.S. and non-U.S. pension plan obligations. These gains were partially offset by experience losses in the U.S. related to annuity purchases completed as part of the plan termination process. Non-U.S. plans also recorded experience gains in 2024 due to involuntary terminations. Actuarial losses in the U.S. postretirement medical plan in 2025 were driven primarily by unfavorable experience and a decrease in the discount rate, compared to 2024, when actuarial gains were mainly attributable to favorable experience.

The following table presents future benefits expected to be paid:

<i>(in millions)</i>	December 31, 2025		
	U.S. pension plans	Non-U.S. pension plans	U.S. medical plan
2026	\$ 0.7	\$ 10.1	\$ 0.9
2027	0.7	10.3	0.9
2028	0.7	11.4	0.9
2029	0.7	13.2	1.0
2030	0.7	12.7	1.0
2031 – 2035	3.0	63.8	4.6

We do not expect to make any material contributions to our defined benefit plans in 2026.

The following table presents the allocation of plan assets:

<i>(in millions)</i>	December 31, 2025					December 31, 2024				
	Total	Level 1	Level 2	Level 3	NAV <sup>1</sup>	Total	Level 1	Level 2	Level 3	NAV <sup>1</sup>
U.S. plans:										
Cash	\$ —	\$ —	\$ —	\$ —	\$ —	\$ 25.4	\$ 25.4	\$ —	\$ —	\$ —
Fixed income	—	—	—	—	—	122.8	23.3	99.5	—	—
Equity	—	—	—	—	—	5.5	5.5	—	—	—
Total	<u>\$ —</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ 153.7</u>	<u>\$ 54.2</u>	<u>\$ 99.5</u>	<u>\$ —</u>	<u>\$ —</u>
Non-U.S. plans:										
Cash	\$ 1.0	\$ 1.0	\$ —	\$ —	\$ —	\$ 1.2	\$ 1.2	\$ —	\$ —	\$ —
Fixed income	56.7	—	44.7	—	12.0	46.5	—	42.3	—	4.2
Equity	17.8	—	12.9	—	4.9	20.0	—	11.8	—	8.2
Other	2.0	—	1.5	—	0.5	2.9	—	1.3	—	1.6
Insurance contracts	42.7	—	—	42.7	—	38.4	—	—	38.4	—
Total	<u>\$ 120.2</u>	<u>\$ 1.0</u>	<u>\$ 59.1</u>	<u>\$ 42.7</u>	<u>\$ 17.4</u>	<u>\$ 109.0</u>	<u>\$ 1.2</u>	<u>\$ 55.4</u>	<u>\$ 38.4</u>	<u>\$ 14.0</u>

- Investments are measured at fair value using the net asset value per share practical expedient, and therefore, are not classified in the fair value hierarchy.

For periods prior to the plan's termination, the U.S. pension plan's investment strategy focused on aligning the duration of plan assets with the duration of benefit obligations. This strategy utilized diversified fixed-income funds to hedge movements in the discount rate, with investments primarily in long-duration, investment-grade corporate bonds across industrial, financial, and utility sectors. Surplus assets were invested in equity funds. The plan was fully settled and terminated in 2025, and therefore no U.S. pension plan assets remained invested as of December 31, 2025.

For the non-U.S. plans, in many cases we enter into insurance contracts to guarantee payment of benefits for an annual fee. Otherwise, our primary investment strategy is to seek a return on plan assets sufficient to achieve our long-term funding objectives. To seek this return, we invest significantly in global equity funds and secondarily in fixed income funds to mitigate inflation and interest rate risk. These funds primarily invest in inflation-linked and other types of government bonds. We estimate the expected long-term rate of return on plan assets in a similar manner to the U.S. plans.

The following table presents changes to plan assets of non-U.S. plans that were measured using unobservable inputs:

<i>(in millions)</i>	Year ended December 31,	
	2025	2024
Beginning balance	\$ 38.4	\$ 45.7
Purchases	6.3	5.0
Actual returns	0.4	0.4
Settlements	(7.8)	(9.7)
Currency translation	5.4	(3.0)
Ending balance	<u>\$ 42.7</u>	<u>\$ 38.4</u>

## 18. Stock-based compensation

The following table presents the components of stock-based compensation expense:

<i>(in millions)</i>	Classification	Year ended December 31,		
		2025	2024	2023
Stock options	Equity	\$ 9.3	\$ 10.5	\$ 13.7
RSUs	Equity	37.1	35.0	25.5
Other	Both	—	1.3	1.3
Total		<u>\$ 46.4</u>	<u>\$ 46.8</u>	<u>\$ 40.5</u>
Award classification:				
Equity		\$ 47.6	\$ 47.0	\$ 40.2
Liability		(1.2)	(0.2)	0.3

At December 31, 2025, unvested awards have remaining expense of \$67.1 million to be recognized over a weighted average period of 1.5 years.

We recognized a reduction to income tax expense as a result of tax benefits associated with our stock-based compensation plans of \$3.0 million, \$5.9 million and \$5.0 million, in 2025, 2024 and 2023, respectively.

Our stock-based compensation awards have been issued under a succession of plans sponsored by the ultimate parent of our business, which is currently Avantor, Inc. In connection with our IPO, we adopted the 2019 Plan. The 2019 Plan provides for up to 23.5 million shares of common stock to be issued in the form of stock options, RSUs or other equity-based awards or cash-based awards. The 2019 Plan also provides for 1% annual increases to the number of shares of common stock available for issuance unless reduced by our Board of Directors. At December 31, 2025, 43.7 million shares were available for future issuance. The 2019 Plan will automatically terminate on May 17, 2029, and no award under the plan may be granted after this date.

## Stock options

The following table presents information about outstanding stock options:

<i>(options and intrinsic value in millions)</i>	<b>Number of options</b>	<b>Weighted average exercise price per option</b>	<b>Aggregate intrinsic value</b>	<b>Weighted average remaining term</b>
Balance on December 31, 2024	11.9	\$ 21.94		
Granted	1.5	16.01		
Exercised	(0.1)	7.80		
Forfeited	(1.6)	22.57		
Balance on December 31, 2025	<u>11.7</u>	\$ 21.18	\$ —	4.2 years
Expected to vest	2.0	19.16	—	8.6 years
Vested	9.7	21.57	—	3.4 years

During 2025, we granted stock options with a contractual life of ten years that vest annually over two to three years, as specified in the underlying grant agreements, subject to the recipient continuously providing service to us through each applicable vesting period.

The following table presents weighted-average information about stock options granted:

	<b>Year ended December 31,</b>		
	<b>2025</b>	<b>2024</b>	<b>2023</b>
Grant date fair value per option	\$ 6.05	\$ 9.86	\$ 9.64
Assumptions used to determine grant date fair value:			
Expected stock price volatility	32 %	34 %	33 %
Risk free interest rate	4.2 %	4.3 %	4.1 %
Expected dividend rate	nil	nil	nil
Expected life of options	6.0 years	6.0 years	6.2 years

The following table presents other information about stock options:

<i>(in millions)</i>	<b>Year ended December 31,</b>		
	<b>2025</b>	<b>2024</b>	<b>2023</b>
Fair value of options vested	\$ 12.5	\$ 13.7	\$ 14.2
Intrinsic value of options exercised	0.8	11.7	7.1

## RSUs

The following table presents information about unvested RSUs:

<i>(awards in millions)</i>	Number of awards	Weighted average grant date fair value per award
Balance on December 31, 2024	4.6	\$ 26.63
Granted	4.9	15.33
Vested	(1.3)	27.14
Forfeited	(1.5)	21.36
Balance on December 31, 2025	6.7	\$ 17.88

During 2025, we granted RSUs that vest annually over one to three years, as specified in the underlying grant agreements, subject to the recipient continuously providing service to us throughout the vesting period. Certain of those awards contain performance and market conditions that impact the number of shares that will ultimately vest. We recorded expense on such awards of \$2.8 million, \$9.3 million and \$3.1 million, for the years ended December 31, 2025, 2024 and 2023, respectively.

The fair value of RSUs that vested in 2025, 2024 and 2023 was \$32.4 million, \$31.0 million and \$29.5 million, respectively.

## 19. Other income or expense, net

The following table presents the components of other income or expense, net:

<i>(in millions)</i>	Year ended December 31,		
	2025	2024	2023
Net foreign currency (loss) gain from financing activities	\$ (7.7)	\$ 4.7	\$ 3.1
(Expense) income related to defined benefit plans	(15.9)	(6.6)	2.6
Other	2.9	0.7	0.1
Other (expense) income, net	<u>\$ (20.7)</u>	<u>\$ (1.2)</u>	<u>\$ 5.8</u>

Most of the net foreign currency remeasurement (loss) gain from financing activities was caused by the volatility of the U.S. dollar on unhedged intercompany loan positions as disclosed in note 6. Other income or expense related to our defined benefit plans primarily relates to pension termination charges as described in note 17, and the expected returns on defined benefit plan assets.

## 20. Income taxes

The following table presents detail about captions appearing on the statements of operations:

<i>(in millions)</i>	Year ended December 31,		
	2025	2024	2023
(Loss) income before income taxes:			
United States	\$ (580.6)	\$ 521.2	\$ 527.6
Foreign	139.3	332.7	(117.1)
Total	<u>\$ (441.3)</u>	<u>\$ 853.9</u>	<u>\$ 410.5</u>
Current income tax (expense) benefit:			
Federal	\$ (24.9)	\$ (97.6)	\$ (110.7)
State	(9.5)	(30.4)	(35.5)
Foreign	(46.8)	(61.3)	(115.6)
Subtotal	<u>(81.2)</u>	<u>(189.3)</u>	<u>(261.8)</u>
Deferred income tax (expense) benefit:			
Federal	(23.4)	18.5	18.9
State	20.3	(0.4)	0.9
Foreign	(4.6)	28.8	152.6
Subtotal	<u>(7.7)</u>	<u>46.9</u>	<u>172.4</u>
Income tax expense	<u>\$ (88.9)</u>	<u>\$ (142.4)</u>	<u>\$ (89.4)</u>

The following table reconciles the income tax provision calculated at the United States federal corporate rate to the amounts presented in the statements of operations:

<i>(in millions)</i>	Year ended December 31,					
	2025		2024		2023	
	\$	%	\$	%	\$	%
(Loss) income before income taxes	(441.3)		853.9		410.5	
United States federal corporate rate	(92.7)	21.0 %	179.3	21.0 %	86.2	21.0 %
State and Local Income Taxes, Net of Federal Income Tax Effect <sup>1</sup>	(8.6)	1.9 %	24.3	2.9 %	27.3	6.7 %
Foreign Tax Effects						
Germany						
German Trade Tax	2.9	(0.7)%	1.9	0.2 %	5.5	1.3 %
Statutory tax rate difference between Germany and United States	(7.5)	1.7 %	(9.1)	(1.1)%	(21.1)	(5.1)%
Valuation Allowance	16.0	(3.6)%	22.5	2.6 %	24.6	6.0 %
Other Germany	(1.0)	0.2 %	(1.7)	(0.1)%	(1.6)	(0.4)%
Netherlands						
Valuation Allowance	(9.5)	2.1 %	—	— %	—	— %
Other Netherlands	2.3	(0.5)%	2.0	0.2 %	(6.9)	(1.7)%
Singapore						
Tax Exempt Income	—	— %	(14.5)	(1.7)%	(14.7)	(3.6)%

Other Singapore	0.2	— %	(3.4)	(0.4)%	(3.3)	(0.8)%
Switzerland						
Change in Applicable Cantonal Tax Rate	15.6	(3.5)%	—	— %	0.3	0.1 %
Other Switzerland	(3.2)	0.7 %	3.1	0.4 %	(0.6)	(0.1)%
United Kingdom						
Clinical Services Sale	—	— %	(38.5)	(4.5)%	—	— %
Tax Exempt Income	(19.2)	4.4 %	(0.6)	(0.1)%	—	— %
Other United Kingdom	4.4	(1.0)%	4.3	0.5 %	(2.3)	(0.6)%
Other Foreign Jurisdictions	7.5	(1.7)%	(1.2)	(0.1)%	4.5	1.1 %
Effect of Cross-Border Tax Laws						
FDII	(14.4)	3.3 %	(13.9)	(1.6)%	(17.1)	(4.2)%
GILTI	(0.1)	— %	8.0	0.9 %	(0.1)	— %
Other Effect of Cross-Border Tax Laws	1.7	(0.4)%	1.2	0.1 %	—	— %
Tax Credits						
Research and development tax credits	(1.4)	0.3 %	(2.1)	(0.2)%	(1.9)	(0.5)%
Nontaxable or Nondeductible Items						
Executive Compensation Limitation	4.7	(1.1)%	2.2	0.3 %	6.1	1.5 %
Impairment of Goodwill	164.9	(37.4)%	—	— %	—	— %
Other Permanent differences	6.1	(1.3)%	6.2	0.7 %	1.7	0.4 %
Changes in Unrecognized Tax Benefits	17.0	(3.8)%	(22.7)	(2.8)%	(0.3)	(0.1)%
Other Adjustments	3.2	(0.7)%	(4.9)	(0.5)%	3.1	0.8 %
Income tax benefit	<u>\$ 88.9</u>	<u>(20.1)%</u>	<u>\$142.4</u>	<u>16.7%</u>	<u>\$ 89.4</u>	<u>21.8%</u>

1. State taxes in California, Massachusetts, Pennsylvania, and Maryland make up the majority (greater than 50 percent) of the tax effect in this category.

## ***Deferred taxes***

The following table presents the components of deferred tax assets and liabilities:

<i>(in millions)</i>	<b>December 31,</b>	
	<b>2025</b>	<b>2024</b>
<b>Deferred tax assets:</b>		
Reserves and accrued expenses	\$ 49.0	\$ 54.7
Pension, postretirement and environmental liabilities	0.5	8.2
Net operating loss and deferred deductions	367.2	458.7
Other	38.3	3.1
Deferred tax assets, gross	455.0	524.7
Less: valuation allowances	(190.1)	(214.1)
Deferred tax assets, net	264.9	310.6
<b>Deferred tax liabilities:</b>		
Intangibles	(611.8)	(656.1)
Property, plant and equipment	(64.8)	(57.8)
Investment in partnerships	(71.0)	(58.5)
Deferred tax liabilities	(747.6)	(772.4)
Net deferred tax liability	\$ (482.7)	\$ (461.8)
<b>Classification on balance sheets:</b>		
Other assets	\$ 74.4	\$ 95.5
Deferred income tax liabilities	(557.1)	(557.3)

The (decrease) increase to the valuation allowance was \$(24.0) million in 2025, \$8.0 million in 2024 and \$26.4 million in 2023.

At December 31, 2025, \$132.1 million of the valuation allowances presented above relate to foreign net operating loss carryforwards that are not expected to be realized. We evaluate the realization of deferred tax assets by considering such factors as the reversal of existing taxable temporary differences, expected profitability by tax jurisdiction and available carryforward periods. The extent and timing of any such reversals will influence the extent of tax benefits recognized in a particular year. Should applicable losses, credits and deductions ultimately be realized, the resulting reduction in the valuation allowance would generally be recognized as an income tax benefit.

## ***Uncertain tax positions***

We file federal income tax returns in the United States and other tax returns in various states and international jurisdictions. In the normal course of business, we are subject to examination by taxing authorities throughout the world. In these cases, we evaluate our tax position using the recognition threshold and the measurement analysis in accordance with the accounting guidance. A tax position that meets the more-likely-than-not recognition threshold is measured to determine the amount of benefit recognized in our financial statements. Tax years are subject to examination in the United States since 2021 at the federal level, since 2017 for certain states and in certain international jurisdictions since 2014.

The following table reflects changes to the reserve for uncertain tax positions, excluding accrued interest and penalties:

<i>(in millions)</i>	<b>Year ended December 31,</b>		
	<b>2025</b>	<b>2024</b>	<b>2023</b>
Beginning balance	\$ 83.3	\$ 106.9	\$ 51.8
Additions:			
Tax positions related to the current year	1.1	1.1	—
Tax positions related to prior years	34.0	1.6	65.2
Reductions:			
Settlements with taxing authorities	(18.1)	—	(6.3)
Lapse of statutes of limitations	(1.4)	(25.6)	(4.5)
Currency translation	8.0	(0.7)	0.7
Ending balance	<u>\$ 106.9</u>	<u>\$ 83.3</u>	<u>\$ 106.9</u>

At December 31, 2025, December 31, 2024 and December 31, 2023, the total amount of unrecognized tax benefits that, if recognized, would reduce income tax expense and the effective tax rate by \$79.1 million, \$31.3 million and \$50.8 million, respectively.

Accrued interest and penalties related to the reserve for uncertain tax positions were \$11.1 million at December 31, 2025, \$7.2 million at December 31, 2024 and \$8.2 million at December 31, 2023.

The development of reserves for uncertain tax positions requires judgments about tax issues, potential outcomes and the timing of settlement discussions with tax authorities. If we were to prevail on all uncertain tax positions, we would recognize an income tax benefit.

#### ***Deferred tax treatment of retained goodwill***

The Company completed the sale of its Clinical Services business on October 17, 2024. Under ASC 350-20-40-3, the Company determined the amount of goodwill that was deconsolidated in the sale by allocating goodwill between the Clinical Services business and the Company. The goodwill that was retained from the Clinical Services business by the Company has been treated as non-deductible goodwill, which creates a permanent basis difference for tax purposes for which no deferred tax liability has been provided.

#### ***Deferred tax treatment of goodwill impairment***

In the third quarter of 2025, the Company recorded a goodwill impairment charge of \$785.0 million related to our Distribution reporting unit, formerly referred to as our Buy Sell reporting unit. The impairment charge was recorded against “Component 2 goodwill”, which relates to book goodwill exceeding the amount that is tax-deductible resulting in the goodwill being non-deductible as a permanent difference.

#### ***Other matters***

Undistributed earnings of foreign subsidiaries that are deemed to be permanently reinvested amount to \$2,776.2 million at December 31, 2025. In addition to the one-time transition tax imposed on all accumulated foreign undistributed earnings through December 31, 2017, undistributed earnings of foreign subsidiaries as of December 31, 2025 may still be subject to certain taxes upon repatriation, primarily

where foreign withholding taxes apply. We assert indefinite reinvestment related to investments in foreign subsidiaries. It is not practicable to calculate the unrecognized deferred tax liability on undistributed foreign earnings due to the complexity of the hypothetical calculation.

At December 31, 2025, we had federal net operating loss carryforwards of \$3.1 million that have indefinite expirations and state net operating loss carryforwards of \$70.8 million that expire at various times through 2041. In addition, we had foreign net operating loss carryforwards of \$560.5 million, which predominantly have indefinite expirations.

On July 4, 2025, the U.S. enacted H.R. 1, commonly referred to as the One Big Beautiful Bill Act (“Act”). As a result of the Act, our current cash tax obligations were reduced by approximately \$43.0 million due to changes to several provisions, including the reinstatement of immediate expensing for domestic research and development expenditures, the extension of 100% bonus depreciation for qualified properties and the relaxation of limitations on the deductibility of business interest expense. The impact on income tax expense resulting from the Act was immaterial.

## **21. Derivative and hedging activities**

### ***Hedging instruments:***

We engage in hedging activities to reduce our exposure to foreign currency exchange rates and interest rates. Our hedging activities are designed to manage specific risks according to our strategies, as summarized below, which may change from time to time. Our hedging activities consist of the following:

- *Economic hedges* — We are exposed to changes in foreign currency exchange rates on certain of our euro-denominated term loans and notes that move inversely from our portfolio of euro-denominated intercompany loans. The currency effects for these non-derivative instruments are recorded through earnings in the period of change and substantially offset one another;
- *Other hedging activities* — Certain of our subsidiaries hedge short-term foreign currency denominated business transactions, external debt and intercompany financing transactions using foreign currency forward contracts. These activities were not material to our consolidated financial statements.

### ***Cash flow hedges of interest rate risk***

Our objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish this objective, the Company primarily uses interest rate swaps as part of its interest rate risk management strategy. Interest rate swaps designated as cash flow hedges involve the receipt of variable amounts from a counterparty in exchange for the Company making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount.

For derivatives designated and that qualify as cash flow hedges of interest rate risk, the gain or loss on the derivative is recorded in AOCI and subsequently reclassified into interest expense in the same period(s) during which the hedged transaction affects earnings. Amounts reported in AOCI related to derivatives will be reclassified to interest expense as interest payments are made on the Company’s variable-rate debt. During the next twelve months, the Company estimates that an immaterial amount will be reclassified as an increase to interest expense.

In April of 2023, we executed an interest rate swap with a notional amount of \$100.0 million to convert SOFR based floating rate interest to fixed rate interest. The swap was designated as a cash flow hedge and was intended to mitigate exposure to fluctuations in interest rates.

During the quarter ended December 31, 2025, the hedging relationship for the \$100.0 million interest rate swap became ineffective because the forecasted transaction was deemed no longer probable of occurring. As a result, hedge accounting was discontinued, and an immaterial gain was reclassified from AOCI into earnings. Following the discontinuation of hedge accounting, we terminated the interest rate swap and received an immaterial amount of cash proceeds in October 2025.

During the quarter ended September 30, 2024, the hedging relationship for our existing \$750.0 million interest rate swap became ineffective because the forecasted transaction was deemed no longer probable of occurring. As a result, hedge accounting was discontinued, and a \$6.2 million gain was reclassified from AOCI into earnings. Following the discontinuation of hedge accounting, we terminated the interest rate swap and received \$6.2 million of cash proceeds in October 2024.

As of December 31, 2025, we had no outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk.

### Effect of cash flow hedge accounting on AOCI

The table below presents the effect of cash flow hedge accounting on AOCI for the years ended December 31, 2025 and 2024.

(in millions)

Hedging relationships	Amount of gain or (loss) recognized in OCI on Derivative		Location of gain or (loss) reclassified from AOCI into income	Amount of gain or (loss) reclassified from AOCI into income	
	Year ended December 31,			Year ended December 31,	
	2025	2024		2025	2024
Interest rate products	\$ 0.1	\$ 5.4	Interest expense, net	\$ 0.4	\$ 21.7
Total	\$ 0.1	\$ 5.4		\$ 0.4	\$ 21.7

### Effect of cash flow hedge accounting on the income statement

The table below presents the effect of our derivative financial instruments on the statement of operations for the years ended December 31, 2025 and 2024.

	Year ended December 31,	
	2025	2024
	Interest expense, net	Interest expense, net
(in millions)		
Total amounts of line items presented in the statements of operations where the effects of cash flow hedges are recorded	\$ (169.8)	\$ (218.8)
Amount of gain reclassified from AOCI into income	\$ 0.4	\$ 21.7

### *Net investment hedges*

We are exposed to foreign currency exchange rate fluctuations on the investments we hold in foreign entities, specifically related to the risk of changes in the EUR-USD exchange rates affecting our net investment in EUR-functional-currency consolidated subsidiaries.

For derivatives designated as net investment hedges, gains and losses are recorded in AOCI as part of the cumulative translation adjustment. These amounts are reclassified from AOCI into earnings only when the hedged net investment is sold or substantially liquidated.

As of December 31, 2025, we had the following outstanding foreign currency derivatives that were used to hedge our net investments in foreign operations:

*(value in millions)*

<b>Foreign currency derivative</b>	<b>Number of instruments</b>	<b>Notional sold</b>	<b>Notional purchased</b>
Cross-currency swaps	3	€ 732.1	\$ 750.0

As of December 31, 2024, we held a cross-currency swap with a notional amount of \$750.0 million, which was scheduled to mature in April 2025. In April 2025, prior to maturity, we executed a transaction to amend and extend the original swap. The liability position of the original cross-currency swap was blended and rolled into three separate cross-currency swap agreements, each with a notional amount of \$250.0 million, maturing in April 2027, April 2028, and April 2029, respectively.

Our cross-currency swaps involve the receipt of functional-currency fixed-rate amounts from a counterparty in exchange for making foreign-currency fixed-rate payments over the life of the agreement.

### **Effect of net investment hedges on AOCI and the income statement**

The table below presents the effect of our net investment hedges on AOCI and the statement of operations for the years ended December 31, 2025 and 2024.

*(in millions)*

<b>Hedging relationships</b>	<b>Amount of gain or (loss) recognized in OCI on Derivative</b>		<b>Location of gain or (loss) recognized in income on Derivative (amount excluded from effectiveness testing)</b>	<b>Amount of gain or (loss) recognized in income on Derivative (amount excluded from effectiveness testing)</b>	
	<b>Year ended December 31,</b>			<b>Year ended December 31,</b>	
	<b>2025</b>	<b>2024</b>		<b>2025</b>	<b>2024</b>
Cross currency swaps	\$ (89.9)	\$ 60.9	Interest expense, net	\$ 9.2	\$ 12.7
Total	<u>\$ (89.9)</u>	<u>\$ 60.9</u>		<u>\$ 9.2</u>	<u>\$ 12.7</u>

The Company did not reclassify any other deferred gains or losses related to net investment hedges from accumulated other comprehensive income (loss) to earnings for the years ended December 31, 2025 and 2024 other than those mentioned above.

The table below presents the fair value of our derivative financial instruments as well as their classification on the Balance Sheet as of December 31, 2025 and 2024:

	Derivative assets				Derivative liabilities			
	December 31,		December 31,		December 31,		December 31,	
	2025	2024	2025	2024	2025	2024	2025	2024
(in millions)	Balance sheet location	Fair value	Balance sheet location	Fair value	Balance sheet location	Fair value	Balance sheet location	Fair value
<i>Derivatives designated as hedging instruments:</i>								
Interest rate products	Other current assets	\$ —	Other current assets	\$ 0.3	Other current liabilities	\$ —	Other current liabilities	\$ —
Foreign exchange products	Other current assets	—	Other current assets	—	Other current liabilities	(106.1)	Other current liabilities	(7.0)
<b>Total</b>		<u>\$ —</u>		<u>\$ 0.3</u>		<u>\$ (106.1)</u>		<u>\$ (7.0)</u>

***Non-derivative financial instruments which are designated as hedging instruments:***

We designated all of our outstanding €400.0 million 3.875% senior unsecured notes, issued on July 17, 2020, and maturing on July 15, 2028, as a hedge of our net investment in certain of our European operations. In October 2024, we de-designated these notes as a net investment hedge. The de-designation had no impact on earnings because accumulated gains or losses on a net investment hedge are only reclassified into earnings upon a liquidation event or deconsolidation of the hedged foreign subsidiary.

In November 2025, we designated €144.0 million of our outstanding €400.0 million 3.875% senior unsecured notes as a hedge of our net investment in certain European operations.

For instruments that are designated and qualify as net investment hedges, remeasurement gains or losses on the foreign-currency denominated debt are recorded as a component of AOCI. Net investment hedge effectiveness is assessed based on changes in the spot rate of the foreign currency denominated debt. The critical terms of the foreign currency notes match the portion of the net investments designated as being hedged. For all periods presented, the net investment hedge was equal to the designated portion of our European operations and was considered perfectly effective.

The accumulated gain related to the foreign currency denominated debt designated as a net investment hedge, classified within the foreign currency translation adjustment component of AOCI, was \$3.0 million and \$6.0 million as of December 31, 2025 and December 31, 2024, respectively.

The amount of loss related to the foreign currency denominated debt designated as a net investment hedge, classified within the foreign currency translation adjustment component of other comprehensive income or loss, is presented below:

	Year ended December 31,		
	2025	2024	2023
(in millions)			
Net investment hedges	\$ 3.0	\$ 3.3	\$ 15.0

## **22. Financial instruments and fair value measurements**

Our financial instruments include cash and cash equivalents, accounts receivable, accounts payable and debt.

Certain financial and non-financial assets and liabilities are measured at fair value on a nonrecurring basis and are subject to fair value adjustments in certain circumstances, such as when there is evidence of impairment.

As discussed in note 10 and 11, during the second quarter of 2023, property, plant and equipment, customer relationships and developed technology related to Ritter were deemed to be impaired and their carrying values were reduced to estimated fair values of \$25.9 million, \$31.4 million and \$19.3 million, respectively. This was the result of an impairment charge of \$160.8 million. We estimated the fair value of these assets using Level 3 inputs, which included a discounted cash flow analysis.

As discussed in note 11, during the third quarter of 2025, goodwill associated with our Distribution reporting unit was determined to be impaired. As a result, the carrying amount was reduced to its estimated fair value of \$3,500.0 million, resulting in an impairment charge of \$785.0 million. We estimated the fair value of the Distribution reporting unit using Level 3 inputs under the fair value hierarchy, which included a discounted cash flow analysis and a guideline public company method.

### ***Assets and liabilities for which fair value is only disclosed***

The carrying amount of cash and cash equivalents was the same as its fair value and is a Level 1 measurement. The carrying amounts for trade accounts receivable and accounts payable approximated fair value due to their short-term nature and are Level 2 measurements.

The following table presents the gross amounts, which exclude unamortized deferred financing costs, and the fair values of debt instruments:

<i>(in millions)</i>	<b>December 31, 2025</b>		<b>December 31, 2024</b>	
	<b>Gross amount</b>	<b>Fair value</b>	<b>Gross amount</b>	<b>Fair value</b>
Receivables facility	\$ —	\$ —	\$ 125.0	\$ 125.0
Senior secured credit facilities:				
Euro term loans B-4	—	—	81.6	82.1
Euro term loans B-5	—	—	324.5	326.1
Euro term loans B-6	645.2	652.0	—	—
Euro term loans A-1	469.2	445.5	—	—
U.S. dollar term loans B-6	—	—	86.6	87.2
2.625% secured notes	—	—	672.6	668.4
3.875% unsecured notes	800.0	765.9	800.0	729.9
3.875% unsecured notes	469.2	470.2	413.9	413.6
4.625 % unsecured notes	1,550.0	1,542.2	1,550.0	1,480.6
Finance lease liabilities	26.9	26.9	15.0	15.0
Other	7.4	7.4	8.6	8.6
Total	<u>\$ 3,967.9</u>	<u>\$ 3,910.1</u>	<u>\$ 4,077.8</u>	<u>\$ 3,936.5</u>

The fair values of debt instruments are based on standard pricing models that take into account the present value of future cash flows, and in some cases private trading data, which are Level 2 measurements.

### 23. Leases

The following table presents lease assets and liabilities and their balance sheet classification:

<i>(in millions)</i>	<b>Classification</b>	<b>December 31,</b>	
		<b>2025</b>	<b>2024</b>
Operating leases:			
Lease assets	Other assets	\$ 164.5	\$ 156.5
Current portion of liabilities	Other current liabilities	33.5	29.8
Liabilities, net of current portion	Other liabilities	152.0	143.2
Finance leases:			
Lease assets	Property, plant and equipment, net	27.4	15.2
Current portion of liabilities	Current portion of debt	6.1	4.0
Liabilities, net of current portion	Debt, net of current portion	20.8	11.0

The following tables present information about lease expense:

<i>(in millions)</i>	<b>Year ended December 31,</b>		
	<b>2025</b>	<b>2024</b>	<b>2023</b>
Operating lease expense <sup>1</sup>	\$ 59.8	\$ 58.2	\$ 52.5
Finance lease expense <sup>2</sup>	7.5	10.6	11.6
Total	<u>\$ 67.3</u>	<u>\$ 68.8</u>	<u>\$ 64.1</u>

- (1) Operating lease expense for 2025 and 2024 includes \$16.5 million and \$14.6 million, respectively, classified as cost of sales and \$43.3 million and \$43.6 million classified within SG&A expenses, respectively.
- (2) Finance lease expense consists primarily of amortization of finance lease assets that is classified within SG&A expenses.

<i>(dollars in millions)</i>	<b>December 31,</b>		
	<b>2025</b>	<b>2024</b>	<b>2023</b>
<b>Weighted average remaining lease term at end of the year:</b>			
Operating leases	8.9 years	9.3 years	6.6 years
Finance leases	4.8 years	4.4 years	11.7 years
<b>Weighted average discount rate at end of the year:</b>			
Operating leases	6.1 %	6.2 %	4.4 %
Finance leases	5.4 %	3.8 %	7.9 %
<b>Statement of cash flows:</b>			
Operating lease right-of-use assets obtained in exchange for operating lease liabilities	\$ 36.2	\$ 100.1	\$ 39.3
Finance lease right-of-use assets obtained in exchange for Finance lease liabilities	17.5	4.4	4.2

The following table presents future payments due under leases reconciled to lease liabilities:

<i>(in millions)</i>	<b>December 31, 2025</b>	
	<b>Operating leases</b>	<b>Finance leases</b>
2026	\$ 43.0	\$ 7.3
2027	36.6	6.4
2028	28.9	5.9
2029	21.9	5.4
2030	18.2	3.1
Thereafter	<u>97.1</u>	<u>2.6</u>
Total undiscounted lease payments	245.7	30.7
Difference between undiscounted and discounted lease payments	<u>(60.2)</u>	<u>(3.8)</u>
Lease liabilities	<u>\$ 185.5</u>	<u>\$ 26.9</u>

## **24. Subsequent Events**

In February 2026, the Company announced its intention to implement a new operating model and reporting segment structure effective January 1, 2026. Under the new structure, the Company will report its financial results through two segments: VWR Distribution & Services and Bioscience & Medtech Products. This realignment reflects the Company's updated management structure and the manner in which the CODM will assess performance and allocate resources beginning in 2026.

These changes to the reporting segment structure do not affect the Company's consolidated financial statements for the year ended December 31, 2025. Comparative prior-period segment information will be recast in future filings to conform to the new segment presentation.

## **25. Condensed unconsolidated financial information of Avantor, Inc.**

Pursuant to SEC regulations, the following presents condensed unconsolidated financial information of the registrant, Avantor, Inc.

The following condensed unconsolidated financial statements should be read in conjunction with our consolidated financial statements and notes thereto because certain applicable disclosures are provided there. In these condensed unconsolidated financial statements, all of our subsidiaries are wholly-owned for the periods presented and presented as investments of Avantor, Inc. under the equity method. Under that method, the equity interest in subsidiaries' assets and liabilities is stated as a net non current asset at historical cost on the balance sheet.

No statements of operations are included because Avantor, Inc. only had equity in the earnings or loss of its subsidiaries for the periods presented in amounts equal to our consolidated net income or loss.

**Avantor, Inc.**  
**Condensed unconsolidated balance sheets**

<i>(in millions)</i>	<b>December 31,</b>	
	<b>2025</b>	<b>2024</b>
<b>Assets</b>		
Investment in unconsolidated subsidiaries . . . . .	\$ 5,565.0	\$ 5,956.7
Total assets . . . . .	<u>\$ 5,565.0</u>	<u>\$ 5,956.7</u>
<b>Stockholders' equity</b>		
Common stock including paid-in capital, 682.0 and 680.8 shares outstanding . . . . .	3,984.8	3,937.7
Treasury stock at cost, 6.6 and 0.0 shares . . . . .	(75.7)	—
Accumulated earnings . . . . .	1,672.8	2,203.0
Accumulated other comprehensive loss . . . . .	(16.9)	(184.0)
Total stockholders' equity . . . . .	<u>\$ 5,565.0</u>	<u>\$ 5,956.7</u>

**Avantor, Inc.**  
**Condensed unconsolidated statements of cash flows**

<i>(in millions)</i>	<b>Year ended December 31, 2025</b>	<b>Year ended December 31, 2024</b>	<b>Year ended December 31, 2023</b>
<b>Cash flows from investing activities:</b>			
Contribution from (to) unconsolidated subsidiaries . . . . .	\$ 0.5	\$ (60.6)	\$ (4.6)
Net cash provided by (used in) investing activities . . . . .	0.5	(60.6)	(4.6)
<b>Cash flows from financing activities:</b>			
Proceeds received from exercise of stock options . . . . .	5.1	69.2	18.3
Shares repurchased to satisfy employee tax obligations for vested stock-based awards . . . . .	(5.6)	(8.6)	(13.7)
Net cash (used in) provided by financing activities . . . . .	(0.5)	60.6	4.6
Net change in cash and cash equivalents . . . . .	—	—	—
Cash, cash equivalents and restricted cash, beginning of year . . . . .	—	—	—
Cash, cash equivalents and restricted cash, end of year . . . . .	<u>\$ —</u>	<u>\$ —</u>	<u>\$ —</u>

## 26. Valuation and qualifying accounts

The following table presents changes to our valuation and qualifying accounts:

<i>(in millions)</i>	<b>Allowance for expected credit losses</b>	<b>Valuation allowances on deferred tax assets</b>
Balance on December 31, 2022	\$ 28.2	\$ 179.7
Charged to costs and expenses	15.3	20.2
Deductions <sup>(1)</sup>	(9.2)	—
Currency translation	0.7	6.2
Balance on December 31, 2023	35.0	206.1
Charged to costs and expenses	5.3	21.8
Deductions <sup>(1)</sup>	(9.0)	—
Currency translation	(1.1)	(13.8)
Balance on December 31, 2024	30.2	214.1
Charged to costs and expenses	4.0	(48.3)
Deductions <sup>(1)</sup>	(6.2)	—
Currency translation	1.6	24.3
Balance on December 31, 2025	<u>\$ 29.6</u>	<u>\$ 190.1</u>

(1) For the allowance for expected credit losses, deductions represent bad debts charged off, net of recoveries.

# Annual Report 2025

## BOARD OF DIRECTORS

### Gregory Summe

Chairman of the Board  
Avantor, Inc.  
Managing Partner  
Glen Capital Partners

### Emmanuel Ligner

President and Chief Executive Officer  
Avantor, Inc.

### Juan Andres

Former President, Strategic Partnerships and  
Enterprise Expansion  
Moderna, Inc.

### John Carethers, M.D.

Vice Chancellor for Health Sciences  
University of California San Diego

### Simon Dingemans

Former Chief Financial Officer  
GlaxoSmithKline plc

### Lan Kang

President and Chief Executive Officer  
Azkarra Therapeutics

### Gregory T. Lucier

Executive Chairman and Chief Executive Officer  
Corza Medical

### Dame Louise Makin

Chair  
Halma plc

### Joseph Massaro

Vice Chair and President, Engineered Components  
Aptiv PLC

### Sanjeev Mehra

Co-Founder and Managing Partner  
Periphos Capital LP

### Mala Murthy

Chief Financial Officer  
TriNet Group, Inc.

### Michael Severino, M.D

Chief Executive Officer  
Tessera Therapeutics

## COMPANY AND INVESTOR INFORMATION

### 2026 Annual Meeting

May 7, 2026, 11:00 a.m. Eastern Daylight Time

Avantor will be hosting a virtual Annual Stockholder Meeting this year. Stockholders entitled to vote at the meeting will be able to participate by accessing: [www.virtualshareholdermeeting.com/AVTR2026](http://www.virtualshareholdermeeting.com/AVTR2026)

### Additional Information

Financial documents, such as our Annual Report on Form 10-K, quarterly reports on Form 10-Q and other reports and filings, such as the Company's Code of Ethics and Conduct, may be obtained from the Company website at [ir.avantorsciences.com](http://ir.avantorsciences.com) or by calling the Company's Investor Relations Department at (610) 386-1524.

### Stockholder Services

Our transfer agent, Equiniti Trust Company, LLC ("EQ"), can assist you with a variety of stockholder services, including change of address, ownership transfer and account consolidation, and can be reached at:

Tel.: (800) 937-5449; outside the U.S. and Canada at (718) 921-8124

Internet: [www.equiniti.com](http://www.equiniti.com)

Mail: PO Box 500  
Newark, NJ 07101

Email: [HelpAST@equiniti.com](mailto:HelpAST@equiniti.com)

### Investor Relations

Stockholders, security analysts, portfolio managers and other investors desiring further information about the Company may direct questions or requests to:

Avantor, Inc.  
Building One, Ste. 200  
100 Matsonford Road  
Radnor, PA 19087

Tel.: (610) 386-1524

Email: [AvantorIR@avantorsciences.com](mailto:AvantorIR@avantorsciences.com)

### Independent Auditors

Deloitte & Touche LLP, Philadelphia, Pennsylvania

### Stock Listing

Common stock  
New York Stock Exchange I Ticker Symbol: AVTR



**CORPORATE  
HEADQUARTERS**

One Radnor Corporate Center  
Building One, Suite 200  
100 Matsonford Road  
Radnor, PA 19087  
(610) 386-1700